REGULATION OF DRUG METABOLISM AND INFLAMMATION BY PREGNANE X RECEPTOR by Xu, Chenshu
 
 
 
 
 
 
 
 
REGULATION OF DRUG METABOLISM AND INFLAMMATION BY 
PREGNANE X RECEPTOR  
 
By 
 
Chenshu Xu 
 
 
 
 
 
Submitted to the graduate degree program in Pharmacology and Toxicology and the 
Graduate Faculty of the University of Kansas in partial fulfillment of the requirements 
for the degree of Doctor of Philosophy. 
 
 
 
 
                 Chairperson   Dr. Jeff Staudinger     
 
 
 
Dr. Rick Dobrowsky    
 
 
 
Dr. Honglian Shi    
 
 
 
Dr. Alex Moise   
 
 
 
Dr. Erik Lundquist   
 
   Date defended: 11/18/2011   
 
 ii 
 
 
 
 
 
 
 
The Dissertation Committee for Chenshu Xu certifies 
that this is the approved version of the following dissertation: 
 
 
 
 
 
 
REGULATION OF DRUG METABOLISM AND INFLAMMATION BY 
PREGNANE X RECEPTOR  
 
 
 
 
 
 
 
 
                                   Chairperson      Dr. Jeff Staudinger  
 
 
 
 
Date approved:               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 iii 
 
 
 
 
 
 
 
 
 
Dedicated to my father Qiaoyu Xu and my mother Yuling Chen 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 iv 
Abstract 
Liver-enriched nuclear receptor (NR) proteins regulate the expression and activity 
of several pivotal hepatic biochemical pathways including the uptake, metabolism and 
excretion of cholesterol, bile acids, glucose, and xenobiotic compounds from the body.  
The pregnane x receptor (PXR, NR1I2) was first identified in 1998 as a member of the 
NR superfamily.  Over the past decade, it has been well established that PXR 
functions as a master-regulator of xenobiotic- and drug-inducible expression and 
activity of numerous genes that encode key members of the phase I and phase II 
metabolic enzymes, as well as several membrane transporter proteins.  In this way, 
activation of PXR serves as the principal defense mechanism defending the body from 
toxic insult.  Similarly, the PXR protein also forms the molecular basis of an important 
class of drug-drug interactions in the clinical setting.  Moreover, ligand-activated PXR 
negatively regulates inflammatory processes in both liver and intestine.  An integrated 
model is emerging to reveal a key role for the post-translational modification of PXR in 
the selective suppression of gene expression, and is opening the door to the study of 
completely new modes of PXR-mediated gene regulation. 
This dissertation contributes mainly to two key areas of PXR research: (1) 
Identification a novel PXR target gene- carboxylesterase 6 (Ces6); (2) a study of the 
SUMOylation and ubiquitination of PXR protein.  The results presented in this 
dissertation were primarily obtained from mouse and cell-culture systems.  Data 
presented here reveal that activation of the inflammatory response modulates the 
SUMOylation and ubiquitination status of ligand-bound PXR protein.  The 
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SUMOylation and ubiquitination of the PXR protein functions to feedback-repress the 
inflammatory and xenobiotic responses, respectively.  Taken together, the data 
represent a likely mechanism and provides initial molecular details for the connection 
between the PXR signaling pathway and inflammation.  Studies on post-translational 
modification of PXR indicate how this protein is converted from a positive regulator in 
drug metabolism into a transcriptional repressor in inflammatory response.  Finally, 
detailed protocols for purification of mammalian proteins necessary to perform in vitro 
SUMOylation reactions are presented.  Taken together, the work presented in this 
dissertation contributes to understanding the interface between PXR, drug metabolism, 
and inflammation, which is expected to produce new opportunities for the development 
of novel therapeutic strategies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 vi 
Acknowledgements 
I would never have been able to finish my dissertation without the support, 
guidance and patience of the following people.   
I would like to express my deepest gratitude to my graduate advisor Dr. Jeff 
Staudinger.  There are actually no words to describe my appreciation for him.  Jeff's 
creativity and enthusiasm for scientific learning inspires me all the time.  I will always 
remember and be grateful for the lessons I have learned from him.  Although my 
graduate student career is ending, I am thankful that my relationship with my Ph.D 
advisor will continue to grow, a fact that can be attributed to Jeff's unique passion and 
thoughtfulness for his students. 
I would like to thank former and current members of the Staudinger lab, 
specifically Dr. Kristin Lichti-Kaiser, Dr. Gang Hu and Mr. Dan Brobst for their 
patience, instruction and help.   
I would like to thank my committee members, Dr. Rick Dobrowsky, Dr. Honglian 
Shi, Dr. Alex Moise, and Dr. Erik Lundquist for dedicating their time and providing me 
with insightful suggestions and constructive criticisms to improve my work. 
Finally, I would like to thank my family.  To my parents, Qiaoyu Xu and Yuling 
Chen, thank you for instilling in me the importance of education and the work ethic 
needed to get where I am.  To my husband, Chenyu Wang, thank you for supporting 
my goals and standing by me to achieve them. 
The research presented in this dissertation was funded by the NIH grant 
1R01DK068443-NIDDK. 
 
 vii 
List of Abbreviations 
ABCA1: ATP Binding Cassette Transporter A1 
ACBP: Acyl-CoA Binding Protein  
ADR: Adverse Drug Reaction 
ALLN: Acetyl-L-Leucyl-L-Leucyl-L-Norleucinal 
CAR: Constitutive Androstane Receptor 
CAR-KO: Constitutive Androstane Receptor Knockout 
CDK2: Cyclin-dependent Kinase 2 
CES: Carboxylesterase 
CHIP: Chromatin Immunoprecipitation 
CRE: Cyclic AMP Response Element  
CREB: Cyclic AMP Response Element Binding Protein 
CYP: Cytochrome P450 
DBD: DNA-binding Domain 
DME: Drug Metabolizing Enzyme 
ER Estrogen Receptor 
ERK: Extracellular Regulated Kinase 
FOXA2: Forkhead box A2  
FOXO1: Forkhead Box Transcription Factor O1 
FXR: Farnesoid X Receptor 
G6Pase: Glucose 6 Phosphatase 
GR: Glucocorticoid Receptor 
 
 viii 
GST: Glutathione S Transferase 
HA: Hydrolase A 
HB: Hydrolase B 
HNF4 Hepatocyte Nuclear Factor 4 Alpha 
HS: Hydrolase S 
HSD17B11: 17-beta-Hydroxysteroid dehydrogenase type 11 
IBD: Inflammatory Bowel Disease 
IL: Interleukin 
JNK: Jun-kinase 
LBD: Ligand-binding Domain 
LXR: Liver X Receptor 
MAPK: Mitogen-activated Protein Kinase 
MDR1: Multi-drug Resistance 1 
MEK: Mitogen-activated Protein Kinase Kinase  
MEKK1: Mitogen-activated Protein Kinase Kinase Kinase 
MG132: Benzyloxycarbonyl- L-Leucyl-L-Leucyl-L-Leucinal 
MRP2/3: Multi-drug Resistance Associated Protein 2/3 
NCoR: Nuclear Receptor Co-repressor 
NFB: Nuclear Transcription Factor Kappa B 
NR: Nuclear Receptor 
OATP2: Organic Ion Transporting Protein 2 
RANGAP1: Ran GTPase Activating Protein 1 
 
 ix 
PB: Phenobarbital 
PBREM: Phenobarbital Response Enhancer Module 
PC2: Polycomb 2 Homolog 
PCN: Pregnenolone 16-carbonitrile 
PDK4: Pyruvate dehydrogenase kinase, Isozyme 4 
PEPCK: Phosphoenolpyruvate Carboxykinase 
PGC-1 Peroxisome Proliferator Activated Receptor Gamma Co-activator 1 Alpha 
PIAS: Protein Inhibitors of Activated STAT 
PKA: Cyclic-AMP-dependent Protein Kinase 
PPAR: Perioxisome Proliferator Activated Receptor 
PXR: Pregnane X Receptor 
PXR-KO: Pregnane X Receptor Knockout 
RANBP2: Ran Binding Protein 2 
RAR: Retinoic Acid Receptor 
RIF: Rifampicin 
RXR: Retinoid X Receptor 
SENP: Sentrin-specific Proteases  
SUG1: Suppressor for Gal1 
SULT: Sulfotransferase 
SUMO: Small Ubiquitin-like Modifier 
TCPOBOP: 1,4-bis[2-(3,5-dichloropyridyloxy)] benzene 
TNF: Tumor Necrosis Factor Alpha 
 
 x 
UGT: UDP Glucuronosyltransferase 
XREM: Xenobiotic Responsive Enhancer Module 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xi 
Table of Contents 
Abstract ........................................................................................................................ iv 
Acknowledgements ...................................................................................................... vi 
List of Abbreviations .................................................................................................. vii 
Table of Contents ......................................................................................................... xi 
List of Tables ...............................................................................................................xv 
List of Figures ............................................................................................................ xvi 
Chapter 1: Introduction ..............................................................................................1 
Chapter 2: Nuclear Receptor-mediated Regulation of Carboxylesterase 
Expression and Activity 
2.1  An Introduction to Carboxylesterase .....................................................................6 
2.1.1 Classification of Carboxylesterase ............................................................6 
2.1.2 Function of Carboxylesterase Enzymes ....................................................7 
2.1.3 Structure of CES Enzymes ........................................................................8 
2.1.4 Substrate Selectivity of CES Enzymes .....................................................8 
2.1.5 Tissue Distribution of CES Enzymes .......................................................9 
2.2  PXR and CAR, Two Xenobiotic-Sensing NRs .....................................................9 
2.3  Regulation of CES Enzymes by PXR and CAR ..................................................11 
2.3.1 Regulation by PXR .................................................................................11 
2.3.2 Regulation by CAR .................................................................................13 
2.3.3 Coordinate Regulation of Gene Expression by PXR and CAR ..............14 
2.4  Other Nuclear Receptors Regulate CES Enzymes ..............................................19 
 
 xii 
2.5  Conclusions..........................................................................................................21 
2.6  References ............................................................................................................24 
Chapter 3: Post-translational Modification of Pregnane X Receptor 
3.1  An Introduction to Pregnane X Receptor ............................................................29 
3.2  Negative Physiological Functions of PXR ..........................................................30 
3.2.1 Glucose Homeostasis ..............................................................................31 
3.2.2 Lipid Metabolism and Ketogenesis ........................................................35 
3.2.3 Inflammatory Response ..........................................................................36 
3.3  Post-translational Modification of PXR ..............................................................37 
3.3.1 Ubiquitination of PXR ............................................................................37 
3.3.2 Phosphorylation of PXR .........................................................................38 
3.3.3 SUMOylation of PXR .............................................................................43 
3.3.4 Acetylation of PXR .................................................................................50 
3.4  Conclusions..........................................................................................................53 
3.5  References ............................................................................................................55 
Chapter 4:  Regulation of Tissue-specific Carboxylesterase Expression by 
Pregnane X Receptor and Constitutive Androstane Receptor 
4.1  Introduction..........................................................................................................60 
4.2  Materials and Methods ........................................................................................64 
4.3  Results..................................................................................................................68 
4.4  Discussion ............................................................................................................90 
4.5  References ............................................................................................................97 
 
 xiii 
Chapter 5:  Pregnane X Receptor is Targeted by the Ubiquitin-proteasome 
Pathway in a Signal-dependent Manner 
5.1  Introduction........................................................................................................100 
5.2  Materials and Methods ......................................................................................105 
5.3  Results................................................................................................................108 
5.4  Discussion ..........................................................................................................121 
5.5  References ..........................................................................................................125 
Chapter 6:  Pregnane X Receptor is Sumoylated to Repress the 
Inflammatory Response 
6.1  Introduction........................................................................................................128 
6.2  Materials and Methods ......................................................................................130 
6.3  Results................................................................................................................135 
6.4  Discussion ..........................................................................................................152 
6.5  References ..........................................................................................................161 
Chapter 7:  Expression, Isolation, and Purification of In Vitro SUMOylation 
Components 
7.1  Introduction........................................................................................................164 
7.2  Materials and Methods ......................................................................................167 
7.3  Results................................................................................................................170 
7.4  Discussion ..........................................................................................................172 
7.5  References ..........................................................................................................177 
 
 
 xiv 
Chapter 8:  The Future Outlook of PXR 
8.1  PXR and Drug Metabolism ...............................................................................179 
8.2  PXR and Inflammation ......................................................................................181 
8.3  Concluding Remarks .........................................................................................183 
8.4  References ..........................................................................................................184 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xv 
List of Tables 
Table 4-1: Genes Up-regulated by PCN Treatment in Duodenum. .............................72 
 
 xvi 
List of Figures 
Figure 2-1: PXR protein binds „site 2‟ in vivo with the highest affinity .....................15 
Figure 2-2: Site 2 contains several NR-response elements. .........................................17   
Figure 2-3: EMSA using the „long‟ and „short‟ double-stranded radiolabeled 
oligonucleotides. ..........................................................................................................18 
Figure 2-4: Model of the significance of PXR-and CAR-mediated gene activation in 
liver and intestine. ........................................................................................................20   
Figure 3-1: Negative Regulation Roles of PXR ..........................................................32 
Figure 3-2: Ubiquitination of PXR ........................................................................ 39-41 
Figure 3-3: SUMOylation of PXR ......................................................................... 46-49   
Figure 3-4: Acetylation of PXR ............................................................................. 51-52 
Figure 4-1: The basal expression of Cyp3a11, Pxr, and Car gene expression levels in 
liver, duodenum, jejunum, and ileum. .........................................................................69 
Figure 4-2: Induction of Ces6 and Cyp3a11 gene expression by PCN treatment in 
mouse duodenum is PXR-dependent ..................................................................... 73-74 
Figure 4-3: Induction of Ces6 and Cyp3a11 gene expression by PCN treatment in 
mouse liver is PXR-dependent............................................................................... 76-77 
Figure 4-4: Expression of Ces6 and Cyp3a11 protein is induced by PCN in a 
PXR-dependent manner in mouse liver. ................................................................ 79-80 
Figure 4-5: Induction of Ces6 and Cyp2b10 gene expression by TCPOBOP treatment 
in mouse liver is CAR-dependent. ......................................................................... 81-82 
 
 xvii 
Figure 4-6: Expression of Ces6 and Cyp2b10 protein is induced by TCPOBOP in a 
CAR-dependent manner in mouse liver ................................................................. 84-85 
Figure 4-7: Induction of Ces6 and Cyp2b10 gene expression by phenobarbital 
treatment in mouse liver is CAR-dependent. ......................................................... 86-87 
Figure 4-8: Expression of Ces6 and Cyp2b10 protein is induced by phenobarbital in a 
CAR-dependent manner in mouse liver. ................................................................ 88-89 
Figure 4-9: Model of Coordinated PXR- and CAR-mediated Gene Activation in Liver 
and Intestine .................................................................................................................91 
Figure 5-1: The Ubiquitin-proteasome Pathway........................................................103   
Figure 5-2:  Expression of PXR Protein is Increased by Proteasome Inhibitors in Cells.
............................................................................................................................ 110-111 
Figure 5-3: PXR is Ubiquitinated in Cells. ................................................................112   
Figure 5-4: Poly-ubiquitination of PXR Protein is Stimulated by Cyclic-AMP and 
Constitutively Active MEKK Signaling ....................................................................114 
Figure 5-5: Cyclic-AMP Mediates Poly-ubiquitination of PXR via neither Lys-48 nor 
Lys-63-linked Ubiquitin Chains ................................................................................115 
Figure 5-6: Co-treatment of Hepatocytes with Rifampicin and TNFa Increases 
Ubiquitination of Human PXR Protein ......................................................................117   
Figure 5-7. Inhibition of the Proteasomal Degradation Pathway Abolishes PXR 
Transactivation Capacity in Transfected CV-1 Cells ................................................119 
Figure 5-8: The Biological Effect of Ubiquitin Modification of Human PXR on PXR 
Activity. .....................................................................................................................120 
 
 xviii 
Figure 6-1: Ablation of PXR from Mice Increases Expression of Inflammatory 
Cytokines in Liver......................................................................................................136 
Figure 6-2: Cotreatment of Wild-type Hepatocytes with PCN and TNFα Represses 
Expression of IL-1β in Liver, but not in Hepatocytes from PXR-KO Mice...... 138-139 
Figure 6-3A: Analysis of Consensus Sumoylation Sites in the Human PXR Protein ..... 
....................................................................................................................................140 
Figure 6-3B: In Vitro Sumoylation of Human PXR Protein .....................................141 
Figure 6-4A: Detection of Sumoylated Human PXR Protein in HeLa Cells ............144 
Figure 6-4B: Dominant-negative Ubc9 (C93S) Protein Inhibits Sumoylation of Human 
PXR in a Dose-dependent Manner. ...........................................................................145 
Figure 6-5: Detection of Sumoylated PXR in Hepatocytes. .............................. 149-151 
Figure 6-6: Functional Significance of SUMO3 Modification of the PXR Protein ........ 
............................................................................................................................ 153-155 
Figure 6-7:  Model of PXR-mediated Repression of Inflammatory Response Pathways
....................................................................................................................................158 
Figure 7-1: The SUMOylation Pathway ....................................................................166 
Figure 7-2: Purification Scheme for His-tagged E1, E2, SUMO1, SUMO2, and 
SUMO3 Proteins ........................................................................................................171 
Figure 7-3: SDS-PAGE Analysis of Purified Proteins ..............................................173 
Figure 7-4: Western Blot of In Vitro SUMOylation Assay for RanGap1. ................174 
 
 
 
 
 
 1 
Chapter 1: Introduction 
Nuclear receptor (NR) proteins comprise a large superfamily of ligand-activated 
transcription factors that are involved in diverse physiological, developmental and 
metabolic processes.  They share certain amount of structural homology with a 
conserved N-terminal zinc-finger type DNA-binding domain (DBD) and a C-terminal 
ligand-binding domain (LBD) [1].  The pregnane x receptor (PXR, NR1I2) was first 
identified in 1998 as a member of the NR superfamily.  In mammals, PXR is highly 
expressed in the major organs that are important in xenobiotic biotransformation 
including the liver and the intestine [2].  Over the past decade, it has been well 
established that PXR functions as a master-regulator of xenobiotic- and drug-inducible 
expression and activity of numerous genes that encode key members of the cytochrome 
P450 (CYP) drug-metabolizing enzymes in humans and rodents [3, 4].  PXR target 
genes also encode several glutathione S-transferase, sulfotransferase, and 
UDP-glucuronosyltransferase enzymes in the liver, as well as key hepatic drug 
transporter proteins, such as organic anion transporting polypeptide 2, multidrug 
resistance 1/P-glycoprotein, and multidrug resistance proteins 2 and 3 [5-10]. 
In addition to serving as a positive regulator in mediating drug metabolism and 
transport, clinical evidence has been accumulated to reveal the repressive function of 
the PXR protein.  Recent studies indicate that ligand-mediated activation of PXR 
negatively regulates several key biochemical functions in the liver and intestine, 
including the synthesis of glucose and ketone bodies, -oxidation, transport of lipids, 
as well as inflammatory processes. 
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The overall goal of this dissertation is to characterize the regulation of nuclear 
receptor PXR in drug metabolism and inflammation.  Chapter 2 summarizes the 
current state of knowledge regarding NR-mediated regulation of carboxylesterase 
(CES) enzymes in mammals and highlights their importance in drug metabolism, 
drug-drug interactions and toxicology.  Elucidation of the role of NR-mediated 
regulation of CES enzymes in liver and intestine will have a significant impact on 
rational drug design and the development of novel prodrugs, especially for patients on 
combination therapy. 
Chapter 3 reviews PXR-mediated repression of gene expression programs 
underlying several pivotal physiological functions, including decreased capacities for 
gluconeogenesis, lipid metabolism, and inflammation.  An integrated model is 
emerging that reveals a sophisticated interplay between ligand binding and the 
ubiquitination, phosphorylation, SUMOylation, and acetylation status of this important 
nuclear receptor protein.  These discoveries point to a key role for the 
post-translational modification of PXR in the selective suppression of gene expression, 
and open the door to the study of completely new modes of regulation of the biological 
activity of PXR. 
In Chapter 4, microarray analysis is used to identify PXR target genes in 
duodenum in mice.  We show that a gene encoding a member of the carboxylesterase2 
(CES2) subtype of liver- and intestine-enriched CES enzymes, called Ces6, is induced 
after treatment with pregnenolone 16alpha-carbonitrile (PCN) in a PXR-dependent 
manner in duodenum and liver in mice.  Treatment of mice with the CAR activator 
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1,4-bis[2-(3,5-dichloropyridyloxy)] benzene (TCPOBOP) also induces expression of 
Ces6 in duodenum and liver in a CAR-dependent manner, whereas treatment with 
phenobarbital (PB) produces induction of Ces6 exclusively in liver.  These data 
identify a key role for PXR and CAR in regulating the drug-inducible expression and 
activity of an important CES enzyme in vivo. 
In Chapter 5, we identify PXR as a molecular target of ubiquitin.  We show that 
ubiquitination of PXR is stimulated in cells by treatment with cyclic-AMP and 
activation of the MEKK1 signaling pathway, suggesting distinct regulation of PXR 
activity by metabolic- and inflammatory-mediated signaling.  Interestingly, inhibition 
of the proteasomal degradation pathway and increased ubiquitination of PXR represses 
rifampicin-inducible PXR transactivation capacity in an engineered PXR reporter gene 
assays.  Taken together, this novel data provides a plausible and testable hypothesis 
for how inflammatory- and cyclic AMP/PKA-mediated signaling pathways selectively 
repress the drug-inducible expression and activity of hepatic drug metabolizing and 
drug transporter activities in the liver and the intestine. 
In Chapter 6, we show that activation of the inflammatory response in hepatocytes 
strongly modulates SUMOylation of ligand-bound PXR.  We provide evidence that 
the SUMOylated PXR contains SUMO3 chains, and feedback represses the immune 
response in hepatocytes.  This information represents the first step in developing novel 
pharmaceutical strategies to treat inflammatory liver disease and prevent adverse drug 
reactions in patients experiencing acute or systemic inflammation.  These studies also 
provide a molecular rationale for constructing a novel paradigm that uniquely defines 
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the molecular basis of the interface between PXR-mediated gene activation, drug 
metabolism, and inflammation. 
In Chapter 7, we present detailed protocols for bacterial expression, isolation, and 
purification of mammalian proteins necessary to perform in vitro SUMOylation 
reactions, namely the SUMO E1 enzyme (AOS1/UBA2 heterodimer), Ubc9, and 
SUMO1, SUMO2, and SUMO3.  Detailed methods for performing in vitro 
SUMOylation assay by SUMO1, SUMO2, and SUMO3 using RanGap1 as substrate 
are also described.  SUMOylation is a relatively new protein modification and 
methods for research are still being developed.  The protocols described in Chapter 7 
are useful for research of this post-translational modification. 
Taking together, the work presented in this dissertation contributes mainly to two 
key areas of PXR research: (1) Identification of carboxylesterase6 as a novel PXR 
target gene in liver and intestine tissues further characterizes the well-established role 
for PXR in drug metabolism; (2) Revealing the SUMOylation and ubiquitination of 
ligand-bound PXR provides a possible molecular mechanism connecting PXR and 
inflammation.  The identification of novel ligands and target genes continues to be an 
important aspect of PXR research.  Studies on post-translational modification of PXR 
contribute to the investigation of how PXR is converted from a positive regulator in 
drug metabolism into a transcriptional repressor in inflammatory response.  
Understanding of the interface between PXR, drug metabolism, and inflammation is 
critical for the development of safe and effective therapeutic strategies. 
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Chapter 2: Nuclear Receptor-mediated Regulation of 
Carboxylesterase Expression and Activity 
    2.1 An Introduction to Carboxylesterase 
    2.1.1 Classification of Carboxylesterase 
    In 1953, Aldridge classified esterase enzymes in rabbit, rat, and horse serum based 
upon the nature of their interaction with organophosphates [1].  Esterases that were 
unaffected by organophosphates and degraded the compounds were classified as 
A-esterases, whereas esterases that were inhibited by organophosphates were classified 
as B-esterases.  Studies by Bergmann et al. revealed the presence of a third group of 
esterases (the C-esterases) that were not affected by and did not interact with 
organophosphates at all [2].  Using this classification scheme, the superfamily of 
carboxylesterase (CES) enzymes belong to the B-esterase group.  Several attempts 
have been made to classify the CES enzymes.  Walker and Mentlein et al., attempted 
to classify CES enzymes on the basis of their substrate specificity [3, 4].  However, 
this classification scheme was ambiguous because of the broad and overlapping 
substrate specificity of CES enzymes.  In 1998, Satoh and Hosokawa originally 
proposed a novel classification scheme of CES enzymes across species that was based 
upon the extent of amino acid homology and substrate selectivity [5].  This scheme 
classified the known CES enzymes into four main groups (CES 1-4), and several 
additional subgroups.  More recently, the same authors have used this same scheme to 
show that there are five groups of CES enzymes (CES 1-5), and revealed that the 
majority of identified CES enzymes belong to either the CES 1 or CES 2 sub-family [6].  
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Importantly, it is now known that the CES-1 and CES-2 sub-families are the major 
source of carboxylesterase enzymatic activity in liver and intestine tissues that 
participate in the hydrolysis of drugs and xenobiotics in mammals [6]. 
    2.1.2 Function of Carboxylesterase Enzymes 
    The CES family of enzymes is a key participant in the phase-I drug metabolism 
process, catalyzing the hydrolysis of a wide range of ester- and amide-containing 
compounds.  Of particular clinical relevance, these enzymes participate in the 
biotransformation of numerous drugs and prodrugs including the anti-platelet drugs 
aspirin and clopidogrel [7], the angiotensin-converting enzyme inhibitors delapril, 
imidapril, and temocapril [8], the anti-tumor drugs irinotecan and pentyl PABC-doxaz 
[9, 10], the narcotics cocaine and heroin [11], and the anti-influenza prodrug 
oseltamivir [12, 13].  The CES family of enzymes is involved in the detoxification of 
environmental toxicants, such as pyrethoids, a major class of insecticides used 
worldwide and extensively in the United States [14].  CES enzymes also play a role in 
the conversion of pro-carcinogens into carcinogens.  For example, vinyl acetate, 
which is used in the paint, adhesive, and paper-board industry, is metabolized by CES 
enzymes into acetaldehyde in the liver.  Acetaldehyde subsequently binds to DNA and 
proteins eventually leading to nasal tumor formation in rodents [15].  Numerous 
endogenous compounds are substrates for CES enzymes including 
palmitoyl-coenzyme A, short- and long-chain acyl-glycerols, as well as medium- and 
long-chain acylcarnitines [5, 16].  Because a large number of clinically used drugs and 
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prodrugs are metabolized by CES enzymes, it is important to clarify the structure, 
substrate selectivity, tissue distribution, and species specificity of CES enzymes.   
    2.1.3 Structure of CES Enzymes 
    The crystal structure of human carboxylesterase 1 (hCE-1) was determined in 2003.  
The enzyme is comprised of three structural domains: a central catalytic domain, an 
 domain, and a regulatory domain.  The central catalytic domain contains the 
serine hydrolase catalytic triad at the base of the active site gorge, whereas the 
regulatory domain contains the low-affinity surface ligand-binding Z-site [17, 18].  
The CES enzymes are localized in the endoplasmic reticulum and cytosol of many 
tissues, but are highly enriched in liver and intestine [6, 19].  It has been determined 
that an 18-amino acid N-terminal hydrophobic signal peptide is responsible for the 
localization of these proteins to the endoplasmic reticulum [20], whereas enzymatic 
activity is lost by removing the N-terminal domain.  The His-X-Glu-Leu (HXEL) 
sequence present at the C-terminal, which can bind with KDEL receptor, is essential 
for retention of the protein in the luminal site of the endoplasmic reticulum.   
    2.1.4 Substrate Selectivity of CES Enzymes 
    Amino acid sequence homology between human carboxylesterase 1 (hCE-1), a 
member of CES 1 family, and human carboxylesterase 2 (hCE-2), which belongs to 
CES 2 family is 48% [10].  However, the substrate selectivity of these two enzymes is 
different.  The hCE-1 enzyme mainly hydrolyzes substrates with small alcohol groups 
and large acyl groups, such as cocaine (methyl ester), meperidine, and delapril.  In 
contrast to hCE-1, the hCE-2 enzyme efficiently hydrolyzes compounds with large 
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alcohol groups and relatively smaller carboxylate groups, such as 4-methylumbelliferyl 
acetate, heroin, and 6-acetylmorphine [21]. 
    2.1.5 Tissue Distribution of CES Enzymes 
    The expression of CES enzymes is ubiquitous in mammals.  Among various 
tissues of mammals, the highest hydrolase activity is present in liver [22].  In addition 
to liver, CES enzymes are also detected in small intestine, kidney, and lung [6].  The 
hCE-1 enzyme is highly expressed in the liver, and also detected in macrophages, 
human lung epithelia, heart, and testis [23].  The hCE-2 enzyme is found in the small 
intestine, colon, kidney, liver, heart, brain, and testis [19, 24].  Although these two 
enzymes are present in various tissues, hCE-1 and hCE-2 contribute predominantly to 
the hydrolase activity of liver and small intestine, respectively.  It has also been shown 
that CES enzymes exhibit species differences.  For example, Li et al demonstrated that 
human plasma contains no CES enzyme activity, in contrast, the mouse, rat, rabbit, 
horse, cat, and tiger all have high levels of plasma CES enzymes [25].  However, in 
humans it is likely that serum butyrylcholinesterase and paraoxonase enzymes perform 
analogous functions to the CES enzymes found in serum from these other species. 
    2.2 PXR and CAR, Two Xenobiotic-Sensing NRs 
    As CES enzymes play very important roles in drug metabolism, their expression 
levels are tightly controlled by the NR proteins pregnane X receptor (PXR, NR1I2) and 
constitutive androstane receptor (CAR, NR1I3).  NR proteins comprise a large 
superfamily of ligand-activated transcription factors that are involved in diverse 
physiological, developmental, and metabolic processes.  They are characterized by a 
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conserved N-terminal zinc-finger type DNA-binding domain and a C-terminal 
ligand-binding domain [26].  The PXR and CAR proteins are two closely related 
members of this superfamily.  Both of these proteins function as ligand-activated 
transcription factors by interacting with the retinoid-x-receptor-alpha (RXR, NR2B1) 
on response elements located in the control regions of specific genes that they regulate.  
    PXR functions as a master-regulator of xenobiotic- and drug-inducible cytochrome 
P450 (CYP) gene expression in liver and it is now well established that PXR regulates 
the drug-inducible expression and activity of numerous genes that encode key 
members of the CYP3A, CYP2B and CYP2C subfamily of drug-metabolizing 
enzymes in humans and rodents [27, 28].  PXR also regulates the drug-inducible 
expression of other genes whose gene products are involved in the metabolism of 
xenobiotic compounds including glutathione S-transferase, sulfotransferase, and 
UDP-glucuronosyltransferase enzymes in liver [29-32].  Moreover, additional 
PXR-target genes encode key hepatic drug transporter proteins such as organic anion 
transporting polypeptide 2, multidrug resistance 1/P-glycoprotein, and multidrug 
resistance proteins 2 and 3 [33-35]. 
    Similar to PXR, the NR superfamily member CAR is also recognized as a 
xenobiotic-sensing NR mainly expressed in hepatic tissue.  It was originally 
demonstrated to regulate the phenobarbital-inducible expression of several genes 
encoding important members of the CYP2B subfamily of enzymes [36].  CAR has 
since been shown to regulate the expression and activity of a number of phase-I and 
phase-II metabolic enzymes, as well as the expression and activity of numerous 
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important membrane transporter proteins involved in the metabolism and elimination 
of xenobiotics [37].  It has been demonstrated that PXR and CAR share distinct but 
overlapping sets of target genes involved in drug and xenobiotic metabolism, often 
through shared NR-response elements.  For instance, PXR can regulate CYP2B genes 
through recognition of the Phenobarbital-response element (PBREM), whereas CAR is 
also found to activate gene expression through the xenobiotic response element 
(XREM) in the upstream promoter of the CYP3A4 gene in humans [29, 38, 39].  
Because PXR and CAR are activated by a myriad of xenobiotic compounds and 
regulate the expression of numerous genes involved in drug and xenobiotic metabolism, 
the activation of these two receptors serves as a principal defense mechanism 
defending the body from toxic insult.  In this way, activation of PXR and CAR by 
xenobiotic compounds and drugs coordinately regulates the expression and activity of 
functionally linked metabolic enzymes and membrane-bound transporter proteins to 
increase the elimination of potentially toxic compounds from the body [27, 32, 39-41].  
Additionally, these two transcription factors form the molecular basis of an important 
class of drug-drug interactions in the clinical setting.  PXR and CAR-mediated gene 
activation by one drug increases the metabolism and elimination of a myriad of other 
co-administered drugs from the body. 
    2.3 Regulation of CES Enzymes by PXR and CAR 
    2.3.1 Regulation by PXR 
    The hCE-1 and hCE-2 genes encode the two major forms of human liver 
microsomal carboxylesterase enzymes.  Studies by Zhu et al. show the involvement of 
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PXR in regulating the expression and activity of these two enzymes [42].  Exposure of 
primary cultures of human hepatocytes to micromolar concentrations of 
dexamethasone induces hCE-1 and hCE-2 protein expression in a 
concentration-dependent manner.  Treatment of human hepatocytes with ten 
micromolar rifampicin, the prototypical human PXR-activating compound, causes 
moderate induction of hCE-1 and hCE-2 gene expression [43].  In addition to 
dexamethasone, treatment of cultured human hepatocytes with 8-methoxypsoralen, 
which is a prototypical photochemotherapeutic drug, increases hCE-2 gene expression 
[13].  Moreover, knockdown of PXR using si-RNA technology decreases hCE-2 
mRNA levels, whereas over-expression of the PXR protein significantly increases 
hCE-2 expression at both the messenger RNA and protein levels. 
    PXR also induces the expression of CES enzymes in rodents.  In rats, the best 
characterized carboxylesterase enzymes include hydrolase A, B and S (HA, HB, HS).  
Co-transfection of PXR stimulates the promoter activity of HB and HS in response to 
dexamethasone at micromolar concentrations [43].  Tully et al. characterized the 
effects of triazole fungicides in SD rats using microarray analysis [31].  Gene 
expression profiling of liver shows induction of Ces2 is produced by four triazole 
fungicides, and is likely dependent on PXR/CAR-mediated gene activation pathways.  
A similar study by Goetz et al., utilized gene expression profiling of the liver of CD-1 
mice treated with four triazole fungicides.  Expression of the Ces2 gene is induced by 
three triazole fungicides, suggesting involvement of PXR/CAR-regulated pathways in 
triazole metabolism and perhaps toxicity [44].  Earlier research by Rosenfeld et al., 
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indicates that over-expression of a constitutively active form of human PXR in mouse 
liver has a positive effect on the expression of mouse genes encoding Ces2 and Ces3 
enzymes in liver [45]. 
    The mouse Ces6 gene was first identified in 2004 and encodes a protein of 558 
amino acid residues in length that functions to hydrolyze select pyrethroid compounds 
[46].  Recently, our lab has demonstrated that the Ces6 gene represents a likely 
PXR-target gene in mouse liver and small intestine [47].  By exploiting the PXR 
knockout mouse model, we reveal that induction of Ces6 messenger RNA and protein 
by pregnenalone 16-carbonitrile (PCN), a well known rodent PXR activator, is 
PXR-dependent in both mouse liver and intestine.  
    2.3.2 Regulation by CAR 
    Compared to PXR, relatively little is known about the regulation of drug-inducible 
CES gene expression by CAR activation in any species or tissue.  Historical reports 
indicate that treatment of rats with phenobarbital (PB) increases CES expression in 
liver tissue [48].  Studies from Xu et al. show that Ces6 represents a CAR-target gene 
in mouse liver and small intestine [24].  It is interesting to note that in small intestine, 
the expression of Ces6 is exclusively regulated by 
1,4-Bis[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP) but not by PB, both of 
which are CAR activators.  These data suggest that there may be differences in the 
bioavailability of PB and TCPOBOP, or perhaps the differences in the mode of CAR 
activation by these two ligands in small intestine are responsible for the absence of 
Ces6 gene activation by PB.  Moreover, TCPOBOP is a much more potent and 
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efficacious activator of rodent CAR, thus is a much more effective chemical to use in 
rodent studies.   
    2.3.3 Coordinate Regulation of Gene Expression by PXR and CAR 
Using ChIP-seqeuencing analysis of control and PCN-treated mouse livers, we 
observed constitutive PXR-binding to three enhancer elements located in the upstream 
region of the mouse Ces6 gene under physiological conditions  (Figure 2-1, top panel), 
which are approximately 84bp (site 1), 1796bp (site 2), and 2340bp (site 3) upstream of 
the transcription start site of Ces6.  Most interestingly, treatment with the mouse PXR 
agonist PCN produces an approximately 2-fold overall increase in PXR binding to all 
the three sites, particularly to the second site (site 2), which binds to PXR with the 
highest affinity.  In addition, a new PXR binding site occurs further upstream 
(-2772bp) with moderate fold-enrichment (average value = 40) (Figure 2-1, bottom  
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Figure 2-1 
 
Figure 2-1. PXR protein binds ‘site 2’ in vivo with the highest affinity. Total 
crosslinked chromatin was subject to immunoprecipitation with an anti-PXR antibody 
(n=2). The anti-PXR enriched immunoprecipitated chromatin was subjected to 
high-throughput DNA sequence analysis and mapped back to the mouse genome. The 
exact locations of enriched fragments along with their proximities to the annotated Ces6 
gene were then determined. A. Control mouse liver treated i.p. with corn oil only. B. 
Mouse liver that were treated with PCN (200 mg/kg, i.p. in corn oil). ChIP-sequencing raw 
data were normalized by the sequencing depths. Significant PXR binding is determined 
based on a threshold value of 20-fold enrichment based upon the false discovery rate. Data 
are visualized by the integrated genome browser and are expressed as fold-enrichment. 
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panel).  Close examination of the DNA sequences that constitute site 2 reveals a 
cluster of likely NR-response elements located within 70 base pairs of each other and 
these are depicted in figure 2-2.  Using two oligonucleotides, designated as „long‟ and 
„short‟, derived from this DNA sequence we performed electrophoretic mobility-shift 
analysis and show that both CAR/RXR and PXR/RXR protein complexes bind 
directly to these putative response elements (Figure 2-3).  Importantly, 
competition-binding using an oligonucleotide that comprises the prototypical shared 
PXR/CAR response element, an everted repeat spaced by 6 nucleotides (ER6) derived 
from the well-characterized promoter of the CYP3A4 gene, shows that binding to the 
putative Ces6 response elements is specific.  Conversely, a mutant form of the same 
oligonucleotide (mtER6) did not compete for binding, whereas the homologous 
oligonucleotides comprising the „long‟ and „short‟ experimental oligonucleotides 
compete well for binding of both the CAR/RXR and PXR/RXR protein complexes. 
Hence, the PXR and CAR NR superfamily members play direct and competitive roles 
in regulating the drug-inducible expression and activity of an important liver- and 
intestine-enriched mouse CES enzyme.  Together with numerous other 
drug-metabolizing enzymes and drug transporter proteins in liver and intestine, PXR 
and CAR regulate the expression and activity of key CES enzymes that coordinately 
determine the pharmacokinetic and pharmacodynamic properties of numerous 
clinically prescribed and xenobiotic compounds in vivo in liver and intestine.  Taken 
together, the data lead to a model in which drug-inducible activation of intestinal CES  
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Figure 2-2 
 
Figure 2-2.  Site 2 contains several NR-response elements.  DNA sequence of site 
2 was examined using Nubiscan (http://www.nubiscan.unibas.ch/) and NHR scan 
(http://asp.ii.uib.no:8090/cgi-bin/NHR-scan/nhr_scan.cgi) websites to identify all NR 
half-sites and predict putative PXR- and CAR-binding sites.  The „long‟ and „short‟ 
double-stranded oligonucleotides encompassing the putative-binding sites were 
generated. 
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Figure 2-3 
 
Figure 2-3.  EMSA using the ‘long’ and ‘short’ double-stranded radiolabeled 
oligonucleotides.  EMSA analysis was performed using the radiolabeled 
double-stranded „long‟ and „short‟ oligonucleotides using standard methods as 
described previously.  The shifted complex was effectively competed with the 
non-radiolabeled and prototypical shared PXR/CAR response element derived from 
the CYP3A4 gene that is called ER6, the „long‟ and the „short‟ oligonucleotides as 
indicated.  However, the mutant ER6 (mtER6) did not compete for binding to any 
detectable degree.  Thus, binding of RXR/CAR and RXR/PXR complexes to these 
two oligonucleotides that are derived from the Ces6 upstream promoter was specific. 
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activity in intestine would be expected to increase the conversion of prodrugs to the 
active form of the drug, thereby increasing transport to portal vein and liver (Figure 
2-4).  In the liver, high levels of cytochrome P450 and CES activity would be expected 
to further increase metabolism of co-administered drugs, thereby leading to increased 
prospects for drug-drug interaction in patients on combination therapy.  Moreover, 
activation of these pathways by PXR and CAR would be expected to increase the 
conversion of pro-carcinogens into carcinogenic compounds in these tissues. 
    2.4 Other Nuclear Receptors Regulate CES Enzymes 
    In addition to PXR and CAR, CES enzymes are also regulated by other NR 
proteins, such as hepatocyte nuclear factor-4 (HNF-4NR2A1), peroxisome 
proliferator-activated receptor  (PPAR, NR1C1), and glucocorticoid receptor (GR, 
NR3C1).  HNF-4 is mainly expressed in liver, intestine, pancreas and kidney, and is 
critical for transcriptional regulation of many genes in liver, such as Cyp7a1, CAR, and 
genes involved in the control of lipid homeostasis, glucose transport and glycolysis 
[49-52].  HNF-4 has also been implicated in the regulation of mouse Ces2 gene 
transcription.  In the same study, bile acids are shown to repress expression of mCES2 
by inhibiting the HNF-4-mediated transactivation of the mCES2 gene promoter [53].   
Proxisome proliferator-activated receptors (PPARs) are mainly involved in lipid 
and glucose homeostasis, control of inflammation and wound healing, and regulation 
of food intake and body weight [54, 55].  However, there appears to be a connection 
between PPARs and hepatic CES gene expression in rodents as well.  The PPAR  
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Figure 2-4 
 
Figure 2-4.  Model of the significance of PXR-and CAR-mediated gene 
activation in liver and intestine.  A. Activation of PXR in intestine produces 
elevated levels of Ces6 and Cyp3A activity.  This would be expected to accelerate 
conversion of prodrug to active drug and increase uptake into the portal circulation.  B. 
The liver would then mediated further uptake metabolism and excretion into bile and 
elimination in feces or back into blood for eventual elimination through the kidney and 
in urine. 
 
 
 
 21 
protein, one of the three subtypes of PPARs, is predominantly expressed in tissues with 
a high oxidative capacity such as heart and liver.  Research by Poole et al. showed that 
exposure to peroxisome proliferators, strong activators of PPAR in liver, leads to 
down-regulation of the expression of CES family members.  The alteration in CES 
expression is dependent on the PPAR protein in mouse [56]. 
    2.5 Conclusions. 
    NRs are key regulators of many drug metabolizing enzymes that play diverse roles 
in xenobiotic and endobiotic metabolism.  This review summarizes the evidence that 
several key NR proteins, including PXR, CAR, HNF-4PPARand GR, are 
involved in the regulation of CES enzymes.  Because CES enzymes are one of the 
major determinants of the metabolism and disposition of numerous prodrugs through 
their actions in liver and small intestine, elucidating the mechanism governing the 
regulation of CES enzyme expression and activity by NR proteins will have a 
significant impact on rational drug design and the future development of prodrugs.   
    It is well known that activation of NRs, such as PXR and CAR, coordinately 
regulates the expression and activity of numerous drug-metabolizing enzymes as well 
as multiple drug transporter proteins.  Not only can this coordinated regulation protect 
cells from toxic insult, but it also represents the molecular basis for an important class 
of drug-drug interactions in clinical settings.  For example in multi-drug therapy, if 
one drug activates PXR and/or CAR, and the other is administered as a prodrug that is 
metabolized and eliminated by PXR/CAR-target genes, the resulting increased 
biotransformation of the prodrug into an active drug would probably lead to markedly 
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discrepant pharmacological activities and pharmacokinetic behavior, or even serious 
and toxic side effects.  As is the case with several anticancer drugs, there is an 
emerging role for PXR and CAR in regulating CES enzymes that exert an important 
effect on the hydrolytic biotransformation of a number of clinically used drugs and 
prodrugs.  Additional evidence is emerging which points to a key role for PXR in 
regulating blood-brain barrier permeability in response to drug treatment [57, 58], and 
also in modulation of multi-drug resistance and estrogen sensitivity in certain breast 
cancers [59].  Further elucidation of the role of the PXR protein in these clinically 
significant areas will likely produce important information that could be exploited as 
novel targets for cancer treatments. 
    Numerous classes of xenobiotic compounds activate either PXR or CAR including 
numerous clinically prescribed drugs, active compounds in popular herbal remedies, 
several prodrugs that are anti-cancer agents, drug metabolites, and the list is growing.    
Activation of these receptors by anti-cancer drugs would be expected to have profound 
impact on the pharmacokinetics of drug metabolism in patients taking prodrugs 
activated by CES and eliminated by the action of the CYP3A4 enzyme in liver.  
Moreover, both PXR and CAR activities appear to be modulated through alterations in 
post-translational modifications such as phosphorylation [60-63].  It is likely that 
these and other key signaling pathways are altered in patients experiencing disease 
states such as inflammation or diabetes.  There is increasing recognition that key drug 
metabolism pathways are under metabolic control, and are altered in patients who are 
administered drugs while fasting or are cachectic.  Because the activity of PXR and 
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CAR proteins also appear to be under metabolic control [61, 63], these two 
transcription factors are likely to be, in part, responsible for such alterations.  If true, 
this would have enormous implications in the field of drug-drug interactions in the 
most ill cancer patients that are undergoing polytherapy with simultaneous 
pharmacological interventions who are experiencing cachexia.  More research needs 
to be conducted into the possible metabolic control of PXR and CAR activity. 
The observation that treatment with GR and PPAR agonists produces repression 
of CES gene expression in rodent models could also have a significant impact on 
patient care.  If the same is true for humans, it would be expected that the numerous 
clinically prescribed medications and newly discovered drug candidates that work 
through GR and PPAR would suppress the biotransformation of the anticancer 
prodrugs that are targeted for biotransformation by CES enzymes.  Obviously, more 
research is necessary to clearly elucidate differences in the regulation of drug-inducible 
expression and activity of CES enzymes in liver and intestine across species.  This is 
particularly important because of the use of rodent models to determine drug efficacy 
and drug toxicity screening by the pharmaceutical industry.  Thus, continued research 
using knockout mice, “humanized” mouse models, and human cell-based model 
systems will undoubtedly contribute significant knowledge that will elucidate the 
molecular mechanisms governing the regulation of CES enzyme expression and drug 
metabolism activity by these important metabolic enzymes.   This thrust of research 
highlights the importance of monitoring the ratio and efficacy of the conversion of 
prodrug into active drug in patients receiving novel combination therapies.   
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Chapter 3: Post-translational Modification of Pregnane X Receptor 
    3.1 An Introduction to Pregnane X Receptor 
    Pregnane x receptor (PXR, NR1I2) was originally identified on the basis of its 
sequence homology with other nuclear receptor (NR) proteins in the expressed 
sequence tag database.  The full-length mouse PXR cDNA was characterized in 1998 
using the expressed sequence tag to screen a mouse liver cDNA library, and the 
receptor was named PXR based on its activation by pregnane (21-carbon) steroids [1].  
Shortly after its discovery, PXR was classified as a broad specificity receptor that is 
activated by a wide variety of drugs and xenobiotic compounds as a heterodimer with 
RXR.  Upon ligand binding the PXR-RXR heterodimer binds to multiple sites on the 
cytochrome P450 3A (CYP3A) promoter and activates gene expression and provides 
the molecular basis for the induction of CYP3A gene expression by xenobiotics [1-3].   
    Numerous ligands for PXR have been identified across various species, and it is 
now well accepted that a species-specific PXR-activation profile exists.  For example, 
mouse and rat PXR are activated by the CYP3A inducer pregnenalone 16-carbonitrile 
(PCN), whereas PCN has little effect on human and rabbit PXR.  On the other hand, 
rifampicin (Rif) activates human and rabbit PXR but has virtually no effect on the 
mouse and rat receptors [3-6].  In fact, PXR is activated by a broad range of lipophilic 
compounds including a myriad of synthetic and endogenous steroids, certain bile acids, 
and a variety of drugs and plant products.  In contrast to the classic steroid hormone 
receptors, high-affinity (sub-nanomolar) ligands for PXR have not been discovered.  
For example, the lowest EC50 values of steroids that activate PXR are low-micromolar, 
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generally two to three orders of magnitude higher than concentrations found in 
circulating plasma [5, 6].   
    PXR ligands have been shown to stimulate expression of genes that encode 
enzymes involved in the oxidation (phase I), conjugation (phase II) and transport 
(phase III) of xenobiotics.  The first genes shown to be directly regulated by 
ligand-mediated PXR activation were CYP3A family members in both mouse and 
human liver and intestine [1, 3].  Additional phase I drug metabolism gene products 
regulated by PXR include numerous cytochrome P450s, aldehyde dehydrogenases, 
alcohol dehydrogenases, carboxylesterases, and several enzymes involved in heme 
production and support of the CYP cycle such as aminolevulonic acid synthase and 
P450 oxidoreductase [7, 8].  Phase II drug metabolism gene products regulated by 
PXR activation include UDP-glucuronosyl-transferases, sulfotransferases and 
glutathione S-transferases [8-13].  Finally, phase III drug transporters gene products 
regulated by PXR include numerous ATP-binding cassette membrane pumps of the 
multidrug resistant family and organic anion transporting protein 1A4 in rodents 
[14-16]. 
    3.2 Negative Physiological Functions of PXR 
    While the molecular basis for ligand-mediated PXR gene activation programs 
controlling drug metabolism and drug transport activity is relatively well described, 
much less is known about the molecular mechanisms governing the observed 
ligand-dependent repressor function of the PXR protein.  Recent research efforts 
indicate that ligand-mediated activation of PXR negatively regulates several key 
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biochemical functions in liver and intestine including the synthesis of glucose, ketone 
bodies, -oxidation and transport of lipids, as well as inflammatory processes (Figure 
3-1).  The general mechanism for drug-mediated repression of these important 
physiological functions appears to involve protein-protein interactions between 
liganded-PXR and the transcription factors and accessory proteins required for driving 
full-activation of respective programs of gene expression.  The molecular basis for 
reciprocity between these biochemical pathways is currently the focus of several 
research groups, and the biochemical details are currently emerging. 
    3.2.1 Glucose Homeostasis 
Glucose production by liver is tightly controlled by the insulin and glucagon 
signaling pathways.  These counter-regulatory signaling pathways play a critical role 
in survival during fasting and starvation by regulating the transcription of key target 
genes comprising the gluconeogenic gene expression program including 
glucose-6-phosphatase (G6Pase) and phosphoenolpyruvate carboxykinase (PEPCK).  
Glucagon increases glucose production by up-regulating the transcription of key genes 
that encode the rate-limiting enzymes in the gluconeogenic pathway, whereas insulin 
signaling rapidly suppresses the expression of the genes encoding these tightly 
regulated enzymes.  The CREB protein is a cellular transcription factor that binds to 
certain DNA sequences called cyclic AMP response elements (CREs), thereby 
increasing the transcription of downstream genes.   Glucagon stimulates cyclic 
AMP-dependent protein kinase (PKA) that phosphorylates CREB.  
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Figure 3-1 
 
Figure 3-1. Negative Regulation Roles of PXR.  PXR was originally characterized 
for its role in xenobiotic and endobiotic detoxification.  However, recent evidence has 
described a role for PXR in glucose and lipid homeostasis, as well as repression of 
inflammatory programs of gene expression.  A central role for post-translational 
modification of PXR is hypothesized to selectively repress biochemical pathways in 
liver and intestine. 
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PKA-phosphorylated CREB binds to CREs and activates the transcription of genes that 
contain CREs in their promoter such as G6Pase and PEPCK1.  Phosphorylated CREB 
then transactivates the expression of G6Pase and PEPCK.   
    Previous observations have revealed functional links between glucose metabolism 
and PXR-mediated signaling pathways.  For example, it is known that PXR ligands 
repress expression of G6Pase and PEPCK [17-19].  Treatment with the potent rodent 
PXR activator PCN decreased blood glucose levels in fasting wild-type mice, but not in 
PXR-null mice [19].  Moreover, the genes that encode G6Pase and PEPCK are 
decreased in transgenic mice that express a constitutively activated form of human 
PXR [20].  These data suggest that sustained PXR activation actively represses the 
gluconeogenic pathway through interference with or sequestration of transcription 
factors and protein cofactors that are involved in transcriptional regulation. 
    Forkhead box protein O1 (FOXO1) belongs to the forkhead family of transcription 
factors which are characterized by a distinct fork head domain.  In hepatic cells, a 
dephosphorylated form of FOXO1 drives the transcription of G6Pase and PEPCK and 
its presence in the nucleus is required for full activation of the gluconeogenic program 
of gene expression.  Insulin signaling activates the phosphatidylinositol 3-kinase-Akt 
pathway to phosphorylate FOXO1, excluding it from the nucleus and resulting in the 
insulin-dependent repression of G6Pase and PEPCK [21, 22].  Interestingly, FOXO1 
has been shown to interact with several NR proteins to function as either a 
transcriptional corepressor or coactivator protein [23, 24].  Moreover, the FOXO1 
protein was found to function as a coactivator of PXR-mediated gene activation.  In 
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contrast, ligand-mediated activation of PXR suppressed FOXO1 transcriptional 
activity by preventing binding to its response element in target genes such as G6Pase 
and PEPCK [25].   
    It has also been proposed that PXR inhibits the expression of gluconeogenic 
enzymes by interfering with CREB signaling.  PXR activation results in the repression 
of CREB-mediated activation of the G6Pase promoter in both mice and in a human 
hepatocarcinoma cell line.  This apparently occurs through the binding of 
liganded-PXR protein directly to CREB, which thereby prevents CREB interaction 
with the CRE on the G6Pase promoter [19].   
 The NR coactivator protein peroxisome proliferator-activated receptor gamma 
coactivator 1-alpha (PGC-1 is induced by glucagon and coactivates hepatocytes 
nuclear factor 4 (HNF-4-mediated transcription of G6Pase and PEPCK.  
Ligand-activated PXR dissociates PGC-1 from HNF-4 through a direct 
competition/squelching mechanism, thereby repressing the transcription of PEPCK 
and G6Pase [18].  Since PGC-1 is also a co-factor for CREB- and FOXO1-mediated 
expression of gluconeogenic-target genes, a similar mechanism implicating 
sequestration of PGC-1 from these two transcription factors by PXR is likely to be 
responsible for drug-mediated repression of gluconeogenesis.  Hence, the underlying 
molecular mechanism of PXR-mediated repression of glucose production appears to be 
the direct binding of PXR to transcription factors and accessory proteins that activate 
gene expression programs critical for the gluconeogenisis such as FOXO1, CREB, 
HNF4, and PGC-1.   
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    3.2.2 Lipid Metabolism and Ketogenesis 
    It is well known that treatment with drugs, now classified as PXR activators, affect 
lipid metabolism in patients.  For example, treatment with Rif or carbamazepine can 
induce hepatic steatosis, characterized by the abnormal accumulation of triglycerides 
in liver [26, 27].  It appears that drug- and lipid-metabolism are interconnected 
through a complex network of transcriptional regulators that include PXR.  The role 
for PXR in the development of hepatic steatosis raises some concern regarding the 
development and safety of drugs that are potent PXR ligands.  Overall, the role of 
PXR in lipid metabolism and steatosis warrants further investigation, however, recent 
studies indicate a clear role for this receptor in the regulation of hepatic lipid 
metabolism.   
    When blood glucose is low, the liver metabolizes fatty acids via -oxidation to 
provide ketone bodies to extra-hepatic tissues.  Forkhead box A2 (FOXA2) has been 
shown to positively regulate this process by controlling the transcription of target genes 
including carnitine palmitoyltransferase 1A and 3-hydroxy-3-methylglutaryl-CoA 
synthase 2 [28, 29].  It has been suggested that ligand-activated PXR represses hepatic 
energy metabolism by decreasing both -oxidation and ketogenesis.  Treatment with 
PCN down-regulates the expression of genes encoding carnitine palmitoyltransferase 
1A and 3-hydroxy-3-methylglutaryl-CoA synthase 2 in wild type, but not in PXR-null 
mice.  It was further shown that activated PXR and FOXA2 physically interact 
through their ligand- and DNA-binding domains, respectively.  This interaction 
prevents FOXA2 from binding to its response elements and leads to the repression of 
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carnitine palmitoyltransferase 1A and 3-hydroxy-3-methylglutaryl-CoA synthase 2 
[30].  In addition, it has been shown that HNF-4 directly regulates expression of 
carnitine palmitoyltransferase 1A [31].  It has been demonstrated that PXR interferes 
with HNF-4 signaling by targeting PGC-1 and producing a squelching effect [18].  
Since HNF-4 and PGC-1 are jointly involved in the regulation of carnitine 
palmitoyltransferase 1A it is likely that crosstalk with ligand-activated sequestering by 
PXR applies to this gene promoter as well through its interaction with FOXA2. 
    3.2.3 Inflammatory Response 
    Exposure to xenobiotics can impair immune function.  In fact, it is a long-standing 
observation that Rif tends to suppress immunological responses in liver cells [32-34].  
Recent publications have demonstrated a mutual inhibition between PXR and the 
inflammatory mediator nuclear transcription factor kappa B (NF-B), thus providing a 
potential molecular mechanism that links xenobiotic metabolism and inflammation 
[35].  Activation of PXR by Rif suppresses the expression of typical NF-B 
target-genes such as cyclooxygenase-2, tumor necrosis factor  (TNF), intercellular 
adhesion molecule-1 and several interleukins [36].  Conversely, NF-B activation by 
lipopolysaccharide and TNF results in the suppression of CYP3A activity through 
interactions of NF-B with the PXR-retinoid-x-receptor complex [37].  Furthermore, 
hepatocytes derived from PXR-null mice have elevated NF-B target-gene expression 
compared to hepatocytes from wild-type mice.  The PXR-null mice also exhibit 
heightened signs of inflammation in their liver and small bowel [36, 38].  This could 
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be due to the loss of negative regulation of NF-B activity following PXR activation, 
or is perhaps due to inadequate clearance of toxic substances in the absence of PXR. 
    Several fundamental questions remain regarding the molecular mechanisms of 
PXR-mediated gene repression.  For instance, (1) does the selective interaction of 
liganded-PXR with transcription factors and accessory proteins involve 
post-translational modification of the PXR protein?  (2) Is the selective repression of 
specific programs of gene expression dependent upon modification-mediated 
conformational change of the PXR protein? (3) How do ubiquitination, 
phosphorylation, SUMOylation, and acetylation of PXR integrate to affect PXR-target 
gene activation and subsequent biochemical functions in the entero-hepatic system?  It 
is therefore important to briefly review the direct evidence for post-translational 
modification of PXR, and also discuss the likely interplay of ligand binding with the 
ubiquitylation, phosphorylation, SUMOylation, and acetylation status of PXR. 
    3.3 Post-translational Modification of PXR 
    3.3.1 Ubiquitination of PXR 
    While degradation is known to play an important role in NR function [39], 
relatively little is known about the degradation of PXR.  PXR was found to interact 
with suppressor for gal-1, a key component of the 26S proteasome complex, in the 
presence of progesterone but not in the presence of endocrine disrupting chemicals [40].  
A follow up study confirmed that PXR is differentially degraded in response to 
progesterone when compared with endocrine disrupting chemicals [41].  This finding 
suggests that proteasomal-mediated PXR degradation may be differentially affected by 
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various PXR agonists.  The extent to which ubiquitination and/or degradation of PXR 
protein affects glucose, lipid, ketone body, and inflammatory status in mammals is 
worthy of further investigation.    
    Our laboratory has recently developed a cell-based over-expression and western 
blot experimental approach for direct detection of ubiquitinated PXR (Figure 3-2A).  
As expected, detection of ubiquitinated PXR protein is dramatically increased in 
response to pharmacological inhibition of 26S proteasome activity with MG132 
(Figure 3-2B, lane 4).  Interestingly, forced activation of the PKA signaling pathway 
selectively increases the ubiquitination of PXR (Figure 3-2B, lane 6, note the asterisks).  
Notably, pharmacological inhibition of the proteosomal degradation pathway abolishes 
PXR transactivation of the CYP3A4 promoter in reporter gene transfected CV-1 cells 
(Figure 3-2C).  This is consistent with an ubiquitin-dependent promoter clearance 
mechanism, and is highly reminiscent of recent reports detailing similar modes of 
regulation of NR proteins peroxisome proliferator-activated receptor gamma (PPAR, 
NR1C3) and liver-x receptor alpha/beta (LXR, NR1H3/NR1H2) [42-44].  The 
interaction between PXR and the ubiquitin signaling pathway appears to be relatively 
complex and warrants further investigation. 
    3.3.2 Phosphorylation of PXR 
Protein phosphorylation plays an important role in the regulation of PXR function 
[45].  Treatment of mouse hepatocytes with the cyclic AMP-dependent protein kinase 
(PKA) activator 8-Bromo-cyclic AMP increased the induction of Cyp3a11 by the PXR  
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Figure 3-2A 
 
Figure 3-2. Ubiquitination of PXR.  (A) Mammalian expression vectors encoding 
affinity-tagged (6X-histidine) ubiquitin and human PXR are introduced into cultured 
HeLa cells using lipofectamin as described [36].  Twenty-four hours post-transfection, 
cells were treated with Rif (10 M), MG132 (25 M), 8-Bromo cyclic AMP (0.5 mM, 
8-Br-cAMP), or 8-bromo cyclic GMP (0.5 mM, 8-Br-cGMP) for an additional 24 
hours.  Whole-cell lysates were generated using denaturing conditions as described 
[64].   
 
 
 
 
 40 
Figure 3-2B 
 
Figure 3-2. Ubiquitination of PXR.  (B) Western blotting was performed using a 
monoclonal antibody specific for human PXR (sc-48340, Santa Cruz).   
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Figure 3-2C 
 
Figure 3-2. Ubiquitination of PXR.  (C)  The PXR-dependent XREM-LUC 
reporter gene [2] was transfected together with an expression vector encoding human 
PXR.  24 hours post-transfection, cells were treated with vehicle, Rif (10mM), ALLN 
(100 M), MG132 (25 M), or lactacystin (10 M) for an additional 24 hours.  The 
data are reported as relative light units and represent the mean of assays performed in 
triplicate ± SE.  
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agonist taxol and enhanced the binding of mouse PXR to the transcriptional coactivator 
proteins Steroid Receptor Coactivator-1 and Peroxisome Proliferator-activated 
Receptor (PPAR)-binding Protein.  Furthermore, kinase assays show that PXR can 
serve as a substrate for catalytically active PKA in vitro, suggesting one potential 
mechanism for PKA-mediated modulation of CYP3A gene expression [46].  
Additionally, there appears to be significant species differences in the effect of kinase 
signaling pathways.  For example, while PKA activation increases PXR activity in 
mouse hepatocytes, it serves as a repressive signal in both human and rat hepatocytes.  
Similar to the PXR-ligand response, this suggests a species-specific effect for the 
modulation of drug-inducible CYP3A gene expression by PKA signaling [47].   
    Activation of protein kinase C signaling by phorbol myristate acetate repressed 
PXR activity in reporter gene assays and in hepatocytes by increasing the strength of 
interaction between PXR and the nuclear receptor corepressor (NCoR) protein, and by 
abolishing the ligand-dependent interaction between PXR and Steroid Receptor 
Coactivator-1.  Interestingly, the protein phosphatase PP1/2A inhibitor okadaic acid 
strongly represses PXR-dependent transactivation [48].  In addition, cyclin-dependent 
kinase 2 (Cdk2) attenuated the activation of CYP3A4 gene expression. PXR is a 
suitable substrate for the Cdk2 enzyme in vitro, and a phosphomimetic mutation at a 
putative Cdk2 phosphorylation site at (S350D) impaired the function of human PXR, 
whereas a phosphorylation-deficient mutation (S350A) conferred resistance to the 
repressive effects of Cdk2 on a reporter gene in HepG2 cells [49].  The results of these 
studies confirm that the activity of PXR is modulated by changes in its overall 
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phosphorylation status.  Determining whether phosphorylation of PXR at specific 
sites influences the integration between cell-signaling pathways and PXR-mediated 
repression remains an open and important question for future research. 
    3.3.3 SUMOylation of PXR 
    Long-term treatment of patients with Rif inhibits the inflammatory-response in 
liver [34, 37].  Though the molecular basis for this phenomenon has remained obscure, 
it was recently predicted that it should involve SUMOylation of PXR in intestine and 
liver [50].  We have demonstrated that activation of the inflammatory response in 
hepatocytes strongly modulates the SUMOylation status of ligand-bound PXR [38].  
The SUMOylated PXR protein contains SUMO2/3 chains and feedback represses the 
immune response in hepatocytes and likely in intestinal tissue as well.  Future studies 
of SUMOylation are expected to provide a novel paradigm that uniquely defines the 
molecular basis of the interface between PXR-mediated gene activation, drug 
metabolism and inflammation in intestine and liver tissue. 
A non-biased approach for identification of the sites and molecular mechanisms of 
PXR SUMOylation is badly needed.  We have therefore designed a strategy that is 
based upon a very recent report in the literature [51].  Our experimental approach 
utilizes a forced over-expression cell-based assay and is depicted in figure 3-3A.  A 
novel SUMO expression construct based on the amino acid sequence of SUMO-3 
encodes a protein which we have termed SUMO-X, and the amino acid substitutions 
are depicted in figure 3-3B.  
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The SUMO-X protein incorporates several key features to allow non-biased 
enrichment and identification of SUMOylated PXR peptides produced in vitro, in 
cultured cells, or in live animals.  This novel strategy creates an identifiable diglycil 
lysine signature tag on SUMOylated PXR peptides that will be detected by mass 
spectrometry.   The key amino acid substitutions in SUMO-X are depicted in red 
lettering in Figure 3-3C.  The SUMO-X contains an N-terminal 6X-histidine-tag that 
allows enrichment of total SUMOylated substrates from an in vitro mixture or from 
whole-cell lysate (Figure 3-3C, Step1).  Cleavage of SUMOylated proteins with the 
LysC protease will produce predictable branched peptides as a result of the substitution 
mutation in SUMO-X at position 82 (T82K) in combination with the lysine residues 
contained in SUMO-substrates.  The substitution of valine and glutamine amino acid 
residues in SUMO-3 with cysteine residues at positions 85 and 87 in SUMO-X (V85C 
and Q87C) creates a unique second affinity-tag for use with thiopropyl sepharose beads 
(Figure 3-3C, Step 2).  This second enrichment step will allow immobilization of the 
desired SUMOylated peptides from a complex mixture.  The site-directed mutation in 
SUMO-X at position 90 (T90K) produces a unique Trypsin cleavage site and leaves the 
diglycyl lysine tag intact on the SUMOylated peptides.  The resulting modified 
peptides will then be detected using a mass spectrometry-based approach.  The 
SUMO-X reagent is adaptable to expression using viral vectors for subsequent 
transduction of primary cultures of hepatocytes, as well as for mouse model systems 
using tail vein injection methods for delivery and isolation of the SUMO-X-labeled 
substrate proteins in vivo.   
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    This novel experimental approach should overcome the observed low 
stoichiometry of SUMOylated substrates within cells, and will likely provide a 
non-biased molecular tool for identification of novel signal-mediated SUMO-3 
substrates.  When coupled with a proteomic approach, this 2-step enrichment strategy 
has previously been used to identify susbstrates and non-consensus SUMO-1 sites in 
cells [52].  As a proof-of-concept, we show here that Ubc9 increases SUMOylation of 
PXR by SUMO-3 in transfected HeLa cells.  Interestingly, over-expression of 
E3-SUMO-ligase family members PIAS1 and PIAS4 also increases SUMOylated form 
of PXR in cultured HeLa cells (Figure 3-3D, compare left panel and middle panel).   
When SUMO-X is substituted for SUMO-3, we observe a similar result (Figure 
3-3D, right panel).  A close examination of the SUMO-modified form of PXR reveals 
that PIAS4 functions as a more effective E3 ligase enzyme when compared with PIAS1.  
Moreover, Ubc9, PIAS1, and PIAS4 can increase SUMO-modified forms of PXR 
independently.  Finally, we note that SUMO-X does not appear to support chain 
formation on PXR as efficiently as wild-type SUMO-3, with the SUMO-X construct 
supporting mainly two primary sites of modification (Figure 3-3, note asterisks).  This 
is highly reminiscent of NR PPAR that also has two primary sites for SUMOylation 
(K77 and K365).  It is interesting to note that only one of the SUMOylation sites 
(K365) serves as the functional link between ligand-activated PPAR and its ability to 
transrepress NF-kB activity [43].  
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Figure 3-3A 
 
Figure 3-3. SUMOylation of PXR.  (A) Mammalian expression vectors encoding 
affinity-tagged (6X-histindine) SUMO-3 and human PXR are introduced into cultured 
HeLa cells in the presence and absence of E2 ligase (Ubc9), and the E3 ligase enzymes 
PIAS1 or PIAS4.  48 hours post-transfection, whole-cell lysates were generated as 
described [64].  
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Figure 3-3B 
 
Figure 3-3. SUMOylation of PXR.  (B) The SUMO-X protein incorporates several 
key point mutations to allow non-biased enrichment and identification of SUMOylated 
PXR peptides when expressed together with substrates in vitro, in cultured cells, or in 
live animals. 
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Figure 3-3C 
 
Figure 3-3. SUMOylation of PXR.  (C) Key altered amino acid residues are colored in RED.  
Sumo-tagged Lysine residues are protected from digestion with LysC protease.  The 
SUMOylated peptide of interest is indicated with GOLD color.  STEP1.  The PXR protein is 
SUMOylated and enriched using Nickel-agarose beads.  After washing, LysC cleavage results 
in the release of the cysteine tag from the rest of SUMOX.  The substrate is also digested, but 
the SUMOylated Lysine residue is protected from cleavage.  STEP2.  Using thiopropyl 
sepharose, the SUMOylated cysteine peptides are covalently retained.  The target peptides are 
eluted with trypsin digestion, and the diglycine (GG)-modifed target lysine in PXR is identified 
as a SUMOylation site using LC-MS/MS. 
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Figure 3-3D 
 
Figure 3-3. SUMOylation of PXR.  (D) The cDNAs encoding His-SUMO-3, 
His-SUMOX, Ubc9, PIAS1, or PIAS4 were transfected alone or together as indicated.  
Isolated PXR protein was detected using a monoclonal antibody that recognizes human 
PXR. 
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    3.3.4 Acetylation of PXR 
Recent evidence suggests that down-regulation of P300-induced 
farnesoid-x-receptor (FXR, NR1H4) acetylation alters expression of FXR-target genes 
involved in lipoprotein and glucose metabolism [53].  A more recent follow-up study 
indicates that FXR is a target of silent mating type information regulation 2 
homolog-SIRT1, a protein deacetylase that mediates nutritional and hormonal 
modulation of hepatic energy metabolism.  The lysine residue in FXR at position 217 
(K217) is the major acetylation site targeted by p300 and SIRT1.  Acetylation of FXR 
increases its stability but inhibits heterodimerization with RXR, DNA binding, and 
transactivation activity [54].  By analogy, PXR is also the likely target of acetylation, 
however, the extent to which PXR is targeted by SIRT1 or p300 is currently unknown.  
An experimental approach using 6X-histidine-tagged human PXR coupled with 
western-blotting analysis utilizing antibodies that recognize acetyl-lysine has been 
recently developed (Figure 3-4A).  Acetylation of PXR is readily detected using this 
experimental approach (Figure 3-4B).  These recently published data strongly 
suggests that PXR is acetylated at some level [55].  The effect of PXR acetylation and 
metabolic status on ligand-mediated PXR gene activation pathways is currently not 
well characterized.  Interestingly, decreased capacity for drug metabolism is observed 
in patients with morbid obesity, hepatic steatosis, and non-alcoholic steatohepatitis 
[56-58].  Future research efforts should seek to determine the extent to which 
acetylation of PXR is involved in crosstalk between drug metabolism and energy 
metabolism.  
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Figure 3-4A 
 
Figure 3-4. Acetylation of PXR.  (A) Cultured 293T cells are transfected with either 
a His-tagged human PXR expression construct (pcDNA-His-hPXR) or an empty 
pcDNA-His vector plasmid as a negative control. 
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Figure 3-4B 
 
Figure 3-4. Acetylation of PXR.  (B) Captured proteins from nuclear extracts were 
subjected to SDS-PAGE and subsequent western blot analysis using an antibody that 
recognizes either human PXR (top panel) or acetyl-lysine (bottom panel). 
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    3.4 Conclusions 
    PXR was originally characterized as a regulator of the homeostatic control of 
steroids, bile acid, and xenobiotics.  However recent evidence has revealed a negative 
regulatory role for PXR in gluconeogenesis, lipid metabolism, and inflammation 
through either direct regulation or signal-activated crosstalk with other transcription 
factors.  Ligand binding is the primary mode of PXR activation, but several signaling 
pathways also interface with PXR and affect its overall responsiveness to 
environmental stimuli, likely by altering the post-translational modification status of 
PXR and subsequent interaction with its associated protein partners.  The extent to 
which competitive post-translational modifications of PXR at individual lysine 
residues by SUMO-, Acetyl-, and ubiquitin-modification is strongly suspected; 
however, the data are just beginning to emerge.    
    Crosstalk between phosphorylation, SUMOylation, ubiquitination or acetylation 
has been demonstrated in studies of other transcriptional regulators including NFκB 
and p53 [59, 60], and this area needs to be further explored with respect to 
post-translational modification of PXR.  Moreover, virtually nothing is known about 
the signal- or cell-type-dependent regulation of the machinery involved in generating 
these post-translational modifications with respect to PXR.  It is well known that 
various cellular stresses including heat shock, osmotic stress, and reactive oxygen 
species can globally affect SUMO conjugation and deconjugation where examined 
using a proteomic approach [61-63].  Whether specific changes in post-translational 
modification of PXR also occurs in response to metabolic, pathogenic, and xenobiotic 
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stress associated with diseases and infection remains an interesting future issue to be 
explored.  Finally, pharmacological manipulation of the complex network of factors 
that contribute to PXR activity present therapeutic opportunities in the treatment of 
numerous diseases including lipid and inflammatory disorders. 
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Chapter 4: Regulation of Tissue-specific Carboxylesterase Expression 
by Pregnane X Receptor and Constitutive Androstane Receptor 
    4.1 Introduction 
    Carboxylesterase (CES) enzymes comprise a multi-gene family, and are 
dominantly involved in hydrolysis activity in liver and small intestine of mammals [1].   
These enzymes participate in the biotransformation of a wide range of ester- and 
amide-containing drugs and prodrugs including angiotensin-converting enzyme 
inhibitors, anti-tumor drugs, and narcotics such as cocaine and heroin [2-4].  Members 
of the CES family of enzymes also hydrolyze numerous endogenous compounds 
including short and long-chain acyl-glycerols, long-chain acyl-carnitine, and 
long-chain acyl-CoA esters [1].   
    The mouse Ces6 gene was first identified in 2004 and encodes a protein of 558 
amino acid residues in length [5].  In this same study, the Ces6 gene product was 
found to hydrolyze selected pyrethroid compounds, a major class of insecticides used 
worldwide and extensively in the United States.  The closest relative of the mouse 
Ces6 protein in humans is the CES2 enzyme, as these two orthologous proteins are 
approximately 61% identical and 72% similar when compared at the amino acid level.    
    Like the human CES2 enzyme, mouse Ces6 is expressed in a liver- and 
intestine-enriched manner.  The CES2 enzyme has come under recent scrutiny 
because it catalyzes the hydrolysis of several clinically used anti-cancer agents that are 
administered as pro-drugs.  Specifically, CES2 is a high-affinity, high-velocity 
enzyme with respect to the pro-drug 7-Ethyl-10-[4-(1-piperidino)- 1-piperidino] 
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carbonyloxy-camptothecin, also called irinotecan, and likely plays a substantial role in 
irinotecan bioactivation in human liver and intestine at relevant pharmacological 
concentrations [4].  While much is known regarding the role of carboxylesterase 
enzymes in biotransformation of prodrugs, little is known regarding the tissue-specific 
transcriptional regulation of these important drug metabolizing enzymes in vivo in 
tissues such as liver and intestine.   
    Nuclear receptors comprise a superfamily of ligand-activated transcriptional 
factors that are involved in diverse physiological, developmental and metabolic 
processes.  The pregnane X receptor (PXR, NR1I2) and constitutive androstane 
receptor (CAR, NR1I3) are two closely related members of „xenobiotic-sensing‟ 
nuclear receptors among this family.  It is now well established that PXR is a key 
regulator of xenobiotic-inducible CYP3A gene expression in liver (reviewed in [6]).  
PXR also regulates the drug-inducible expression and activity of genes encoding key 
members of the CYP2B and CYP2C sub-family of enzymes in liver; as well as the 
drug-inducible expression and activity of several glutathione S-transferase (GST), 
sulfotransferase (SULT), and UDP-glucuronosyltrasferase (UGT) enzymes in liver 
[7-10].  PXR-target genes also encode key hepatic drug transporter proteins such as 
Oatp2, Mdr1/P-glycoprotein, Mrp2, and Mrp3 [11-13].  Recent reports indicate a key 
role for human PXR in regulating the expression of the CES2 gene in human 
hepatocytes and the human hepatoma cell-line, Huh-7, in culture [14].  Other reports 
suggest a positive role for rat PXR in regulating liver-enriched expression of 
carboxylesterase enzymes in rodents [10, 15, 16].  Earlier research indicates that 
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over-expression of constitutively active human PXR increases the expression of mouse 
genes encoding Ces2 and Ces3 enzymes in mouse liver [17]. 
    The nuclear receptor CAR is also recognized as a „xenobiotic-sensing‟ nuclear 
receptor that is mainly expressed in hepatic tissue.  It was originally demonstrated to 
regulate the phenobarbital (PB)-inducible expression of several genes encoding 
important members of the CYP2B sub-family of enzymes [18].  CAR has since been 
shown to regulate the expression and activity of a number of phase I and phase II 
metabolic enzymes, as well as the expression and activity of numerous important 
membrane transporter proteins involved in the elimination of endogenous and 
exogenous substances including bilirubin, steroid hormones, and xenobiotics [19].  
Definitive reports linking CAR activation to drug-inducible carboxylesterase gene 
expression in any species or tissue are currently lacking.  However, historical reports 
indicate that treatment of rodents with PB or PB-like inducers significantly increases 
carboxyleserase expression and activity in liver tissue [20].  Distinct, yet overlapping 
functions of PXR and CAR in liver have been described previously [7, 9], and it is well 
established that these two receptors form the molecular basis of an important class of 
drug-drug interactions through their actions in liver.  While much is known regarding 
the identity and function of PXR-target genes in liver, less is known about its function 
in small intestine. 
In the present study, we report the identification of several PCN-inducible genes in 
duodenum of wild type mice using microarray analysis.  Among the PCN-inducible 
genes identified here, expression of the gene encoding the Ces6 protein was further 
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characterized with respect to its basal and drug-inducible expression in liver and 
intestine.  By exploiting the Pxr knockout (PXR-KO) and Car knockout (CAR-KO) 
mouse models, we reveal that in both duodenum and liver tissues, the drug-inducible 
expression of Ces6 is regulated by both PXR and CAR.  Our data conclusively show 
that Ces6 is a shared PXR- and CAR-target gene in mice.  Interestingly, in small 
intestine, despite significant expression of the CAR nuclear receptor, expression of the 
Ces6 gene is exclusively regulated by i.p. treatment with the prototypical CAR agonist 
1,4-bis[2-(3,5-dichloropyridyloxy)] benzene (TCPOBOP) and not by i.p. treatment of 
mice with PB.  These data suggest that there may be significant differences in the 
bioavailability of PB and TCPOBOP in intestine following treatment with these two 
CAR activators that can produce variable results.  Alternatively, differences in the 
mode of CAR activation, either phosphorylation-dependent in the case of PB or direct 
ligand-mediated activation in the case of TCPOBOP, can likely produce tissue-specific 
differences when using these two compounds to activate the CAR nuclear receptor in 
intestine and liver tissue in vivo.  In any case, these data reveal that liver- and 
intestine-enriched carboxylesterase expression and activity is likely modulated in 
humans on combination therapy in a clinically significant manner.  This is of 
particular importance as numerous drug development programs seek to take advantage 
of intestine- and liver-enriched carboxylesterase enzymes as convenient targets for 
delivery of increasing numbers of pro-drugs. 
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    4.2 Materials and Methods 
    Animal Care.  All rodents were maintained on standard laboratory chow and 
allowed food and water ad libitum.  All mice were treated once a day i.p. with either 
vehicle (corn oil, saline), pregnenalone 16-carbonitrile (PCN) (100 mg/kg in corn oil), 
TCPOBOP (3 mg/kg in corn oil), or phenobarbital (PB) (100 mg/kg in saline) for 4 
days.  The studies reported here have been carried out in accordance with the 
Declaration of Helsinki and/or with the Guide for the Care and Use of Laboratory 
Animals as adopted and promulgated by the National Institutes of Health.   
    Drugs and Chemicals.  Unless otherwise stated, all chemical compounds were 
purchased from Sigma-Aldrich (St. Louis, Mo).  Antibody against CES6 was 
purchased from Abcam Inc. (Cambridge, Ma).  The anti-Cyp3a23 antibody that cross 
reacts with mouse Cyp3a11 protein was used to probe immunoblots (Chemicon).  The 
anti-Cyp2b10 antibody was obtained from Millipore (Temecula, Ca)  
    Microarray Analysis.  Total RNA was isolated from duodenums of wild-type 
mice using TRIzol reagent (Invitrogen) according to the manufacturer‟s instructions.  
The quality and quantity of the total RNA samples were examined with both UV 
spectrophotometry using a Nanodrop (ND-1000) and Bioanalyzer 2100.  For the 
subsequent micorarray study, Affymetrix Mouse Genome GeneChip 430 2.0 
oligonucleotide arrays were employed that cover over 39,000 transcripts from the 
mouse genome.  To carry out the GeneChip analysis, established standard protocols at 
the University of Kansas Genomics Facility were performed on cRNA target 
preparation, array hybridization, washing, staining and image scanning.  After they 
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were generated from the Affymetrix GeneChip Operating Software (GCOS.v1.2), the 
microarray data was first subjected to quality assessment.  All GeneChip data passed 
the quality control (QC) step since data of all chips met established Affymetrix 
GeneChip QC criteria including low background, low noise, positive detection of QC 
probe sets such as bioB, percentage of called present in the normal range (40-60%), 
similar scaling factors across chips, and 3‟/5‟ ratio.  Due to its known response to PCN, 
Cyp3a11 was also used as a positive control in this study.  
    Microarray Data Analysis.  To facilitate direct comparison of gene expression 
data between the PCN- and vehicle-treated samples, the GeneChip data were first 
subjected to preprocessing including background correction, probe summarization and 
normalization using the Affymetrix MAS5 algorithm.  All chips were scaled to a 
target signal of 500.  Prior to identification of differentially expressed genes, genes 
that were called „Absent‟ by the MAS5 algorithm were filtered out.  A volcano-plot 
based approach was subsequently used to identify PCN-inducible gene expression.  
The expression value of a PCN-inducible gene had to pass two criteria, (1) the fold 
change between the compound treatment and the negative control had to be ≥ 1.5, and 
(2) the P value from parametric test using all available error estimates had to be ≤ 0.05. 
    Real-time Quantitative PCR.  After DNase I treatment, 1 g of RNA was reverse 
transcribed using random primers following the manufacturer‟s instruction (Promega).  
Equal amounts of cDNA were used in real-time quantitative PCR reactions.  
Reactions included 200 nM fluorogenic probe and 300 nM primers specific for each 
gene.  The fluorogenic probe and primer sets were designed using the Primer3 
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program (http://frodo.wi.mit.edu/).  The fluorogenic probes were synthesized by 
BioSearch Technologies (Novato, CA).  The sequences (5‟ to 3‟) for the primers and 
probes are as follows: Cyp3a11, forward primer (CAAGGAGATGTTCCCTGTCA), 
fluorogenic probe (FAM-AGAAGGC AAAGAAAGGCAAGCCTG-BHQ1), reverse 
primer (CCACGTTCACTCC AAATGAT); Cyp2b10, forward primer 
(GACTTTGGGATGGGAAAGAG), fluorogenic probe 
(FAM-TAGTGGAGGAACTGCGGAAATCCC-BHQ1), reverse primer 
(CCAAACACAATGGAGCAGAT).  For the Ces6 and 18S genes, 1× SYBR Green 
(BioWhittaker Molecular Applications) was included in the reaction instead of the 
fluorogenic probe. The sequences (5‟ to 3‟) for the Ces6 and 18S are as follows: Ces6, 
forward primer (GTGTGAGAGATGGGACCTCA), reverse primer 
(TCATTCATGGAAGCTGATCC); 18S, forward primer 
(AGTCCCTGCCCTTTGTACACA), reverse primer (CGATCCGAGGGC 
CTCACTA).  Cycling conditions were 95 
0
C for 2 min followed by 45 cycles of 95 
0
C 
for 15 s, 60 
0
C for 15 s, and 68 
0
C for 15 s using the Cepheid Smart Cycler system 
(Sunnyvale, CA).  The fold induction was calculated as described previously [13]. 
    Northern Blot Analysis.  Total RNA was isolated as described in Real-time 
quantitative PCR, and 20 g total RNA per lane were resolved on 3.7% 
formaldehyde/1% agarose gel in MOPS buffer for northern blot analysis.  Blots were 
hybridized with 
32
P-labeled cDNA corresponding to the sequences for mouse Ces6, 
Cyp3a11, and Cyp2b10, and 18S ribosomal RNA as described previously [21]. 
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    Western Blot Analysis.  Approximatedly 250 mg of liver tissue was homogenized 
using a Dounce Teflon homogenizer in 1 ml of homogenization buffer (50 mM 
Tris-HCl, pH 7.4 at 4
0
C containing 150 mM KCl and 2 mM EDTA).  The homogenate 
was subjected to centrifugation at 500 x g for 15 min at 4 
0
C to remove cell debris and 
nuclei.  The supernatant fraction was subjected to centrifugation at 12,000 x g for 15 
min at 4
0
C.  Microsomes were prepared by ultracentrifugation (50,000 x g for 60 min 
at 4
0
C) of the postmitochondrial supernatant fraction.  The first microsomal pellet was 
resuspended in wash buffer (10 mM EDTA containing 150 mM KCl), then re-isolated 
by ultracentrifugation (50,000 x g for 60 min at 4
0
C).  The washed microsomes were 
suspended in a small volume of 250 mM sucrose.  Liver microsomal protein (20 
µg/lane) were resolved on 10% SDS-PAGE gels and transferred to PVDF microporous 
membranes (Millipore) that were probed with anti-Ces6, anti-Cyp3A23, and 
anti-Cyp2b10 antibodies.  Immunodetection was performed using the ECL kit 
(Amersham) according to the protocol provided by the manufacturer.  Quantitative 
densotometric analyses of western blot images were achieved using the digital Kodak 
EDAS 290 image acquisition system together with the 1D image analysis software 
package. 
Statistical Analyisis.  Statistical differences between treatment groups were 
determined using a one-way ANOVA followed by the Duncan‟s multiple range 
post-hoc test. 
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    4.3 Results 
    The Basal Expression Profiles of Mouse Cyp3a11, Pxr, and Car in Liver, 
Duodenum, Jejunum, and Ileum.  Liver and small intestine are two major organs that 
play an important and primary role in regulating the metabolism, transport, excretion, 
and efflux of xenobiotic compounds.  The relative expression levels of mouse genes 
encoding Cyp3a11, Pxr, and Car in three individual wild type mice were determined 
using total RNA isolated from liver, duodenum, jejunum and ileum (Figure 4-1).  The 
expression of the Cyp3a11 gene was highest in mouse liver, followed by a significant 
reduction of approximately 60% in duodenum.  The Cyp3a11 transcript in jejunum 
and ileum was virtually undetectable.  The expression level of Pxr was also 
determined.  The Pxr mRNA was expressed at the highest levels in liver, with lower 
but easily detectable levels observed in duodenum, jejunum, and ileum.  The Pxr 
mRNA was approximately 60% of that observed in liver when examined in duodenum, 
jejunum, and ileum, respectively.  The expression level of Car was then determined.  
The Car gene was expressed at the highest level in liver, with slightly lower but easily 
detectable expression levels observed in duodenum, jejunum, and ileum. 
Detection of PCN-inducible Cyp3a11 Gene Expression in Duodenum.  Prior to 
performing microarray analysis, we sought to determine whether the known 
PXR-target gene, Cyp3a11, was induced in small intestine following administration of 
PCN, a well-known rodent PXR activator.  Wild type mice (n=3) were treated for four 
days using an i.p. injection of either vehicle (corn oil) or PCN (100 mg/kg).  On the 
morning of day 5, tissues were harvested and total RNA was isolated from the entire  
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Figure 4-1 
 
Figure 4-1. The basal expression of Cyp3a11, Pxr, and Car gene expression levels 
in liver, duodenum, jejunum, and ileum.  Total RNA was isolated from liver, 
duodenum, jejunum, and ileum of 6-week old wild type mice. Real-time quantitative 
PCR analysis was performed in order to measure the relative abundance of the 
transcripts using reverse transcribed cDNA from all tissues examined.  All data are 
normalized to 18S levels and are expressed relative to that observed in liver and 
represent average values ± SEM (n = 3).  Letters different from each other indicate a 
statistical difference between treatment groups (p<0.05). 
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small intestine and resolved on an agarose gel for subsequent northern blotting using a 
cDNA probe to detect Cyp3a11 expression levels.  This analysis revealed that 
Cyp3a11 gene expression was induced in small intestine by treatment with PCN (data 
not shown).  These data indicate that PXR-mediated target gene activation is 
completely intact in the small intestine of wild type mice.  Induction of Cyp3a11 gene 
expression was absent from duodenal tissue isolated from PXR-KO mice (data not 
shown).  Taken together with the data obtained in figure 4-1, we reasoned that 
treatment of wild type mice with PCN should produce robust induction of PXR-target 
genes in the duodenum and that microarray analysis should detect PXR-mediated gene 
activation. 
    Detection of PCN-responsive Genes in Mouse Duodenum by Microarray.  In 
order to identify novel PXR-target genes in mouse duodenum, we performed 
microarray analyses using GeneChip Mouse Genome 430 2.0 oligonucleotide arrays 
from Affymetrix, which interrogate over 39,000 transcripts encompassing the entire 
mouse genome.  As expected, the expression of the prototypical PXR-target gene, 
Cyp3a11, was increased approximately 1.8-fold following treatment with the known 
PXR activator, PCN, in duodenum.  Several additional CYP genes were increased by 
treatment with PCN including Cyp2C55, Cyp2C29, and Cyp3a25, by approximately 
3.9-fold, 3.3-fold, and 2.0-fold, respectively.  Seven genes encoding distinct members 
of the glutathione S-transferase family of enzymes were up-regulated following 
treatment with PCN.  Three different glutathione S-transferase mu isoenzymes were 
increased following treatment with PCN including the Gstm1, Gstm3, and Gstm6 
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isoforms by 5.3-fold, 2.6-fold, and 1.9-fold, respectively.  The glutathione 
S-transferase Gsta2 and Gsta4 isoforms were increased following treatment with PCN 
by 2.2-fold and 1.9-fold, respectively.  The microsomal glutathione S-transferase 
Mgst1 and Mgst2 enzymes were increased 1.6-fold and 2.0-fold, respectively.  The 
gene encoding microsomal epoxide hydrolase was increased approximately 7.0-fold 
following treatment with PCN.  Table 4-1 shows a complete listing of selected genes 
identified following this analysis.  The gene that was induced to the highest absolute 
level as judged by the overall strength of the signal detected from the PCN-treated 
sample following Cyp3a11 and Gsta2 was Ces6.  Therefore, we chose to further 
characterize the potential role of PXR and CAR in modulating the drug-inducible 
expression of this gene in both liver and intestine. 
Regulation of Ces6 mRNA by PCN in Mouse Duodenum is PXR-dependent.  To 
determine whether Ces6 represents a bona fide PXR-target gene in duodenum, we 
performed both northern blot and real-time quantitative PCR (rt-QPCR) analysis using 
wild type and PXR-KO mice.  Northern blot analysis using total RNA isolated from 
the duodenum of three individual animals was performed to determine the relative 
expression levels of both Cyp3a11 and Ces6 (Figure 4-2A).  Treatment of wild type 
mice with PCN produced marked increases in Ces6 and Cyp3a11 mRNA levels, 
however, PCN-inducible increases in the expression of both the Ces6 and Cyp3a11 
mRNAs were totally absent when the analysis was performed using total RNA isolated 
from the duodenum of individual PXR-KO mice.  The results obtained using northern 
blot analysis were quantified using rt-QPCR (Figure 4-2B).  The Ces6 (left panel) and  
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Table 4-1. Genes Up-regulated by PCN Treatment in Duodenum 
 
Gene 
Fold 
Induction 
Description 
Ephx1 7.0 Epoxide hydrolase 1, microsomal 
Gstm1 5.3 Glutathione S-transferase, mu 1 
Gstm3 2.6 Glutathione S-transferase, mu 3 
Gstm6 1.9 Glutathione S-transferase, mu 6 
Cyp2c55 3.9 Cytochrome P450, family 2, subfamily c, polypeptide 55 
Cyp2c29 3.3 Cytochrome P450, family 2, subfamily c, polypeptide 29 
Cyp3a25 2.0 Cytochrome P450, family 3, subfamily a, polypeptide 25 
Cyp3a11 1.8 Cytochrome P450, family 3, subfamily a, polypeptide 11 
Ces6 3.2 Carboxylesterase 6 
Akr1b7 3.0 Aldo-keto reductase family 1, member B7 
Hsd17b11 2.4 Hydroxysteroid 17-beta dehydrogenase 9 
Gsta4 2.2 Glutathione S-transferase, alpha 4 
Gsta2 1.9 Glutathione S-transferase, alpha 2 (Yc2) 
Mgst2 2.0 Microsomal glutathione S-transferase 2 
Mgst1 1.6 Microsomal glutathione S-transferase 1 
Abca1 2.0 ATP-binding cassette, sub-family A (ABC1), member 1 
Aldh1a7 1.9 Aldehyde dehydrogenase family 1, subfamily A1 
Pdk4 1.8 Pyruvate dehydrogenase kinase 4 
Sgk 1.7 Serum/glucocorticoid regulated kinase 
Hpgd 1.7 Hydroxyprostaglandin dehydrogenase 15 (NAD) 
Dbi 1.6 Diazepam binding inhibitor 
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Figure 4-2A 
 
Figure 4-2. Induction of Ces6 and Cyp3a11 gene expression by PCN treatment in 
mouse duodenum is PXR-dependent.  Total RNA was isolated from the duodenum 
of wild type and PXR knockout mice (n=3) treated i.p. with vehicle (corn oil) or PCN 
(100 mg/kg) for 4 days.  (A) Northern blot analysis was performed using 20 g total 
RNA/lane and the blots were probed sequentially with 
32
P-labeled cDNA fragments 
encoding Ces6, Cyp3a11, and 18S ribosomal RNA.  Each lane represents an 
individual animal.   
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Figure 4-2B 
 
Figure 4-2. Induction of Ces6 and Cyp3a11 gene expression by PCN treatment in 
mouse duodenum is PXR-dependent.  Total RNA was isolated from the duodenum 
of wild type and PXR knockout mice (n=3) treated i.p. with vehicle (corn oil) or PCN 
(100 mg/kg) for 4 days.  (B) Real-time quantitative PCR analyses were performed to 
determine the expression levels of Ces6 and Cyp3a11.  All data are normalized to 18S 
levels and represent the average values ± SEM (n=5) and are expressed as fold 
induction over vehicle control.  Letters different from each other indicate a statistical 
difference between treatment groups (p<0.05).  
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Cyp3a11 (right panel) mRNAs exhibited a significant increase in their expression level, 
respectively, with each gene exhibiting an approximate increase of 5-fold in wild type 
mice.  In contrast, no significant increases in expression were detected when total 
RNA was analyzed from the duodenum of PXR-KO mice.  
    Regulation of Drug-inducible Ces6 is PXR- and CAR-dependent.  A number of 
studies have shown that PCN treatment induces Cyp3a11 gene expression in both 
mouse liver and intestine [22-24].  Other research has shown that PXR and CAR share 
distinct but overlapping target genes in liver [9, 25-27].  We next investigated whether 
induction of Ces6 gene expression in liver and intestine by treatment with PCN, 
TCPOBOP, or PB is dependent upon PXR or CAR.  We therefore treated wild type, 
PXR-KO, and CAR-KO mice with vehicle, PCN, TCPOBOP, or PB and isolated total 
RNA from liver and duodenum and microsomes from liver for subsequent analysis of 
gene expression and protein levels, respectively.  We first analyzed Ces6 and 
Cyp3a11 gene expression levels using northern blot analysis (Figure 4-3A).  As 
expected, treatment of wild type mice with PCN produced increased levels of Cyp3a11 
gene expression in liver in a PXR-dependent manner.  Treatment with PCN also 
produced increased Ces6 mRNA levels in liver in a PXR-dependent manner.  
Subsequent quantitative analysis using rt-QPCR analysis revealed that statistically 
significant induction of both Ces6 (left panel) and Cyp3a11 (right panel) gene 
expression by PCN treatment in mouse liver is PXR-dependent (Figure 4-3B).   
We next examined the relative expression levels of microsomal Ces6 and Cyp3a11 
protein in mouse liver.  Hepatic microsomes were isolated and resolved on an  
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Figure 4-3A 
 
Figure 4-3. Induction of Ces6 and Cyp3a11 gene expression by PCN treatment in 
mouse liver is PXR-dependent.  Total RNA was isolated from the liver of wild type 
and PXR knockout mice (n=3) treated i.p. with corn oil (vehicle) or PCN (100 mg/kg) 
for 4 days.  (A) Northern blot analysis was performed using 20 g total RNA/lane and 
the blots were probed sequentially with 
32
P-labeled cDNA fragments encoding Ces6, 
Cyp3a11 and 18S ribosomal RNA.  Each lane represents an individual animal.   
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Figure 4-3B 
 
Figure 4-3. Induction of Ces6 and Cyp3a11 gene expression by PCN treatment in 
mouse liver is PXR-dependent.  Total RNA was isolated from the liver of wild type 
and PXR knockout mice (n=3) treated i.p. with corn oil (vehicle) or PCN (100 mg/kg) 
for 4 days.  (B) Real-time quantitative PCR analyses were performed to determine the 
expression of Cyp3a11 and Ces6.  All data are normalized to 18S levels and represent 
the average values ± SEM (n=5) and expressed as fold induction over vehicle control.  
Letters different from each other indicate a statistical difference between treatment 
groups (p<0.05). 
 
 
 
 78 
SDS-PAGE gel for subsequent western blot analysis.  Expression of both the Ces6 and 
Cyp3a11 proteins were induced by PCN treatment in a PXR-dependent manner in 
hepatic microsomes (Figure 4-4A).  Quantitative analyses of these data indicate that 
both Ces6 (left panel) and Cyp3a11 (right panel) protein levels are significantly 
induced in liver in a PXR-dependent manner (Figure 4-4B).  Deletion of the PXR 
protein in vivo significantly increased the basal expression of both Ces6 and Cyp3a11 
protein levels. 
    We next sought to determine whether expression of the Ces6 gene in liver is 
regulated by the nuclear receptor CAR.  Mice were treated for four days i.p. with 
vehicle, TCPOBOP, or PB.  Liver and duodenum were removed and total RNA and 
protein was isolated on the morning of day 5.  Gene expression levels were 
qualitatively and quantitatively determined using northern blot and rt-QPCR analyses, 
respectively.  In liver, the expression of genes encoding Cyp2b10 and Ces6 were 
increased following treatment with TCPOBOP in a CAR-dependent manner in liver 
(Figure 4-5A).  Quantitative analysis using rt-QPCR confirmed that both Ces6 and 
Cyp2b10 gene expression levels were significantly induced by treatment with 
TCPOBOP in liver and duodenum in a CAR-dependent manner (Figure 4-5B). 
We next examined Ces6 and Cyp2B10 protein levels in mouse hepatic microsomes 
qualitatively and quantitatively using western blot analysis and photo-densitometry, 
respectively.  These analyses revealed that treatment of mice with TCPOBOP 
produced robust increases in hepatic microsomal Ces6 and Cyp2b10 proteins in a  
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Figure 4-4A 
 
Figure 4-4. Expression of Ces6 and Cyp3a11 protein is induced by PCN in a 
PXR-dependent manner in mouse liver.  Hepatic microsomes were from the liver of 
wild type and PXR knockout mice (n=3) treated i.p. with corn oil (vehicle) or PCN 
(100 mg/kg) for 4 days.  (A) Western blot analysis was performed to determine the 
expression levels of Ces6, Cyp3a11 and -actin protein, respectively.  Each lane 
represents an individual animal.   
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Figure 4-4B 
 
Figure 4-4. Expression of Ces6 and Cyp3a11 protein is induced by PCN in a 
PXR-dependent manner in mouse liver.  Hepatic microsomes were from the liver of 
wild type and PXR knockout mice (n=3) treated i.p. with corn oil (vehicle) or PCN 
(100 mg/kg) for 4 days.  (B) The results from (A) were quantified using scanning 
densitometry.  All data are normalized to -actin levels and represent the average 
values ± SEM (n=3) and expressed as fold induction over vehicle control.  Letters 
different from each other indicate a statistical difference between treatment groups 
(p<0.05). 
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Figure 4-5A 
 
Figure 4-5. Induction of Ces6 and Cyp2b10 gene expression by TCPOBOP 
treatment in mouse liver is CAR-dependent.  Total RNA was isolated from the 
liver of wild type and CAR knockout mice (n=3) treated i.p. with corn oil (vehicle) or 
TCPOBOP (3 mg/kg) for 4 days.  (A) Northern blot analysis was performed using 20 
g total RNA/lane and the blots were probed sequentially with 
32
P-labeled cDNA 
fragments encoding Ces6, Cyp2b10 and 18S ribosomal RNA.  Each lane represents an 
individual animal.   
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Figure 4-5B 
 
Figure 4-5. Induction of Ces6 and Cyp2b10 gene expression by TCPOBOP 
treatment in mouse liver is CAR-dependent.  Total RNA was isolated from the 
liver of wild type and CAR knockout mice (n=3) treated i.p. with corn oil (vehicle) or 
TCPOBOP (3 mg/kg) for 4 days.  (B) Real-time quantitative PCR analyses were 
performed to determine the expression levels of Ces6 and Cyp2b10 in duodenum and 
liver tissues.  All data are normalized to 18S levels and represent the average values ± 
SEM (n=5) and expressed as fold induction over vehicle control.  Letters different 
from each other indicate a statistical difference between treatment groups (p<0.05). 
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CAR-dependent manner in liver microsomal fractions (Figure 4-6A).  Densotimetric 
analysis showed that the increased levels of Ces6 (left panel) and Cyp2b10 (right panel) 
protein observed in wild type mice treated with TCPOBOP was statistically significant 
(Figure 4-6B).  Similar results in liver were obtained when PB treatment was used to 
activate the CAR nuclear receptor protein in vivo.   Qualitative analysis using 
northern blotting revealed that PB treatment produced robust increases in the 
expression levels of the genes encoding Ces6 and Cyp2b10 in a CAR-dependent 
manner in liver (Figure 4-7A).  Quantitative analysis using rt-QPCR revealed that 
treatment with PB produced significant increases in the Ces6 and Cyp2b10 genes in 
liver (Figure 4-7B).  Examination of Ces6 and Cyp2B10 protein levels in mouse 
hepatic microsomes was accomplished qualitatively and quantitatively using western 
blot analysis and photo-densitometry, respectively.  These analyses revealed that 
treatment of mice with PB produced robust increases in hepatic microsomal Ces6 and 
Cyp2b10 proteins in a CAR-dependent manner in liver microsomal fractions (Figure 
4-8A).  Densotimetric analysis showed that the increased levels of Ces6 (left panel) 
and Cyp2b10 (right panel) protein observed in wild type mice treated with TCPOBOP 
was statistically significant (Figure 4-8B).  Interestingly, no increases in the basal 
levels of either Ces6 or Cyp2b10 proteins were observed on CAR-KO mice.  This is in 
stark contrast to that observed in the PXR-KO mice.  This observation likely indicates 
that the CAR protein does not play an active repressive role in a non-stimulated state in 
liver.  Treatment of all genotypes of mice examined here with PB did not produce any 
significant changes in expression levels of genes encoding Ces6, Cyp3a11, or Cyp2b10  
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Figure 4-6A 
 
Figure 4-6. Expression of Ces6 and Cyp2b10 protein is induced by TCPOBOP in 
a CAR-dependent manner in mouse liver.  Hepatic microsomes were from the liver 
of wild type and CAR knockout mice (n=3) treated i.p. with corn oil (vehicle) or 
TCPOBOP (3 mg/kg) for 4 days.  (A) Western blot analysis was performed to 
determine the expression levels of Ces6, Cyp2b10 and -actin protein, respectively.  
Each lane represents an individual animal.   
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Figure 4-6B 
 
Figure 4-6. Expression of Ces6 and Cyp2b10 protein is induced by TCPOBOP in 
a CAR-dependent manner in mouse liver.  Hepatic microsomes were from the liver 
of wild type and CAR knockout mice (n=3) treated i.p. with corn oil (vehicle) or 
TCPOBOP (3 mg/kg) for 4 days.  (B) The results from (A) were quantified using 
scanning densitometry.  All data are normalized to -actin levels and represent the 
average values ± SEM (n=3) and expressed as fold induction over vehicle control.  
Letters different from each other indicate a statistical difference between treatment 
groups (p<0.05). 
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Figure 4-7A 
 
Figure 4-7. Induction of Ces6 and Cyp2b10 gene expression by phenobarbital 
treatment in mouse liver is CAR-dependent.  Total RNA was isolated from the 
liver of wild type and CAR knockout mice (n=3) treated i.p. with saline (vehicle) or PB 
(100 mg/kg) for 4 days.  (A) Northern blot analysis was performed using 20 g total 
RNA/lane and the blots were probed sequentially with 
32
P-labeled cDNA fragments 
encoding Ces6, Cyp2b10 and 18S ribosomal RNA.  Each lane represents an individual 
animal.  
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Figure 4-7B 
 
Figure 4-7. Induction of Ces6 and Cyp2b10 gene expression by phenobarbital 
treatment in mouse liver is CAR-dependent.  Total RNA was isolated from the 
liver of wild type and CAR knockout mice (n=3) treated i.p. with saline (vehicle) or PB 
(100 mg/kg) for 4 days.  (B) Real-time quantitative PCR analyses were performed to 
determine the expression of Cyp2b10 and Ces6.  All data are normalized to 18S levels 
and represent the average values ± SEM (n=5) and expressed as fold induction over 
vehicle control.  Letters different from each other indicate a statistical difference 
between treatment groups (p<0.05). 
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Figure 4-8A 
 
Figure 4-8. Expression of Ces6 and Cyp2b10 protein is induced by phenobarbital 
in a CAR-dependent manner in mouse liver.  Microsomes were isolated from the 
livers of wild type and CAR-KO mice treated with saline (vehicle) or phenobarbital for 
4 days (n = 3).  (A) Western blot analysis was performed to determine the expression 
levels of Ces6, Cyp2b10 and -actin protein, respectively.  Each lane represents an 
individual animal.  
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Figure 4-8B 
 
Figure 4-8. Expression of Ces6 and Cyp2b10 protein is induced by phenobarbital 
in a CAR-dependent manner in mouse liver.  Microsomes were isolated from the 
livers of wild type and CAR-KO mice treated with saline (vehicle) or phenobarbital for 
4 days (n = 3).  (B) The results from (A) were quantified using scanning densitometry.  
All data are normalized to -actin levels and represent the average values ± SEM (n=3) 
and expressed as fold induction over vehicle control.  Letters different from each other 
indicate a statistical difference between treatment groups (p<0.05). 
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in duodenum (data not shown).  These data indicate that the drug-inducible expression 
and activity of the Ces6 and Cyp2b10 gene products are regulated by both PXR and  
CAR nuclear receptor proteins.  Taken together, these data lead to a model in which 
drug-inducible activation of intestinal carboxylesterase activity in intestine would be 
expected to increase the conversion of prodrugs to the active drug, thereby increasing 
the transport to portal vein and liver (Figure 4-9).  In the liver, high levels of 
cytochrome P450 and carboxylesterase activity would be expected to further increase 
metabolism of co-administered drugs leading to increased prospects for drug-drug 
interaction in patients on combination therapy. 
    4.4 Discussion 
The first-pass effect is a phenomenon of drug metabolism whereby the 
concentration of a drug is greatly reduced before it reaches the systemic circulation.  
This effect is largely mediated by drug metabolizing enzymes and drug transporter 
proteins in the small intestine and liver of mammals.  When administered in the 
active form, these tissues metabolize many drugs to such an extent that only a small 
amount of the active drug emerges from the liver to the rest of the circulatory system.  
Increasingly, prodrugs are being designed using a rational approach that takes 
advantage of the enzymes and transporter proteins in these tissues in such a manner 
that promotes their biotransformation and absorption following oral administration.  
Specifically, introduction of an ester group generally improves bioavailability due to 
increased transport.  Ester-containing prodrugs including several  
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Figure 4-9 
 
Figure 4-9. Model of Coordinated PXR- and CAR-mediated Gene Activation in 
Liver and Intestine.  Activation of PXR and CAR in intestine produces elevated 
levels of Ces6 and cytochrome P450 drug metabolizing activity (top panel).  This 
would be expected to accelerate conversion of prodrug to active drug, and increase 
uptake into the portal circulation.  The liver would then mediate further uptake 
metabolism and excretion into bile and elimination in feces, or back into blood for 
eventual elimination through the kidney and in urine (bottom panel). 
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angiotensin-converting enzyme inhibitors, anti-tumor drugs, and narcotics are acted 
upon by carboxylesterase enzymes in this manner.  In this regard, carboxylesterase  
enzymes are considered to be one of the major determinants of the metabolism and 
disposition of ester-containing drugs through their actions in liver and intestine.   
Most of what is known regarding the liver- and intestine-enriched 
carboxylesterase enzymes (CES1 and CES2 sub-families) consists of characterization 
of their respective substrate specificities.  Specifically, the CES1 sub-family of 
carboxylesterase enzymes mainly hydrolyzes substrates with small alcohol and large 
acyl groups.  In contrast, the CES2 sub-family of carboxylesterase enzymes mainly 
hydrolyzes substrates with large alcohol and small acyl group.  While much is 
known regarding their substrate selectivity, little is known regarding the regulation of 
expression of these important drug metabolizing enzymes in liver and intestine, 
though it is a topic of intense study in several laboratories.   
    Because expression of the prototypical PXR-target gene, Cyp3a11, was still 
detectable in duodenum when compared with that observed in jejunum or ileum 
(Figure 4-1), we chose to further analyze the expression of PCN-inducible genes in this 
particular tissue.  We demonstrate here that treatment of mice with PCN, a known 
PXR activator, induces the expression of multiple genes in duodenum involved in the 
regulation of drug metabolism and disposition.   It is important to note here that we 
did not observe regulation of CAR-target gene expression following treatment of mice 
with PB, a known indirect and phosphorylation-dependent activator of CAR, in the 
intestine, despite significant expression of the CAR gene itself in intestine.  In contrast, 
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treatment of mice with the direct activating ligand of CAR, TCPOBOP, produced 
significant increases in the expression of CAR-target genes examined here.  Therefore, 
it is now tempting to speculate that the two different modes of activation by these two 
CAR-activating compounds are responsible for the distinct CAR-mediated gene 
activation profiles in liver when compared with that observed in intestine.  
Alternatively, differences in the bioavailability of these two compounds in vivo 
following i.p. administration could in principle be responsible for the apparent 
disparate results observed in this study.  Interestingly, deletion of Pxr produced 
significant increases in the level of Ces6 gene expression in both duodenum and liver.  
While the trend was clearly toward elevated expression, the level of Cyp3a11 gene 
expression did not quite reach statistical significance in duodenum in PXR-KO mice.  
Nonetheless, these data indicate a likely repressive role for non-liganded PXR protein 
in duodenum, similar to what was observed for Cyp3a11 in this study (Figure 4-4B) 
and to what has been previously reported by our group in liver tissue [28].   
    It is well established that relatively small increases in gene expression noted using 
microarray technology can sometimes translate into very big changes in protein levels.  
This is especially true with respect to genes that encode proteins that participate in drug 
metabolism pathways.  Specifically, certain cytochrome P450 genes, as well as those 
encoding other drug metabolizing enzymes such as the glutathione S-transferase 
enzymes, are known to be highly regulated at the level of transcription.  Indeed, 
among the PCN-inducible genes in duodenum reported here, several encode 
glutathione S-transferase enzymes (Gstm1, Gstm3, Gstm6, Gsta2, Gsta4, Mgst1, and 
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Mgst2), drug metabolizing enzymes Cyp2C (Cyp2c55 and Cyp2c29) and Cyp3A 
(Cyp3a25 and Cyp3a11) family members, many of which have been previously 
identified as PXR-target genes in liver [7, 17].  Interestingly, expression of the gene 
encoding epoxide hydrolase was induced in duodenum following treatment with PCN.  
Epoxide hydrolase is well known to be induced by compounds that produce 
electrophilic and oxidative stress via the Nrf2-Maf transcription factor complex [29], 
however, relatively little is known regarding the regulation of this gene by PXR in 
duodenum.  Our observation of significant up-regulation of epoxide hydrolase by 
PXR agonist treatment in small intestine is in agreement with a recent report that 
utilized PXR activators in rat model systems [30].  More research will need to be 
conducted to verify this finding and determine its potential biological relevance to drug 
metabolism and disposition in mammals in both liver and intestine.   
    The Abca1 gene product functions as a cholesterol efflux pump in the cellular lipid 
removal pathway.  Mutations in Abca1 have been associated with Tangier's disease 
and familial high-density lipoprotein deficiency in humans [31].  It is interesting that 
our analysis identified Abca1 as a PCN-inducible gene in duodenum since it has 
previously been identified as being down-regulated by PXR agonist treatment in 
transformed human liver cell lines as well as in rodent hepatocytes [32, 33].  Still other 
studies indicate that Abca1 is up-regulated in small intestine in mice in a 
PXR-dependent manner [34].  Another study indicates that treatment of intestinal cell 
lines Caco2 and Ls174T with the PXR agonist rifampicin induces Abca1 expression, 
but does not affect expression of this gene in liver cell lines [35].  Clearly, more 
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research is necessary to determine the molecular basis by which this important 
cholesterol efflux transporter is regulated differentially in hepatic versus intestinal 
tissue; however, our data are consistent with others that indicate that this gene is 
up-regulated in intestine following treatment with PXR agonists. 
    Our analysis also identified the acyl-CoA-binding protein (ACBP), or diazepam 
binding inhibitor (Dbi), as a PCN-responsive gene.   The ACBP/Dbi gene encodes a 
10-kDa intracellular protein that specifically binds acyl-CoA esters with high affinity.  
This small protein is expressed in most cell types at low levels; however, its expression 
is inducible by metabolic and xenobiotic signals through SREBP and PPAR signaling 
in hepatocytes, respectively [36].  Our data indicate that PXR also likely regulates the 
drug-inducible expression of this important gene in small intestine. 
    Other genes of note up-regulated in mouse intestine following treatment with 
PCN include 17-beta-Hydroxysteroid dehydrogenase type 11 (Hsd17b11), a member 
of the short-chain dehydrogenase/reductase family.  The Hsd17b11 gene product is 
involved in the activation and inactivation of sex steroid hormones in liver and 
intestine.  It is interesting to note that treatment of mice with the potent peroxisome 
proliferator Wy14 643 induced expression of this gene product in both liver and 
intestine [37], presumably through activation of PPAR.  However, since several 
PPAR agonists are also PXR agonists, it is possible that induction of Hsd17b11 
gene expression by treatment with Wy14 643 occurs, in part, through activation of 
PXR by this compound.   
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    Another PCN-inducible gene detected in duodenum by our analysis is pyruvate 
dehydrogenase kinase, isozyme 4 (Pdk4).  This gene encodes a member of the PDK 
protein kinase family that inhibits the pyruvate dehydrogenase complex by 
phosphorylating one of its subunits.  Activation of this gene by GR, PPAR-delta, 
and FXR agonists contributes to the regulation of glucose metabolism in several 
tissues [38, 39].   
    The nuclear receptors PXR and CAR were originally identified and 
characterized as „xenobiotic sensors‟, however, more recent research indicates a 
wider role for these two receptors in regulation of the response to metabolic and 
nutritional stress (reviewed in [40]).  In any case, taken together our data indicate 
that activation of PXR-target gene expression in intestine regulates the expression of 
genes involved in modulating drug metabolism, the response to oxidative stress, as 
well as the disposition of steroids, glucose, and cholesterol homeostasis.  Future 
research should seek to unravel the molecular basis for the differential interaction 
between nuclear receptor signaling and gene activation pathways in a tissue-selective 
manner.  Additional whole animal studies should be performed to test our model that 
would include carboxylesterase activity assays, as well as monitoring prodrug and 
drug plasma levels following administration of PXR and CAR activators in vivo.  
Additional studies should be performed using primary hepatocytes and immortalized 
cell lines to determine whether the signaling pathways investigated here are 
evolutionarily conserved in humans.  Together, these issues represent interesting 
research opportunities for the future.  
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Chapter 5: Pregnane X Receptor is Targeted by the 
Ubiquitin-proteasome Pathway in a Signal-dependent Manner 
5.1 Introduction 
Adverse drug reactions (ADRs) are among the top ten leading causes of death in 
the world.  ADRs are also a major cause of death among hospitalized patients in the 
United States.  It is well known that the majority of ADRs result directly from the 
unexpected abnormal metabolic handling of drugs by patients whose hepatic drug 
metabolizing enzymes (DMEs) have been induced or inhibited.  A substantial 
proportion of ADRs are due to the occurrence of disease-drug interactions in which 
systemic infection and acute inflammation can seriously impair drug metabolism in 
patients, leading to serious and potentially lethal consequences.  Currently, the 
molecular basis for this impairment is not known. 
The pregnane x receptor (PXR, NR1I2) is a member of the nuclear receptor (NR) 
superfamily of ligand-activated transcription factors.  In mammals, PXR is expressed 
at high levels in the liver and the intestine, major organs that are important in 
xenobiotic biotransformation [1].  The expression of PXR has also been detected in 
both normal and neoplastic breast tissue, as well as in peripheral blood mononuclear 
cells [2, 3].  As a heterodimer with the nuclear receptor retinoid x receptor alpha 
(RXRNR2B1, PXR regulates the expression of its target genes through binding to 
specific PXR response elements.  Numerous studies have characterized PXR response 
elements, which have shown that PXR binds to two copies of the consensus nuclear 
receptor binding motif AG(G/T)TCA arrayed as a direct repeats separated by 3 or 4 
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nucleotides (DR-3 and DR-4) or everted repeats separated by 6 or 8 nucleotides (ER-6 
and ER-8) [1].  A recent study using chromatin immunoprecipitation (ChIP)-on-chip 
and ChIP-sequencing (ChIP-Seq) identifies the most frequent PXR DNA-binding 
motif is the AGTTCA-like DR-4.  Surprisingly, there are also high motif occurrences 
with spacers of a periodicity of 5 nucleotides, forming a novel DR-(5n+4) pattern for 
PXR binding [4].   
PXR is now well established to function as a positive regulator of the expression 
of genes that encode key DMEs and drug transporter proteins involved in the uptake, 
metabolism and elimination of xenobiotic compounds in the liver and the intestines 
[5-8].  However, recent research describes the negative regulation of several key 
biochemical activities by ligand-mediated activation of PXR in the liver and the 
intestine including gluconeogenesis, lipid metabolism, ketogenesis, and the 
inflammatory response [9].  For example, activation of PXR by rifampicin, the 
prototypical activator of human PXR, suppresses the expression of several key 
inflammatory response genes including IL-1, TNF… [10].  
    The ubiquitin-proteasome degradation pathway is the major system for selective 
degradation of proteins in eukaryotic cells.  Targeted proteins are covalently modified 
with one or several molecules of the highly conserved 76 amino acid ubiquitin protein.  
Targeted proteins are subsequently degraded by the 26S proteasome complex, a large 
multisubunit protease [11].  Conjugation of ubiquitin to target proteins proceeds via a 
three-step cascade mechanism: (1) initially, a high-energy thioester bond is formed 
between the C terminus of ubiquitin and the active site cysteine on ubiquitin-activating 
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E1 enzyme in an ATP-dependent manner; (2) the activated ubiquitin is then 
trans-esterified to a conserved cysteine on any one of the ubiquitin-conjugating E2 
enzymes; (3) the ubiquitin E3 ligase interacts with both E2 and the substrate, and the 
ubiquitin bound E3 ligase targets the ubiquitin to the protein substrates, which are then 
subjected to proteasome degradation into peptides.  Ubiquitin can be removed from 
protein substrates through the action of deubiquitinating enzymes, which can serve to 
reverse the effects of ubiquitination (Figure 5-1).  
The ubiquitin conjugation process can result in mono-ubiquitination or 
multi-mono-ubiquitination through attachment of a single ubiquitin molecule(s) to 
lysine residues within the target protein.  Poly-ubiquitin chains can also be formed 
through further attachment of ubiquitin molecule to any of the seven lysines within 
ubiquitin itself (Lys-6, Lys-11, Lys-27, Lys-29, Lys-33, Lys-48, and Lys-63) or to the 
N-terminal methionine [12].  The fate of an ubiquitinated protein is thought to be 
determined by the type of ubiquitin linkage associated with it.  Formation of Lys-48 
and Lys-11-linked ubiquitin chains targets the substrate protein for degradation by the 
26S proteasome.  Lys-63-linked chains usually mediate the recruitment of binding 
partners, which can lead to a variety of non-proteolytic biological activities of the 
substrate, namely activation of nuclear factor-B (NF-B), orchestration of different 
steps during DNA repair, or targeting the modified protein to the lysosome.  Other 
ubiquitin chains, such as Lys-6 or Lys 29-linked chains, have been detected in vitro or 
in vivo, but their significance in cellular regulation has not yet been established [13].    
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Figure 5-1 
 
Figure 5-1. The Ubiquitin-proteasome Pathway.  The process initiates through an 
APT-dependent activation of free ubiquitin by an ubiquitin-activating enzyme E1.  
The activated ubiquitin is then transferred to an ubiquitin-conjugating enzyme E2 and 
finally to an ubiquitin ligase E3.  The ubiquitin bound E3 ligase targets the ubiquitin to 
the protein substrate, which is subjected to proteasome degradation into peptides.  
Ubiquitin is deconjutated by deconjutating enzymes and recycled for next round of 
pathway.   
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In order to maintain the cellular activity through a balance between the synthesis 
and breakdown of signaling molecules, degradation of regulatory proteins by the 
ubiquitin-proteasome pathway is an important mechanism for the tight control of 
diverse cellular processes, ranging from gene transcription to cell cycle progression [14, 
15].  Aberrations within protein substrates undergoing ubiquitin-proteasome 
degradation are implicated in several diseases including Alzheimer's disease and 
cancer [16, 17].  Transcription factors are among the proteins regulated by the 
ubiquitin-proteasome pathway, and included in this group are members of the NR 
superfamily [18].  Ligand-dependent regulation by the ubiquitin-proteasome system 
has been demonstrated for several members of the NR family, including estrogen 
receptor alpha (ER, NR3A1), retinoic acid receptor alpha (RAR, NR1B1) and 
gamma (RAR, NR1B3), peroxisome proliferator-activated receptor gamma (PPAR, 
NR1C3) [19-21].  
    Our laboratory has recently shown that PXR exists in cells as a phosphoprotein and 
that activation of PKA signaling interfaces with PXR to inhibit its transcriptional 
activity in hepatocytes [22, 23].  Here, we identify PXR as the molecular target of 
ubiquitin.  Moreover, we show that ubiquitination of PXR is stimulated in cells by 
treatment with cyclic-AMP and activation of the MEKK1 signaling pathway, 
suggesting distinct regulation of PXR activity by metabolic- and 
inflammatory-mediated signaling.  Interestingly, inhibition of the proteasomal 
degradation pathway and increased ubiquitination of PXR represses 
rifampicin-inducible PXR transactivation capacity in an engineered PXR reporter gene 
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assays.  Taken together, this novel data provides a plausible and testable hypothesis 
for how inflammatory- and cyclic AMP/PKA-mediated signaling pathways selectively 
repress the drug-inducible expression and activity of hepatic drug metabolizing and 
drug transporter activities in the liver and the intestine. 
5.2 Materials and Methods 
Compounds and Plasmids.  Unless otherwise stated, all chemical compounds 
were purchased from Sigma (St. Louis, MO).  Plasmids pRK5-HA-Ubiquitin-WT, 
KO, K48R and K63R were purchased from Addgene (Cambridge, MA).  
His-tagged-ubiquitin constructs were subcloned into the pcDNA4/Hismax A 
expression vector (Invitrogen) at EcoRI and NotI restriction sites.  The 
pcDNA4/Hismax-Ubiquitin-K48, 63R expression vector was generated from 
pcDNA4/Hismax-Ubiquitin-K48R by site-directed mutagenesis with use of the 
QuikChange Mutagenesis system (Stratagene, La Jolla, CA).  Primer sequences used 
for site-directed mutagenesis are as follows: forward primer 
(5‟-GCTGTCTGATTACAACATTCAGAGGGAGTCCACCCT-3‟), reverse primer 
(5‟-AGGGTGGACTCCCTCTGAATGTTGTAATCAGACAGC-3‟).  
Cell-based Ubiquitination Assays.  HeLa cells were maintained in Dulbecco‟s 
modified Eagle‟s medium supplemented with 2 mM L-glutamine, 100 U/ml 
penicillin/streptomycin, and 10% fetal calf serum.  For transfection assays, HeLa cells 
were grown for 24 hours until 80% confluence.  Cells were transfected with the 
expression plasmids using Lipofectamine 2000 (Invitrogen, Carlsbad, CA).  24 hours 
post-transfection, cells were treated as indicated for an additional 24 hours.  48 hours 
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after transfection, cells were washed with phosphate-buffered saline and harvested 
with lysis buffer (6 M guanidinium-HCl, 10 mM Tris, 100 mM sodium phosphate 
buffer, pH 8.0).  After sonication, the cell lysates were cleared by centrifugation at 
3000g for 15 minutes.  The cleared cell lysates were mixed with Ni
2+
-linked agarose 
(QIAGEN, Valencia, CA) that had been prewashed with cell lysis buffer.  The mixture 
was incubated for 2 hours on a rotator at room temperature and centrifuged for 2 
minutes at 1000 rpm to gather the beads.  The beads were washed once in lysis buffer, 
three times in wash buffer (8 M urea, 100 mM sodium chloride, 50 mM sodium 
phosphate buffer, pH 6.3), and once in phosphate-buffered saline.  The beads were 
resuspended in SDS-PAGE gel loading buffer and boiled for 5 minutes.  Samples 
were resolved on 10% SDS-PAGE.  The gel was transferred to polyvinylidene 
difluoride membrane (Millipore Bioscience Research Reagents) using standard 
methods, and probed with H-11 monoclonal anti-PXR antibody (Santa Cruz 
Biotechnology, Inc. Antibodies) to detect the ubiquitinated form of PXR.  
Immunodetection was performed using the Pierce ECL western blotting substrate 
(Thermo Scientific) according to the protocol provided by the manufacturer. 
Hepatocyte Culture and Immunoprecipitation of Human PXR Protein.  
Primary cultures of human hepatocytes were purchased (Invitrogen).  48 hours after 
plating, hepatocytes were treated with vehicle (0.1% DMSO), 10 ng/ml TNFα, or 
TNFα plus rifampicin (10 M), proteasome inhibitor MG132 (25 M), and TNFα plus 
MG132.  24 hours after drug treatment, cells were lysed by sonication in a buffer 
composed of 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 
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and 1× protease inhibitors (Thermo Fisher Scientific, Waltham, MA).  Cell lysates 
were precleared with 20 μl of immobilized protein A (Repligen, Waltham, MA).  
Immunoprecipitation of the human PXR protein was accomplished by using a custom 
polyclonal antibody directed against the human PXR ligand-binding domain.  Free 
immune complexes were captured with immobilized protein A and washed three times 
with lysis buffer.  After SDS-PAGE, the protein was transferred to polyvinylidene 
difluoride membrane (Millipore Bioscience Research Reagents, Temecula, CA) that 
was probed with a monoclonal anti-PXR antibody (Santa Cruz Biotechnology, Inc. 
Antibodies).  Immunodetection was performed by using the Pierce ECL Western 
blotting substrate (Thermo Fisher Scientific) according to the protocol provided by the 
manufacturer.  
    Transient Transfection and Reporter Gene Analysis.  The reporter gene assays 
were performed as described previously [24].  In brief, CV-1 cells were plated in 
96-well plates at a density of 7000 cells per well.  After 24 hours the cells were 
transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to the 
manufacturer‟s instructions.  The PXR transactivation assays were performed by 
transfecting cells with CMV--galactosidase (20 ng), XREM-LUC or NF-B-LUC (20 
ng), pSG5-hPXR (5 ng), His-ubiquitin (10 ng), and pBluescript was added to achieve 
110 ng of total DNA per well.  24 hours post-transfection cells were treated with 
vehicle (0.1% DMSO) or drug (10 mM rif, 100 mM ALLN, 25 mM MG132, 10 mM 
LactaC, and 10 ng/ml TNF) for additional 24 hours.  Luciferase activities were 
determined by using a standard luciferase assay system (Promega, Madison, WI).  
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β-Galactosidase activities were determined using an o-nitrophenyl-β-d- 
galactopyranoside (ONPG) assay.  For the ONPG assay, 110 mg of ONPG was 
dissolved in 100 ml of 0.1 M NaHPO4 buffer, which was made by mixing 6.84 ml of 1 
M Na2HPO4, 3.16 ml of 1 M NaH2PO4, and 90 ml of H2O.  20 l of cell lysate and 200 
l of ONPG buffer were mixed, and the mixture was incubated at 37 °C for 30-60 
minutes and read at 420 nm.  
5.3 Results 
PXR is the Molecular Target of Ubiquitin-proteasome Degradation.  Because 
past research from our laboratory identified a strong interface between PKA signaling 
and PXR activity [22, 25, 26], and because several members of the NR family have 
been previously identified to be regulated by the ubiquitin-proteasome pathway 
[19-21], we sought to determine whether PXR is also a regulated molecular target of 
the ubiquitin system.  To initiate these studies, we first tested the effects of proteasome 
inhibitors on levels of exogenously expressed FLAG-tagged human PXR expression in 
the human hepatoma immortalized cell line-HepG2 cells.  The levels of PXR protein 
were increased by treatment with all three proteasome inhibitors examined including 
ALLN (Acetyl-L-Leucyl-L-Leucyl-L-Norleucinal), MG132 (Benzyloxycarbonyl- 
L-Leucyl-L-Leucyl-L-Leucinal), and lactacystin (N-Acetyl-L-Cysteine, 
S-[2R,3S,4R]-3-Hydroxy-2-[(1S)-1-Hydroxy-2-Methylpropyl]-4-Methyl-5-Oxo-2-Py
rrolidinecarbonyl]).  Not much change was observed when cells were treated with 
rifampicin alone, or in combination with proteasome inhibitors (Figure 5-2A).  
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Similar results were also observed in HeLa cells (Figure 5-2B).  These results indicate 
that PXR is the likely target of the 26S proteasomal degradation machinery. 
Since the 26S proteasome recognizes and degrades proteins that are conjugated 
with poly-ubiquitin chains, we next sought to determine whether we could detect 
poly-ubiquitination of PXR in transfected cultured cell lines.  A combination of 
expression vectors encoding the ubiquitin and PXR proteins were employed using a 
cell-based transient transfection based strategy.  Co-expression of 6×-histidine-tagged 
PXR and ubiquitin in HeLa cells allowed us to exam whether PXR is the target of 
ubiquitin.  Cultured HeLa cells expressing both PXR and ubiquitin expressed a protein 
recognized by the anti-PXR antibody that corresponds to the expected size of 
mono-ubiquitinated PXR protein.  Treatment with rifampicin decreased the 
expression of mono-ubiquitinated PXR to a small extent (Figure 5-3, lanes 5 and 6).  
As expected, treatment of HeLa cells over expressing both PXR and ubiquitin with the 
proteasome inhibitor MG132 increased ubiquitination of PXR (Figure 5-3, lanes 7 and 
8).  This data further supports the conclusion that PXR is the molecular target of 
ubiquitin-proteasome pathway.  
    Poly-ubiquitination of the PXR Protein is Regulated by Cyclic AMP and MEKK 
Signaling Pathways.  We next treated cells with activators of pivotal signal 
transduction pathways to determine if poly-ubiquitination of PXR is regulated by cell 
signaling.  Notably, treatment with 8-bromo-cyclic AMP, the cell-permeable activator 
of the PKA signaling pathway increased the level of PXR ubiquitination, while  
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Figure 5-2A 
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Figure 5-2B 
 
Figure 5-2. Expression of PXR Protein is Increased by Proteasome Inhibitors in 
Cells.  The plasmid encoding FLAG-tagged human PXR protein was transfected into 
HepG2 (Figure 5-2A) or HeLa (Figure 5-2B) cells. 24 hours post-transfection, cells 
were treated as indicated for an additional 24 hours.  Total cell extract was subjected 
to SDS-PAGE and western blot analysis was performed to determine the expression 
levels of human PXR and β-actin protein, respectively. 
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Figure 5-3 
 
Figure 5-3. PXR is Ubiquitinated in Cells.  The plasmid encoding the 
6x-His-tagged PXR protein was transfected alone or together with an expression vector 
encoding ubiquitin into HeLa cells.  24 hours post-transfection, cells were treated as 
indicated for an additional 24 hours.  Total cell extract was subjected to purification 
using nickel-linked agarose beads, followed by SDS-PAGE and western blotting using 
a monoclonal antibody against the human PXR protein. 
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treatment with 8-bromo-cyclic GMP had no effect on it (Figure 5-4, lanes 5 and 6).  
This is a significant discovery in light of the fact that the proteasome activity is 
increased by PKA-mediated phosphorylation [27].  Our laboratory has recently shown 
that PXR is also phosphorylated by PKA, and that PKA signaling interfaces with PXR 
to inhibit its transcriptional activity in hepatocytes [22, 23].  Interestingly, forced 
expression of constitutively active kinases MEKK1 (activates JNK) increased PXR 
poly-ubiquitination, while forced expression of MEK1 (activates ERK) and MEK3 
(activates p38) had no effect on ubiquitination of PXR (Figure 5-4, lanes 7-9).  TNF 
treatment is known to induce MEKK1 activation [25].  The question of whether 
ubiquitination of PXR affects transcription of DMEs therefore becomes important to 
address. 
    Cyclic-AMP Mediates Poly-ubiquitination of PXR via neither Lys-48 nor 
Lys-63-linked Ubiquitin Chains.  To directly assess the role of Lys-48 and 
Lys-63-linked ubiquitin chains in cyclic-AMP mediated poly-ubiquitination of PXR, 
different ubiquitin mutants containing lysine-to-arginine mutations were employed to 
prevent the ubiquitin chain formation on indicated lysine residues.  Treatment of HeLa 
cells co-expressing both PXR and KO form of ubiquitin (ubiquitin with all lysines 
mutated to arginine residues) with 8-bromo-cyclic AMP decreased poly-ubiquitination 
of PXR compared to the one with WT form of ubiquitin (Figure 5-5, lanes 5 and 7).  
Importantly, cells co-expressing PXR and three other mutant forms of ubiquitin, 
including K48R (ubiquitin with lysine 48 mutated to arginine), K63R (ubiquitin with  
 
 
 114 
Figure 5-4 
 
Figure 5-4. Poly-ubiquitination of PXR Protein is Stimulated by Cyclic-AMP and 
Constitutively Active MEKK Signaling.  The plasmid encoding the 6x-His-tagged 
ubiquitin protein was co-transfected into the HeLa cells with the expression vector 
encoding the PXR protein and activators of the ERK, p38, and JNK signaling cascades.  
24 hours post-transfection cells were treated as indicated for an additional 24 hours.  
Total cell extract was subjected to purification using nickel-linked agarose beads, 
followed by SDS-PAGE and western blotting using a monoclonal antibody against the 
human PXR protein. 
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Figure 5-5 
 
Figure 5-5. Cyclic-AMP Mediates Poly-ubiquitination of PXR via neither Lys-48 
nor Lys-63-linked Ubiquitin Chains.  The plasmid encoding PXR protein was 
co-transfected into the HeLa cells with an expression vector encoding 6x-His-tagged 
wild type ubiquitin (WT), ubiquitin with all lysines mutated to arginine residues (KO), 
ubiquitin with lysine 48 mutated to arginine (K48R), ubiquitin with lysine 63 mutated 
to arginine (K63R), or ubiquitin with lysines 48 and 63 mutated to arginines (K48, 
63R).  24 hours post-transfection cells were treated as indicated for an additional 24 
hours.  Total cell extract was subjected to purification using nickel-linked agarose 
beads, followed by SDS-PAGE and western blotting using a monoclonal antibody 
against the human PXR protein. 
 
 116 
 lysine 63 mutated to arginine), and K48, 63R (ubiquitin with lysines 48 and 63 
mutated to arginines) still exhibited poly-ubiquitin chain formation on PXR protein 
(Figure 5-5, lanes 9, 11, and 13).  This data indicates that other lysine residues rather 
than K48 or K63 within ubiquitin protein may be involved in cyclic-AMP mediated 
poly-ubiquitination of PXR.   
Ubiquitination of the PXR Protein is Increased by Rifampicin together with 
TNF.  We next used primary cultures of human hepatocytes in order to determine 
whether treatment with proteasome inhibitor MG132, TNF, or co-treatment with 
TNF and rifampicin modulates ubiquitination of the PXR protein.  Co-treatment of 
human hepatocytes with rifampicin and TNF dramatically increases PXR 
ubiquitination as detected using immunoprecipitation followed by western blotting 
(Figure 5-6, lane 3).  As expected, treatment with MG132 increased ubiquitination of 
PXR (Figure 5-6, lane 4), while co-treatment with TNF and MG132 further increased 
PXR ubiquitination (Figure 5-6, lane 5).  This data demonstrates that the PXR protein 
is likely modified by ubiquitin in hepatocytes following co-treatment with TNF and 
rifampicin, an inflammatory cytokine and PXR activator, respectively. 
    Inhibition of the Proteasomal Degradation Pathway Abolishes PXR 
Transactivation Capacity.  In order to determine the effect of inhibition of the 
proteasomal degradation pathway on PXR activity, we used a reporter gene approach 
with the xenobiotic response enhancer element (XREM) from the CYP3A4 promoter.  
This enhancer element fused to the luciferase reporter gene is well known to bind PXR,  
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Figure 5-6 
 
Figure 5-6. Co-treatment of Hepatocytes with Rifampicin and TNFa Increases 
Ubiquitination of Human PXR Protein.  Primary cultures of human hepatocytes 
were treated with vehicle (0.1% DMSO), TNF (10 ng/ml), or TNF plus rifampicin 
(10 uM), proteasome inhibitor MG132 (25 uM), and TNF plus MG132 for 24 hours.  
Cell extracts were subjected to immunoprecipitation with a polyclonal antibody that 
recognizes human PXR followed by SDS-PAGE and western blotting using a 
monoclonal antibody against the human PXR protein (bottom panel).  Equal loading 
was insured using and aliquot of whole cell lysate and immunoblotting with -actin 
(top panel). 
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and we therefore used this reporter gene as a marker for PXR activity in transfected 
CV-1 cells, a standard cell line for determining PXR reporter gene activity.  
Pharmacological inhibition of the proteasomal degradation pathway with three 
proteasome inhibitors ALLN, MG132 and lactacystin abolished PXR transactivation of 
the CYP3A4 promoter in reporter gene transfected CV-1 cells (Figure 5-7).  This is 
consistent with an ubiquitin-dependent promoter clearance mechanism, and is highly 
reminiscent of recent reports detailing similar modes of regulation of NR proteins 
proxisome proliferator-activated receptor gamma (PPAR, NR1C3) and liver x 
receptor alpha/beta (LXR/, NR1H3/NR1H2) [28, 29]. 
Ubiquitination of PXR Represses Rifampicin-inducible PXR Transactivation 
Capacity.  Our recent studies have shown that SUMOylated form of PXR protein 
represses NF-kB activity, but has little effect upon PXR-mediated CYP3A4 gene 
activation [30].  We next sought to determine the biological effect of forced 
expression of ubiquitin and treatment with TNF on PXR activity using a reporter gene 
approach.  When the PXR transfected cells were treated with rifampicin alone, the 
XREM reporter gene activity was induced approximately seven-fold.  Co-treatment of 
cells with TNF repressed activity of the reporter gene to a very modest extent.  
However, when ubiquitin was co-expressed together with PXR, the reporter gene 
activity was significantly lower when cells were co-treated with rifampicin and 
TNFFigure 5-8.  Similar experiments using the NF-B reporter gene revealed that 
forced expression of ubiquitin did not appreciably affect the ability of PXR to repress  
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Figure 5-7 
 
Figure 5-7. Inhibition of the Proteasomal Degradation Pathway Abolishes PXR 
Transactivation Capacity in Transfected CV-1 Cells.  CV-1 cells were transfected 
with an XREM-luciferase reporter gene with plasmid encoding PXR protein.  24 
hours post-transfection cells were treated as indicated for an additional 24 hours.  
Luciferase activity data was determined and reported as fold-induction ± S.E.M. 
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Figure5-8 
 
Figure 5-8. The Biological Effect of Ubiquitin Modification of Human PXR on 
PXR Activity.  CV-1 cells were transfected with an XREM-luciferase reporter gene 
together with PXR alone, or PXR and ubiquitin.  24 hours post-transfection cells were 
treated as indicated for an additional 24 hours.  Luciferase activity data was 
determined, normalized to -glactosidase and reported as fold-induction ± S.E.M.  
（* = p < 0.01; ** = p < 0.001）. 
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NF-B activity in the presence of TNFdata not shown.  This data reveals that 
ubiquitination of PXR protein may selectively clears the promoters of DMEs and other 
PXR target genes, therefore repressing their activity. 
    5.4 Discussion 
The proteome is in a dynamic state of synthesis and degradation, which controls 
the concentration of many proteins.  Over 25 years ago, eukaryotic cells were shown 
to contain a highly specific system for the selective degradation of short-lived proteins.  
This system is known as the ubiquitin-proteasome pathway.  In this pathway, proteins 
are targeted for degradation through covalent modification by a highly conserved 
protein named ubiquitin, while the proteasome is a giant cellular organelle with 
protease activities that degrades intracellular proteins in an ATP-dependent manner.  
Not only does the ubiquitin-proteasome degradation remove abnormal proteins that 
may be misfolded, aged, or damaged, it also plays an important role in numerous cell 
processes, including cell cycle progression, signal transduction and transcriptional 
regulation.  NR proteins comprise a large superfamily of ligand-activated 
transcription factors with forty-eight members in the human genome [31].  
NR-mediated transcriptional regulation is subject to multiple levels of control, 
including changes in chromatin structure within gene promoters and regulation of 
receptor and cofactor levels by the ubiquitin-proteasome pathway [32, 33].  Previous 
studies have shown that mouse PXR interacts with suppressor for gal1 (SUG1), which 
belongs to the 19S regulatory subunit of the 26S, in a progesterone-dependent manner 
[34].  In our recent experiments, human PXR ligand binding domain is also found to 
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interact with SUG1 in a yeast two hybrid screening.  Here, we identify that PXR is the 
molecular target of ubiquitin.  Inhibition of the proteasomal degradation pathway and 
ubiquitination of PXR represses rifampicin-inducible PXR transactivation capacity in 
reporter gene assays.  This data provides an additional link between NR-mediated 
gene transcription and the ubiquitin-proteasome pathway. 
Rapid degradation of a number of NR members by the ubiquitin-proteasome is 
correlated to their phosphorylation state.  Phosphorylation is thought to signal 
substrate recognition by the enzymes in the ubiquitination pathway.  Progesterone 
receptor is phosphorylated by mitogen activated protein kinase (MAPK) and degraded 
via the ubiquitin-proteasome pathway in a ligand-dependent manner [35].  
Phosphorylation of retinoic acid receptor gamma 2 (RAR2) by p38 MAPK leads to its 
degradation in response to retinoic acid [36].  Furthermore, hyperphosphorylation of 
peroxisome proliferator-activated receptor alpha (PPAR) induces its transcriptional 
activity which is accompanied by stabilizing the protein [37].  Our lab has recently 
identified that PXR exists as a phosphoprotein in vivo and that its phosphorylation 
status is modulated by the activation of PKA signaling [22, 23].  In the current studies, 
we demonstrate that ubiquitination of PXR protein can be stimulated in cells by 
treatment with cyclic-AMP, suggesting cross-talk between phosphorylation and 
ubiquitnation, two post-translational modifications of PXR through 
metabolic-mediated signaling.   
The mitogen activated protein kinases (MAPKs) are a family of signal 
transduction proteins that convert extracellular signals, such as stresses and growth 
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factors, to the activation of intracellular pathways.  Their activity is regulated through 
a module of sequentially acting cytoplasmic kinases composed of a MAP kinase, a 
MEK (MAP kinase kinase), and a MEKK (MEK kinase) [38].  Three subfamilies of 
MAP kinases are well characterized, including ERKs (extracellular signal-regulated 
protein kinases), the p38 MAP kinases, and JNKs (c-jun N-terminal kinases) [39].  
Previous studies have shown that the PHD domain of MEKK1, a RING finger-like 
structure, exhibits E3 ubiquitin ligase activity and mediates ubiquitination and 
degradation of ERK1/2 [40].  In the current report, we demonstrate that forced 
expression of constitutively active kinase MEKK1, which activates JNK signaling, 
increases PXR poly-ubiquitination.  MEKK1 may also act as an E3 ligase in this case 
to regulate PXR ubiquitination.  TNF treatment has been shown to induce MEKK1 
activation [25].  On the other hand, inflammatory cytokines are also well known to 
repress drug-inducible expression of hepatic DMEs [41].  Our data supports the idea 
that inflammatory cytokine signaling in the liver increases ubiquitination of PXR 
protein.  Co-treatment of cells over-expressing ubiquitinated form of PXR with TNF 
and rifampicin selectively represses PXR-mediated gene activation, but has no effect 
on NF-B activity.  These phenomena appear to occur in a promoter-selective fashion, 
providing a possible explanation for how inflammation selectively represses hepatic 
DMEs that are regulated through the PXR-mediated gene activation program. 
Patients experiencing acute or systemic inflammation are recognized as being at 
increased risk for ADRs.  Elucidating the precise molecular basis of the interaction 
between inflammation and drug metabolism will contribute to the development of 
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novel pharmaceutical strategies that will improve clinical handling and prevention of 
disease-drug interactions.   
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Chapter 6: Pregnane X Receptor is Sumoylated to Repress the 
Inflammatory Response 
    6.1 Introduction 
    It has been known for 40 years that treatment with the antibiotic rifampicin (Rif), 
the prototypical activator of the nuclear receptor (NR) protein pregnane X receptor 
(PXR; NR1I2), tends to suppress humoral and cellular immunological function in liver 
cells in patients [1].  This phenomenon has clinical significance, especially in 
HIV-infected patients presenting with comorbid and highly drug-resistant strains of 
tuberculosis who are being treated with Rif where a compromised immune response is 
potentially lethal.  An improved understanding of the molecular basis of reduced 
immune function in Rif-treated patients could lead to the development of new 
therapeutic strategies to combat inflammatory liver diseases.  Because PXR is a 
molecular target of Rif, we hypothesized that the PXR protein is targeted by the 
inflammatory signaling pathway in some manner so as to compromise the ability of 
Rif-treated hepatocytes to mount an immunological response to infection and 
inflammation.  
    Several reports indicate that key members of the NR superfamily are sumoylated to 
repress the inflammatory responses in various tissue types.  It is noteworthy that 
Pascual et al., [2] presented a model for repression in mouse macrophages in which 
ligand-dependent sumoylation of peroxisome proliferator-activated receptor γ results 
in its recruitment to the promoters of several inflammatory-response genes where it 
inhibits transcription by preventing clearance of multiprotein corepressor complexes.  
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Other evidence indicates that ligand-mediated sumoylation of liver X receptor NR 
proteins plays a critical role in transrepression of inflammatory response genes in 
cultured brain astrocytes [3].  
    PXR is highly expressed in liver and is the molecular target of numerous clinically 
prescribed drugs, drug metabolites, and active ingredients in several widely used herbal 
remedies [4-7].  Activation of hepatic PXR by these compounds represents the 
molecular basis of an adaptive response that protects hepatocytes from toxic insult, and 
at the same time, produces potentially life-threatening drug–drug, herb–drug, and 
food–drug interactions in patients on combination therapy.  
    Although much is known regarding the identity of ligands and target genes for 
PXR, relatively little is known regarding the molecular interface of signal transduction 
pathways with this important hepatic transcription factor.  The PXR protein has 
recently been shown to be the target of several signal transduction cascades that 
modulate its phosphorylation status and transcriptional activity [8-10].  A study 
indicates a significant increase in liver-enriched transcription factor cross-talk in 
patients with severe liver disease, suggesting that an elevation in the coordinate 
regulation of hepatic gene expression occurs during the inflammatory response [11].  
Two reports have described mutually repressive and negative cross-talk between the 
PXR and NF-κB signaling pathways [12, 13].  It therefore seems likely that coordinate 
regulation of genes involved in both inflammation and xenobiotic metabolism occurs 
as part of a widespread response to the infection and inflammatory responses, although 
the molecular basis for these phenomena is not fully known.  
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    Species-specific effects are often observed when examining signal transduction 
pathways and activating ligands of PXR [9, 14].  It is therefore important to examine 
PXR function in several cell models where possible.  Here, we use immortalized cell 
lines, transgenic “humanized” PXR mice, and primary cultures of mouse and human 
hepatocytes to show that sumoylation of the PXR protein represents the molecular 
basis of the diminished inflammatory response observed across species.  Our data 
support the idea that tumor necrosis factor α (TNFα) signaling in hepatocytes produces 
increased sumoylation of the liganded PXR protein by incorporation of SUMO3 chains.  
We show here that the sumoylated form of the PXR protein represses NF-κB target 
gene expression, but has little effect on CYP3A gene expression in reporter gene assays.  
These data provide a plausible molecular explanation for how the PXR NR protein can 
be converted from a positive regulator of drug-handling genes to a promoter-specific 
repressor of NF-κB target genes and the hepatic inflammatory response during therapy 
with Rif.  
    6.2 Materials and Methods 
    In Vitro Sumoylation Assay.  Each sumoylation reaction (Enzo Life Sciences Inc., 
Farmingdale, NY) contained 1 μM recombinant purified PXR (PanVera Corp., 
Madison, WI) or RanGap1 in total 20-μl volume in the presence or absence of 
Mg
2+
-ATP.  The assay components were mixed in a microcentrifuge tube and 
incubated at 30°C for 60 min, and the reaction was quenched by the addition of 20 μl of 
2× SDS-PAGE gel loading buffer.  To detect the sumoylated proteins, a 5-μl sample 
of each reaction was resolved by using 10% SDS-PAGE, and the immunoblot analysis 
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was conducted by using anti-SUMO1 or anti-SUMO2/3 antibodies (Enzo Life 
Sciences Inc.).  The membrane was stripped and reprobed by using anti-PXR H-11 
monoclonal antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA).  
    Cell-Based Sumoylation Assays.  Plasmids pcDNA3-6His-SUMO1, 
pcDNA3-6His-SUMO2, and pcDNA3-6His-SUMO3 were kind gifts from Dr. Ronald 
T. Hay (University of Dundee, Dundee, United Kingdom).  Plasmids p3258 
(pCMV-hUBC9) and p3259 (pCMV-hUBC9 C93S) were obtained from Addgene 
(Cambridge, MA).  HeLa cells were maintained in Dulbecco's modified Eagle's 
medium supplemented with 2 mM l-glutamine, 100 U/ml penicillin/streptomycin, and 
10% fetal calf serum.  The cell-based sumoylation assay was carried out as described 
with minor modifications [15].  For transfection assays, HeLa cells were grown in 
six-well dishes for 24 h until 80% confluence.  Cells were transfected with the 
expression plasmids using Lipofectamine 2000 (Invitrogen, Carlsbad, CA).  
Forty-eight hours after transfection, cells were washed twice with phosphate-buffered 
saline and harvested in 200 μl of lysis buffer (6 M guanidinium-HCl, 10 mM Tris, 100 
mM sodium phosphate buffer, pH 8.0).  After sonication the cell lysates were cleared 
by centrifugation at 3000g for 15 min.  The cleared cell lysates were mixed with 25 μl 
of Ni
2+
-linked agarose (QIAGEN, Valencia, CA) that had been prewashed three times 
in cell lysis buffer.  The mixture was incubated for 2 h on a rotator at room 
temperature and centrifuged for 2 min at 1000 rpm to gather the beads.  The beads 
were washed once in wash buffer I (8 M urea, 10 mM Tris, and 100 mM sodium 
phosphate buffer, pH 8.0), three times in wash buffer II (8 M urea, 10 mM Tris, 100 
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mM sodium phosphate buffer, pH 6.3, 0.1% Triton X-100, and 5 mM 
β-mercaptoethanol, and once in wash buffer III (150 mM NaCl, 10 mM imidazole, and 
50 mM sodium phosphate buffer, pH 6.75).  The beads were resuspended in 40 μl of 
2× SDS-PAGE gel loading buffer and boiled for 5 min, and 20-μl samples were 
resolved by using 10% SDS-PAGE.  The gel was transferred to polyvinylidene 
difluoride membrane using standard methods, and immunoblot analysis was performed 
to detect the sumoylated form of PXR using the H-11 monoclonal anti-PXR and 
anti-SUMO2/3 antibodies.  
    Transient Transfection and Reporter Gene Analysis.  The XREM-LUC and 
NF-κB-LUC reporter gene assays were performed as described previously [5].  In 
brief, Hela cells were plated in 96-well plates at a density of 7000 cells per well.  Cells 
were transfected by using Lipofectamine 2000 (Invitrogen) according to the 
manufacturer's instructions.  To measure NF-κB activation, cells were transfected 
with CMV-β-galactosidase (20 ng), NF-κB-LUC reporter gene (20 ng), pSG5-hPXR 
(10 ng), and pcDNA3-His-SUMO3 (10 ng).  Various amounts of pBluescript were 
added to wells to achieve 110 ng of total DNA per well.  The PXR transactivation 
assays were performed with CV-1 cells.  In brief, cells were transiently transfected 
with CMV-β-galactosidase (20 ng), XREM-LUC (20 ng), and pSG5-hPXR (5 ng), and 
pBluescript was added to achieve 110 ng of total DNA per well.  Twenty-four hours 
after transfection cells were treated with either vehicle (0.1% dimethyl sulfoxide) or 
drug (10 μM Rif) for an additional 24 h.  Treatment of cells with TNFα was 
accomplished by using 10 ng/ml TNFα.  Luciferase activities were determined by 
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using a standard luciferase assay system (Promega, Madison, WI).  β-Galactosidase 
activities were determined by o -nitrophenyl-β-d-galactopyranoside assay, and plates 
were read at 420 nm.  
    Hepatocyte Culture and Treatment.  Hepatocytes were isolated from congenic 
(C57BL6) wild-type, PXR knockout, or humanized PXR transgenic mice using a 
standard collagenase perfusion method as described previously [5, 16].  Hepatocytes 
were plated in collagen-coated six-well plates at a density of 8 × 105 live cells/well.  
Primary cultures of human hepatocytes were purchased (Invitrogen).  Forty-eight 
hours after plating, hepatocytes were treated with vehicle, 10 μM Rif, 10 μM 
pregnenalone 16α-carbonitrile (PCN), 10 ng/ml TNFα, or 25 μM 
N-(benzyloxycarbonyl)leucinylleucinylleucinal Z-Leu-Leu-Leu-al (MG132) for 24 h.  
    Immunoprecipitation of Human PXR Protein.  After drug treatment, cells were 
lysed by sonication in a buffer composed of 50 mm Tris-HCl, pH 7.4, 150 mm NaCl, 1 
mm EDTA, 1% Triton X-100, and 1× protease inhibitors (Thermo Fisher Scientific, 
Waltham, MA).  Cell lysates were precleared with 20 μl of immobilized protein A 
(Repligen, Waltham, MA).  Immunoprecipitation of the human PXR protein was 
accomplished by using a custom polyclonal antibody directed against the human PXR 
ligand-binding domain.  Free immune complexes were captured with immobilized 
protein A and washed three times with lysis buffer.  After SDS-PAGE, the protein was 
transferred to polyvinylidene difluoride membrane (Millipore Bioscience Research 
Reagents, Temecula, CA) that was probed with a monoclonal anti-PXR antibody and a 
rabbit monoclonal anti-SUMO2/3 antibody (Cell Signaling Technology, Danvers, 
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MA).  Immunodetection was performed by using the Pierce ECL Western blotting 
substrate or SuperSignal west femto maximum sensitivity substrate (Thermo Fisher 
Scientific) according to the protocol provided by the manufacturer.  
RNA Isolation and Real-Time Quantitative-Polymerase Chain Reaction 
Analysis.  Total RNA was isolated from mouse liver or cell culture by using the 
commercially available reagent TRIzol (Invitrogen), according to the manufacturer's 
directions.  After DNase I treatment, 1 μg of RNA was reverse-transcribed by using 
random primers following the manufacturer's instruction (Promega).  Equal amounts 
of cDNA were used in real-time quantitative polymerase chain reactions (RT-QPCRs).  
Reactions included 1× SYBR Green (Lonza Rockland, Inc., Rockland, ME) and 300 
nM primers specific for each gene.  The primer sets were designed by using the 
Primer3 program (http://frodo.wi.mit.edu).  The sequences (5′ to 3′) for the primers 
were as follows: 18S, forward primer 5′-AGTCCCTGCCCTTTGTACACA-3′, reverse 
primer 5′-CGATCCGAGGGCCTCACTA-3′; Cyp3a11, forward primer 
5′-CAAGGAGATGTTCCCTGTCA-3′, reverse primer 5′-CCACGTTCACTCCA 
AATGAT-3′; and IL-1β, forward primer 5′-TTCCAGGATGAGGACATGAG-3′, 
reverse primer 5′-TTCTGTCCATTGAGGTGGAG-3′.  Cycling conditions were 
95°C for 2 min followed by 45 cycles of 95°C for 15 s, 60°C for 15 s, and 68°C for 15 
s using the Cepheid (Sunnyvale, CA) Smart Cycler system.  The fold induction was 
calculated as described previously [17].  
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    6.3 Results 
    The Effect of the PXR Protein on Expression of Inflammatory Cytokines in 
Liver.  The NF-κB transcription factor is a key regulator of the inflammatory response 
in various disease states and tissues [18, 19].  We previously developed a genetically 
engineered line of mice that lack the Pxr gene (PXR-KO) [4].  We isolated total RNA 
from livers of congenic wild-type and PXR-KO mice and examined the relative 
expression levels of several known NF-κB target genes.  Analysis of the expression 
levels of genes encoding TNFα, IL-6, IL-1α, and IL-1β using RT-QPCR showed that 
the expression levels of these inflammatory cytokines were significantly increased in 
the livers of PXR-KO mice (Figure 6-1).  In particular, the IL-1β gene expression 
level was dramatically increased (∼20-fold) in the livers isolated from the PXR-KO 
mice compared with wild-type mice.  These results reveal an active role for PXR in 
repressing expression of genes that encode key inflammatory cytokine in liver.  These 
data provide supporting evidence for establishing the existence of transcription factor 
cross-talk between the PXR and NF-κB in liver.  
We next examined IL-1β gene expression levels after treatment of primary cultures 
of hepatocytes isolated from either wild-type or PXR-KO mice with PCN, TNFα, or 
both PCN and TNFα.  Hepatocytes were treated with the prototypical rodent PXR 
activator PCN for 48 h, and then with TNFα for an additional 12 h.  Treatment of 
wild-type hepatocytes with PCN alone produced significant repression of IL-1β 
mRNA expression (Figure 6-2A).  In contrast, treatment of PXR-KO hepatocytes with 
PCN did not repress expression of IL-1β.  As expected, the expression level of IL-1β 
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Figure 6-1 
 
Figure 6-1. Ablation of PXR from Mice Increases Expression of Inflammatory 
Cytokines in Liver.  Livers were isolated from wild-type and PXR-KO mice (n = 3), 
and total RNA was collected.  The relative expression levels of TNFα, IL-6, IL-1α, 
and IL-1β were determined by RT-QPCR.  Data are expressed as relative expression 
in PXR-KO mice compared with that observed in wild-type mice and are normalized to 
18S.  ∗, p < 0.01.  
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was elevated in PXR-KO hepatocytes (Figure 6-2B).  TNFα treatment produced a 
significant increase in the level of IL-1β mRNA that was effectively repressed by 
cotreatment of wild-type hepatocytes with TNFα and PCN.  PCN-mediated repression 
of TNFα-inducible IL-1β expression was completely absent from hepatocytes isolated 
from PXR-KO mice.  Moreover, the fold increase of IL-1β mRNA expression 
produced by TNFα was dramatically elevated in PXR-KO hepatocytes compared with 
wild-type hepatocytes (Figure 6-2, note the scales).  These data indicate an active and 
suppressive role for liganded PXR in regulating the expression of IL-1β mRNA in 
response to TNFα.  
The PXR Protein Is SUMOylated In Vitro.  A bioinformatic approach was used 
to scan the amino acid sequence of PXR for the presence of a consensus sumoylation 
sequence (Figure 6-3A).  Using this strategy we identified four potential sites of 
sumoylation within human PXR.  We next used in vitro methods to determine the 
extent to which purified recombinant human PXR serves as a substrate in the 
SUMO-conjugation pathway.  We incubated His-tagged purified recombinant human 
PXR in vitro together with purified E1, E2, SUMO1, SUMO2, or SUMO3 proteins in 
the presence and absence of the required magnesium and ATP cofactors.  The known 
SUMO1 substrate RanGap was used as a positive control to ensure the integrity of the 
in vitro conjugation system.  The extent of sumoylation after the incubation was 
determined by SDS-PAGE and Western blot analysis with commercially available 
antibodies that recognize either SUMO1 or SUMO2/3 proteins (Figure 6-3B, left) or  
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Figure 6-2A 
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Figure 6-2B 
 
Figure 6-2. Cotreatment of Wild-type Hepatocytes with PCN and TNFα 
Represses Expression of IL-1β in Liver, but not in Hepatocytes from PXR-KO 
Mice.  Primary hepatocytes were isolated from wild-type (A) and PXR-KO (B) mice.  
Cells were cultured for 24 h and then treated with 10 μM PCN for 48 h before the 
addition of TNFα (10 ng/ml) for an additional 12 h.  Total RNA was collected, and the 
relative expression level of IL-1β mRNA was determined by RT-QPCR.  Data are 
expressed as relative expression (Log10 scale) compared with that observed in 
vehicle-treated wild-type cells and are normalized to 18S.  In A, ∗, p < 0.01.  In B, 
letters different from each other are significantly different (p < 0.01).  
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Figure 6-3A 
 
Figure 6-3A. Analysis of Consensus Sumoylation Sites in the Human PXR Protein.  
The human PXR protein was analyzed for the presence of the consensus sumoylation 
sequence as defined by an online SUMOPlot server 
(http://www.abgent.com/tools/SUMOplot).  This type of bioinformatic analysis 
identifies four potential sites for sumoylation, one of which is predicted as a “high 
probability” sumoylation site and three others that are predicted as “low probability” 
sumoylation sites.   
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Figure 6-3B 
 
Figure 6-3B. In Vitro Sumoylation of Human PXR Protein.  The human PXR 
protein was used as a test substrate for SUMO1, SUMO2, and SUMO3.  Left, the 
protein was detected by Western blot analysis with antibodies that recognize either 
SUMO1 or SUMO2/3.  The RanGap protein was used as a positive control for 
experimental integrity.  Right, the same blot was stripped and reprobed for PXR 
immunoreactivity using a monoclonal antibody that recognizes the human PXR 
protein.  
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with antibodies that recognize the human PXR protein (Figure 6-3B, right).  This type 
of analysis reveals that the human PXR protein can serve as an effective substrate for 
SUMO1, SUMO2, or SUMO3 in the SUMO-conjugation pathway in vitro.  
Poly-SUMO chains form on PXR when SUMO2 or SUMO3 are used in the reaction.  
Studies confirm that the Ubc9 enzyme can effectively catalyze the formation of 
poly-SUMO chains in vitro [20, 21].  The functional significance of the formation of 
poly-SUMO chains on PXR is currently unknown.  Although an in vitro approach is 
highly suggestive of potential PXR sumoylation, it is also necessary to demonstrate 
that PXR is sumoylated in cultured cell lines.  
    PXR is Preferentially Sumoylated in Cultured Cells by SUMO3.  We have 
initiated a series of studies using an overexpression and transfection approach in HeLa, 
CV-1, and HepG2 cultured cells.  For brevity, we will provide the data obtained using 
HeLa cells; however, the data obtained using either CV-1 or HepG2 cells are identical 
(data not shown).  We used cDNA expression vectors encoding 6×His-tagged 
SUMO1, SUMO2, and SUMO3 proteins together with an expression vector that 
encodes the human PXR protein.  Cotransfection of HeLa cells with the PXR 
expression vector together with the 6×His-SUMO1, 6×His-SUMO2, or 
6×His-SUMO3 expression vectors allows the rapid and selective purification of 
sumoylated forms of PXR using nickel-linked agarose and a strong denaturing buffer 
containing high levels of guanidine-HCl.  The SUMO proteases that probably would 
cleave sumoylated forms of PXR upon cell lysis are rapidly deactivated under these 
denaturing conditions.  Using this experimental approach we detected sumoylated 
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PXR using a Western blot with the α-PXR monoclonal antibody (Figure 6-4A, lane 6).  
Moreover, addition of an expression vector encoding the Ubc9 E2 SUMO ligase 
induced the formation of poly-SUMO3 chains on PXR, which was present at a lower 
level in cells expressing only endogenous Ubc9 (Figure 6-4A, lanes 6 and 7).  It is 
noteworthy that addition of an expression vector encoding the dominant-negative Ubc9 
(C93S) dramatically reduced poly-SUMO chain formation (Figure 6-4A, lane 8).  It is 
interesting to note that the human PXR protein was preferentially modified in cells by 
SUMO3.  
    The use of dominant-negative Ubc9 (C93S) can further determine the specificity of 
SUMO3 chain formation on PXR.  If SUMO-3 chain formation on PXR is occurring, 
then increasing amounts of dominant negative Ubc9 (C93S) expression will inhibit 
PXR sumoylation in a dose-dependent manner.  Indeed, expression of increasing 
amounts of dominant-negative Ubc9 (C93S) inhibits sumoylation of PXR by SUMO3 
in cultured cells (Figure 6-4B, left, lanes 3–5).  It is noteworthy that the same blot was 
stripped and reprobed with the α-SUMO2/3 antibody and produced confirmatory 
results that reveal a decrease in SUMO3 immunoreactivity (Figure 6-4B, right, lanes 
3–5).  These data demonstrate specific conjugation of poly-SUMO3 chains to the 
human PXR protein in cultured cells.  Because forced overexpression of PXR together 
with SUMO3 and Ubc9 could potentially lead to the production of experimental 
artifacts, we next sought to examine sumoylation of endogenous PXR in primary 
cultures of hepatocytes.  
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Figure 6-4A 
 
Figure 6-4A. Detection of Sumoylated Human PXR Protein in HeLa Cells.  The 
human PXR protein was coexpressed in HeLa cells together with either His-tagged 
SUMO1, SUMO2, and SUMO3 proteins.  Cells were lysed using denaturing buffer 
containing guanidinium hydrochloride to inactivate de-sumoylation enzymes.  
Sumoylated proteins were purified by using nickel-linked agarose beads.  The blot 
was probed for PXR immunoreactivity using a monoclonal antibody that recognizes 
the human PXR protein.   
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Figure 6-4B 
 
Figure 6-4B. Dominant-negative Ubc9 (C93S) Protein Inhibits Sumoylation of 
Human PXR in a Dose-dependent Manner.  The human PXR protein was 
coexpressed in HeLa cells together with 6×His-tagged SUMO3 and increasing 
amounts of dominant-negative Ubc9 (C93S).  Sumoylated protein was purified using 
nickel-linked agarose beads.  Left, the blot was probed for PXR immunoreactivity 
using a monoclonal antibody that recognizes the human PXR protein.  Right, the blot 
was stripped and reprobed with an antibody that recognizes SUMO2/3.  
 
 
 146 
    The Endogenous PXR Protein is SUMOylated in Response to TNFα in Cultured 
Hepatocytes.  Although a transfection-based approach using immortalized cell lines is 
a valid strategy for detecting SUMO-modified PXR protein, an important next step is 
the use of primary cultures of hepatocytes.  NR proteins are degraded by the 
proteasome (reviewed in [22]).  Because of the expected low stoichiometry of PXR 
sumoylation, we treated cultured human hepatocytes with MG132, a potent inhibitor of 
proteasomal degradation.  We subsequently performed immunoprecipitation of cell 
extracts using a well characterized custom anti-human PXR polyclonal antibody [9].  
The rationale for this experimental approach is that inhibition of proteasome-mediated 
protein degradation would increase the likelihood of successful detection of the 
sumoylated form of PXR protein.  It is noteworthy that this experimental approach 
also enabled us to perform important control experiments using cross-detection with 
both anti-PXR and anti-SUMO2/3 antibodies.  Indeed, Western blot analysis using an 
anti-PXR monoclonal antibody performed on PXR-immuno-enriched cell extracts 
detected the enrichment of a band of the expected size of sumoylated PXR protein (75 
kDa) (Figure 6-5 A, middle).  When the blot was stripped and reprobed with the 
anti-SUMO2/3 antibodies, we detected a band of the identical size that was enriched 
after treatment with MG132 (Figure 6-5A, bottom), thereby further validating our 
antibody-based experimental approach.  
    We have created a novel line of “humanized” PXR transgenic mice in our 
laboratory.  This line of mice harbors the FLAG-tagged human PXR transgene 
(hPXRtg) whose expression is under the control of the transthyretin promoter.  
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Crossing this strain of transgenic mice with the PXR-KO mice has created a novel line 
of humanized PXR transgenic mice that express the FLAG-tagged version of the 
protein exclusively in liver [16].  Primary cultures of both wild-type and transgenic 
humanized PXR hepatocytes were treated with vehicle, rifampicin, TNFα, or TNFα 
plus rifampicin for 24 h.  Immunoprecipitation with the anti-hPXR polyclonal 
antibody followed by Western blot with a monoclonal anti-PXR antibody was 
performed.  The 70-kDa band was increased by treatment with rifampicin and TNFα 
and cotreatment with rifampicin and TNFα exclusively in the transgenic humanized 
PXR mice (Figure 6-5B).  It has already been established that the PXR-KO mice have 
elevated levels of TNFα and related inflammatory cytokines [13].  Thus, treatment of 
humanized PXR mice, which lack expression of murine PXR in small intestine, with 
rifampicin alone increased sumoylation in this model, probably because of the presence 
of increased levels of inflammatory cytokines such as TNFα or IL-1β.  It is interesting 
to note that our custom anti-hPXR antibody directed against the ligand-binding domain 
of human PXR does not capture the murine PXR protein when used for 
immunoprecipitation from extracts isolated from wild-type mice.  These data indicate 
that the human PXR protein is sumoylated in response to TNFα treatment when 
expressed in mouse hepatocytes.  Taken together, the data presented in Figure 6-5, A 
and B reveal that our antibody-based experimental approach successfully detects 
accumulation of sumoylated PXR protein.  
    Our working hypothesis is that inflammatory signaling pathways increase 
sumoylation of liganded PXR protein to repress NF-κB transcriptional activity in 
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human hepatocytes.  Primary cultures of human hepatocytes were therefore treated 
with vehicle, Rif, TNFα, or both Rif and TNFα for 48 h.  Total cell extract was 
subjected to standard preclearing methods and subsequent immunoprecipitation 
techniques using the anti-hPXR polyclonal antibody.  As before, equal loading was 
determined by using an aliquot of whole-cell lysate and Western blotting to detect 
β-actin (Figure 6-5C, top).  Subsequent Western blot analysis with a monoclonal 
α-SUMO2/3 rabbit antibody detected a band at the expected size of sumoylated PXR 
protein (∼70 kDa) (Figure 6-5C, bottom).  Treatment of cells with TNFα alone or 
TNFα together with Rif produced an increased level of sumoylated PXR.  These 
results indicate that TNFα produces increased levels of detectable SUMOylated PXR 
protein in human hepatocytes.  
SUMOylation of PXR Represses TNFα-Inducible NF-κB Reporter Gene 
Activity.  Our experiments using cultures of hepatocytes provide compelling evidence 
that TNFα signaling increases levels of SUMO-modified PXR protein.  We next 
sought to determine the functional role of sumoylated PXR protein using a transient 
transfection approach together with an NF-κB-luciferase reporter gene strategy.  This 
reporter gene contains an NF-κB-response element (-TGGGGACTTTCCGC-) 
multimerized five times.  Previous studies in our laboratory using transient 
transfection and PXR in 96-well reporter gene assays were performed with CV-1 cells 
[6, 8].  It is noteworthy that treatment of cultured CV-1 cells with TNFα produced an 
approximate 10-fold increase in NF-κB reporter gene activity, whereas treatment with 
Rif did not have any effect on NF-κB reporter gene alone or in combination with 
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Figure 6-5A 
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Figure 6-5B 
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Figure 6-5C 
 
Figure 6-5. Detection of Sumoylated PXR in Hepatocytes.  Primary cultures of 
hepatocytes isolated from human donors (A and C) or humanized PXR mice (B) were 
treated for 48 h with Rif (10 μM), TNFα (10 ng/ml), or TNFα + Rif.  Whole-cell protein 
lysates were subjected to SDS-PAGE and blotted with antibodies against β-actin to ensure 
equal loading of the subsequent immunoprecipitation experiment (top).  Whole-cell 
lysates were subjected to immunoprecipitation with the polyclonal antibody that 
recognizes human PXR.  Immunoprecipitates were resolved using SDS-PAGE and 
subjected to Western blot analysis using antibodies that recognize human PXR or 
SUMO2/3 as indicated.  ∗ indicates cross-reaction with the secondary antibody caused by 
the presence of heavy chain.  
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TNFα.  However, addition of the PXR expression vector (10 ng/well) either alone or 
in combination with SUMO3 (10 ng/well) and Ubc9 (10 ng/well) effectively repressed 
TNFα-mediated NF-κB reporter gene activity (Fig. 6 A).  Titration of the 
dominant-negative Ubc9 (C93S) expression vector (5, 10, and 25 ng per well) restored 
TNFα-mediated increases in NF-κB reporter gene activity in a dose-dependent manner 
(Figure 6-6B).  It is noteworthy that expression of SUMO3 and Ubc9 had no effect on 
PXR-mediated gene activation when directed toward the PXR response 
element-controlled luciferase reporter gene (Figure 6-6C).  
    6.4 Discussion 
Several NR proteins play key roles in regulating inflammatory processes.  Among 
these receptors, the glucocorticoid receptor was the first to be characterized as a 
negative regulator of genes encoding cytokines, adhesion molecules, and inflammatory 
receptors through interactions with the activator protein-1 transcription factor [21, 23].  
A key feature of this repression was that it occurred in the absence of DNA binding and 
was therefore thought to be mediated through protein–protein interactions.  A later 
study indicated that the molecular basis for the well-known suppression of 
inflammatory processes by Rif was also mediated through the glucocorticoid receptor 
[24].  However, additional studies were unable to corroborate this finding [25].  Thus, 
the molecular basis of Rif-mediated suppression of inflammation has remained obscure.  
Although two other articles have identified the existence of strong repressive cross-talk 
between the PXR and NF-κB signaling pathways [12, 13], no well-defined molecular  
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Figure 6-6A  
 
Figure 6-6. Functional Significance of SUMO3 Modification of the PXR Protein.  
A, CV-1 cells were transfected with an NF-κB-luciferase reporter gene (20 ng/well) in 
the presence and absence of various combinations of PXR (10 ng/well), SUMO3 (10 
ng/well), and Ubc9 (10 ng/well).  Luciferase activity was determined by using 
standard methods, is reported as fold-induction ± S.E.M., and was normalized to 
β-galactosidase activity.   
 
 
 
 
 154 
Figure 6-6B 
 
Figure 6-6. Functional Significance of SUMO3 Modification of the PXR Protein.  
B,CV-1 cells were transfected as in A; however, increasing amounts of dominant 
negative Ubc9 (C93S) were included (5, 10, and 25 ng/well).  Luciferase activity was 
determined by using standard methods, is reported as fold-induction ± S.E.M., and was 
normalized to β-galactosidase.   
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Figure 6-6C 
 
Figure 6-6. Functional Significance of SUMO3 Modification of the PXR Protein.  
C, CV-1 cells were transfected as in A except a PXR-response element luciferase 
reporter gene (XREM-LUC) was used.  Veh, vehicle.  
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mechanism for Rif-mediated repression of the inflammatory response in hepatocytes 
was identified.  The data presented here are consistent with a review article that 
highlights the increased recognition of the counter-regulatory role of several liver- and 
intestine-enriched NR proteins in entero-hepatic immune responses [26].  The data we 
present here identify sumoylation of PXR as the likely molecular basis for inhibition of 
the hepatic immune response in Rif-treated patients.  Our data also form the basis of a 
new molecular paradigm that will seek to exploit the interface between 
ligand-mediated PXR activation, PXR sumoylation, and inflammatory liver and bowel 
diseases.  
    The sumoylation pathway begins with a SUMO-activating enzyme (also called E1), 
which carries out an ATP-dependent activation of the SUMO C terminus and then 
transfers the activated SUMO protein to a SUMO-conjugating enzyme (E2 ligase) 
called Ubc9.  Ubc9 is the only known E2 SUMO ligase.  In vivo, the SUMO moiety 
is then transferred from Ubc9 to the substrate with the assistance of one of several E3 
SUMO-protein ligases.  When this reaction is carried out in vitro, the E3-SUMO 
ligase is dispensable.  The human genome contains three functional genes that encode 
SUMO proteins called SUMO1, SUMO2, and SUMO3.  The three SUMO proteins 
seem to have different biological functions, but the three-dimensional structures are 
very similar to each other and also share a high degree of structural similarity to the 
ubiquitin protein.  Moreover, there is a preference among substrates for the different 
SUMO proteins.  Although sumoylation controls a large number of cellular processes, 
it clearly plays a prominent role in the repression of transcription [27].  In fact, the 
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consensus sumoylation site was identified as a negative regulatory sequence in a 
bioinformatics comparison of several transcription factors before it was identified as a 
site for sumoylation [28].  When either SUMO or the Ubc9 proteins are tethered to 
DNA through DNA-binding domains such as the GAL4 system, strong transcriptional 
repression is observed [29, 30].  It is noteworthy that in this context the SUMO-2/3 
proteins exhibited greater repression compared with SUMO-1 [29].  Whereas 
SUMO-1 seems to be conjugated mostly to proteins, the SUMO-2/3 proteins are found 
primarily in a free form.  However, an increase in SUMO-2/3 incorporation into 
substrates is detected after exposure to several stress conditions, including heat shock 
[15].  The data presented here provide additional evidence to include xenobiotic stress 
in playing a role in increased conjugation of SUMO3 to the PXR protein.  Conjugation 
of SUMO3 chains to PXR is therefore likely to be intimately involved in mediating 
active repression of NF-κB activity in liver cells.  If analogous to peroxisome 
proliferator-activated receptor-mediated repression, a molecular mechanism for this 
repression could include selective targeting of PXR to NR corepressor/histone 
deacetylase 3 complexes on inflammatory gene promoters [2].  A working model for 
this hypothesis is shown in Figure 6-7.  
PXR regulates key aspects of drug metabolism and drug transporter activity in 
several key tissue types, including liver and intestine, and in capillary endothelial cells 
that comprise the blood-brain barrier [4, 17, 31, 32].  PXR is the molecular target of 
numerous clinically prescribed drugs, drug metabolites, active ingredients in several  
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Figure 6-7 
 
Figure 6-7. Model of PXR-mediated Repression of Inflammatory Response 
Pathways. The TNFα-mediated inflammatory response strongly modulates 
sumoylation of ligand-bound PXR protein to actively repress the expression of 
inflammatory response genes.  
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widely used herbal remedies, and endobiotic compounds [4-6, 16].  Activation of PXR 
by these compounds represents the molecular basis of an adaptive response that 
protects cells from toxic insult and at the same time produces potentially 
life-threatening drug–drug, herb–drug, and food–drug interactions in patients on 
combination therapy.  Previous evidence for PXR involvement in transrepression of 
the inflammatory response is derived from the PXR-KO mouse model.  A study by 
Teng and Piquette-Miller [33] revealed that PXR-KO mice exhibit significant 
diminution of endotoxin-mediated suppression of the expression of the Mrp2 gene in 
liver.  Other investigations have revealed that the activation of NF-κB and PXR 
somehow produces transrepression of the expression of each other's target genes [13].  
It is noteworthy that this study showed that the PXR-KO mice exhibit elevated markers 
of inflammation in the small bowel compared with wild-type mice, including 
significantly increased expression levels of several key NF-κB target genes, including 
cyclooxygenase 2, IL-6, TNFα, IL-2, IL-1α, IL-1β, IL-15, and intercellular adhesion 
molecule 1.  Disruption of the molecular interaction between PXR and DNA through 
increased protein–protein interaction between the p65 subunit of NF-κB and retinoid X 
receptor has been proposed as the molecular basis for transrepression of the xenobiotic 
response by inflammatory cytokines [12], although the precise mechanism that gives 
rise to the selective interaction between these two proteins is not currently known.  
Several studies indicate that PXR-mediated inhibition of NF-κB is required for 
antifibrogenic effects and repression of CYP3A4 expression in hepatocytes [34, 35].  
Further research will be necessary to elucidate the biochemical details of this response; 
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however, the data presented here provide a stable platform for launching these 
important studies.  
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Chapter 7: Expression, Isolation, and Purification of In Vitro 
SUMOylation Components 
7.1 Introduction 
Most proteins undergo some form of post-translational modification after their 
synthesis has been completed.  Covalent modification of proteins by small 
ubiquitin-related modifier (SUMO) regulates various cellular functions including 
protein-protein interaction, sub-cellular localization, regulation of DNA binding, etc 
[1].  The human genome contains three functional genes that encode SUMO proteins 
called SUMO1, SUMO2, and SUMO3.  The amino acid homology between SUMO2 
and SUMO3 is 97%, whereas these two proteins share only 45% amino acid homology 
with SUMO1 [2].   
The mechanism for SUMO conjugation is analogous to that of the ubiquitin 
conjugation system.  All three SUMO proteins are expressed in an immature form, in 
which they carry a C-terminal stretch of amino acids after a Gly-Gly motif.  Before 
conjugation, nascent SUMO needs to be proteolytically processed to reveal its 
C-terminal Gly-Gly motif.  This is accomplished by SUMO-specific isopeptidases, 
also known as the SENP SUMO deconjugating enzymes, which remove 4 C-terminal 
amino acids from SUMO1, 11 amino acids from SUMO2, and 2 amino acids from 
SUMO3 [3].  Mature SUMO is activated by a SUMO-activating enzyme (also called 
E1), which carries out an ATP-dependent activation of the SUMO C-terminus.  The 
activated SUMO protein is then transferred to a SUMO-conjugating enzyme (E2 ligase) 
called Ubc9 [4].  In vivo, the SUMO protein is further transferred from Ubc9 to the 
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lysine residue within the substrate with the assistance of one of several E3 SUMO 
protein ligases.  When this reaction is carried out in vitro, the E3-SUMO ligase is 
dispensable.  SUMOylated targets serve as substrates for SENPs, which ensures the 
reversible and dynamic nature of SUMOylation (Figure 7-1). 
Maturation of newly synthesized SUMOs prior to their initial conjugation is 
accomplished by the action of enzymes called Ubl (ubiquitin-like protein)-specific 
proteases (Ulp) in yeast and Sentrin-specific proteases (SENP) in mammals [5, 6].  
The same group of enzymes is also responsible for SUMO de-conjugation.  
Ulp/SENPs directly regulate the pools of free, conjugatable SUMO protein and the 
half-life of conjugated species [7].   
SUMO-activating enzyme (E1) is a heterodimer, which consists of two proteins 
AOS1 (SAE1) and UBA2 (SAE2) [8].  Interestingly, human AOS1 and UBA2 have 
significant amino acid homology to the N or C-terminal half of E1 enzyme for 
ubiquitin, respectively.  The human E1 heterodimer contains a conserved cysteine 
residue that functions as an active site that is required for formation of the thioester 
bond with all members of the SUMO family in vitro.  Thus, SUMO1, SUMO2, and 
SUMO3 are activated by the same E1 holo-enzyme [9].   
Ubc9, the only identified SUMO E2 enzyme is homologous to E2 ubiquitin 
conjugating enzyme.  It conjugates activated SUMO through a C-terminal isopeptide 
bond formation to the substrate proteins [10, 11]. 
Several proteins have been shown to possess SUMO E3 ligase-like properties.   
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Figure 7-1 
Figure 7-1. The SUMOylation Pathway.  After the C-terminal processing, SUMO is 
activated in an APT-dependent reaction by E1 activating enzyme.  Subsequently, 
SUMO is transferred to the E2 conjugating enzyme (Ubc9), and finally the lysine 
residue within the substrate with the assistance of E3 ligase enzyme.  SUMOylation is 
a reversible process, and SUMO can be cleaved from target proteins by isopeptidases. 
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The E3 sumo-conjugating enzymes have been categorized into three groups: (1) the 
PIAS family (protein inhibitor of activated STAT-signal transducer and activator of 
transcription), (2) RanBP2 (the nuclear pore proteins Ran binding protein 2) , and (3) 
Pc2 (the polycomb group member) [12-14].   
SUMOylation of proteins in vitro is a useful tool for research of this 
post-translational modification.  In this chapter, we detail the bacterial expression, 
isolation, and purification of proteins necessary to perform in vitro SUMOylation 
assays, namely SUMO E1 enzyme (AOS1/UBA2 heterodimer), Ubc9, and SUMO1, 
SUMO2, and SUMO3.  Detailed methods for performing in vitro SUMOylation assay 
by SUMO1, SUMO2, and SUMO3 using RanGap1 as substrate are also described [15]. 
7.2 Materials and Methods 
Preparation of DNA Constructs.  The pcDNA3-6His-SUMO1, 
pcDNA3-6His-SUMO2, and pcDNA3-6His-SUMO3 expression vectors were 
described previously [16].  The 6His-SUMO1 construct was sub-cloned into the 
pRSET expression vector (Invitrogen) at BamHI restriction site, while 6xHis-SUMO2 
and 3 were sub-cloned at BamHI and EcoRI restriction sites.  The 
RSFDuet-Aso1-His-Uba2 and pET23a-Ubc9 expression vectors were kind gifts from 
Dr. Yoshi Azuma, Department of Molecular Bioscience, University of Kansas.   
    Bacterial Expression of His-tagged E1, E2, SUMO1, SUMO2, and SUMO3 
Proteins.  Transform plasmids into E. Coli strain of BL21(DE3) cells, and inoculate 
single colony into LB medium containing ampicillin (final concentration of 200 g/ml).  
Expression was induced by the addition of isopropyl--D-thiogalactopyranoside to a 
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final concentration of 1 mM when the culture reached O.D.600 ~ 0.4-0.6.  The bacteria 
were harvested 4 hours post-induction by centrifugation at 3000 rpm for 10 minutes at 
4 °C. 
Isolation of His-tagged E1, E2, SUMO1, SUMO2, and SUMO3 Proteins.  The 
following buffers were utilized in the isolation and purification of E1, E2, SUMO1, 
SUMO2, and SUMO3 proteins from bacteria.  Lysis buffer for E1 enzyme was 
prepared with 50 mM Na-phosphate, pH 8.0, 300 mM NaCl, and 10 mM imidazole.  
Wash buffer for E1 enzyme was prepared with 50 mM Na-phosphate, pH 8.0, 300 mM 
NaCl, 20 mM imidazole, 1 mM -mercaptoethanol, and 1 g/ml each of aprotinin, 
leupeptin and pepstatin.  Elution buffer for E1 enzyme was prepared with 50 mM 
Na-phosphate pH 8.0, 300 mM NaCl, 250 mM imidazole, 1 mM -mercaptoethanol, 
and 1 g/ml each of aprotinin, leupeptin and pepstatin.  Lysis buffer for E2 enzyme 
was prepared with 50 mM Na-phosphate, pH 6.5, and 50 mM NaCl.  Elution buffer for 
E2 enzyme was prepared with 50 mM Na-phosphate, pH 6.5, 300 mM NaCl, 1 mM 
DTT, and 1 g/ml each of aprotinin, leupeptin and pepstatin.  Lysis buffer for SUMO1, 
SUMO2, and SUMO3 was prepared using 50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 
and 10 mM imidazole.  Wash buffer for SUMO 1, SUMO2, and SUMO3 was 
prepared with 50 mM Tris-HCl, pH 8.0, 100 mM NaCl, and 20 mM imidazole.  
Elution buffer was prepared with 50 mM Tris-HCl, pH 8.0, 50 mM NaCl, and 500 mM 
imidazole.  Dialysis buffer was prepared with 20 mM HEPES, pH 7.3, 110 mM 
potassium acetate, 2 mM magnesium acetate, 1 mM EGTA, and 0.05% Tween 20. 
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The bacterial pellet obtained from centrifugation of 5 L of bacterial culture was 
resuspended in 25 ml of lysis buffer and sonicated on ice for 30 s × 5.  The lysates 
were centrifuged at 16,000 rpm for 45 minutes at 4 °C.  The supernatant was filtered 
with Millex-GP Filter Unit, 0.22 m (Millipore) and stored on ice. 
Purification of His-tagged E1, E2, SUMO1, SUMO2, and SUMO3 proteins.  
HiTrap
TM
 Chelating HP column (GE Healthcare) containing 5 ml of resin was prepared 
according to the manufacturer‟s instructions.  The resins were charged with 25 ml of 
100 mM NiSO4, and the column was equilibrated with 25 ml of lysis buffer.  The 
sample was loaded onto the column, and the column was washed with 50 ml of wash 
buffer following sample binding.  Bound proteins were eluted with 25 ml of elution 
buffer.  The fractions with purified proteins were dialyzed against 2 L of dialysis 
buffer overnight at 4 °C.  Protein samples to be used for in vitro SUMOylation assay 
were concentrated with Amicon Ultra-4 Centrifugal Filter Unit, 10k (Millipore), 
aliquoted, and stored at -80 °C. 
In Vitro SUMOylation Assay.  SUMOylation assay buffer was prepared with 20 
mM HEPES, pH 7.3, 110 mM potassium acetate, 2 mM magnesium acetate, 1 mM 
EGTA, 1 mM DTT, 0.05% Tween 20, 0.2 mg/ml ovalbumin, 1 g/ml each of leupeptin 
and aprotinin.  Each SUMOylation reaction contained 1 l of RanGap1 fragment 
(Enzo Life Sciences Inc., Farmingdale, NY), 1 g of E1 enzyme, 2.5 g of E2 enzyme, 
0.3 g of Sumo1, or 1 g of Sumo2 or Sumo3 in the presence or absence of Mg
2+
-ATP.  
A total of 20 l reaction volume was filled up with SUMOylation assay buffer.  The 
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assay components were mixed and incubated at 30 °C for 60 minutes.  The reaction 
was quenched by the addition of 20 l of 2 × SDS-PAGE gel loading buffer. 
SDS-PAGE and Western Blotting.  The presence of purified proteins was 
determined by 12.5% SDS-PAGE electrophoresis and Coomassie staining.  To detect 
the sumoylated RanGap1, samples of each reaction were resolved on 10% SDS-PAGE 
gels and transferred to PVDF microporous membranes (Millipore), which were probed 
with anti-SUMO1 or anti-SUMO2/3 antibody (Enzo Life Sciences Inc.).  
Immunodetection was performed using the Pierce ECL Western Blotting Substrate 
(Thermo Scientific) according to the protocol provided by the manufacturer.   
7.3 Results 
    Expression and Purification of His-tagged E1, E2, SUMO1, SUMO2, and 
SUMO3 Proteins.  The strategy shown in Figure 7-2 was followed to express, isolate 
and purify His-tagged E1, E2, SUMO1, SUMO2, and SUMO3 proteins.  The first step 
was to express and produce the His-tagged proteins in E. Coli strain of BL21(DE3) 
cells.  Expressed proteins were harvested and lysed 4 hours after induction by 
isopropyl--D-thiogalactopyranoside.  Samples were loaded onto the Ni
2+
 column, 
which selectively retained proteins with histidine exposed on the surface of the protein.  
His-tagged proteins were eluted with buffer containing 500 mM imidazole and 
dialyzed against SUMOylation assay buffer.  Purified components were collected, 
separated on a 12.5% SDS-PAGE gel, and visualized by staining with Coomassie blue.  
The His-tagged purified components had an apparent molecular mass of 38.4kD for  
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Figuire 7-2 
 
Figure 7-2. Purification Scheme for His-tagged E1, E2, SUMO1, SUMO2, and 
SUMO3 Proteins. 
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Aos1, 71.2kD for Uba2, and 18kD for E2 on the gel, respectively.  Interestingly, the 
molecular weight for SUMO1 (15.1kD), SUMO2 (14.4kD), and SUMO3 (14.1kD) was 
shift up on SDS-PAGE (Figure 7-3). 
In Vitro SUMOylation Assays.  RanGTPase-activating protein (RanGap1), the 
key regulator of Ran GTP/GDP cycle, was the first substrate identified to be 
post-translational conjugated with SUMO-1 in an ATP-dependent manner [17].  Here, 
we used RanGap1 as substrate for in vitro SUMOylation assays in order to exam the 
efficiency of the purified components.  We incubated human recombinant RanGap1 
fragment (418-587) together with purified E1, E2, SUMO1, SUMO2, or SUMO3 
proteins in the presence and absence of the required magnesium and ATP cofactors.  
The extent of SUMOylation after the incubation was determined by SDS-PAGE and 
western blot analysis with antibodies that recognize either SUMO1 or SUMO2/3 
proteins.  The analysis revealed that SUMOylation of RanGap1 resulted in a ~20 kD 
mobility shift and RanGap1 could be modified with all three SUMO proteins in the 
presence of SUMO E1, E2 and Mg
2+
-APT to give a single mono-sumoylated product 
(Figure 7-4).  The presence of bands at about 35 kD can be attributed to small amounts 
of di-SUMO substrate, while bands at 25 kD on the western blot probed with 
anti-SUMO1 antibody may be due to the impurities present in the fractions containing 
SUMO1 component.   
7.4 Discussion 
SUMOylation has been reconstituted in vitro for many known targets using  
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Figure 7-3 
 
Figure 7-3. SDS-PAGE Analysis of Purified Proteins.  5 g of purified component 
was loaded onto each lane.  Proteins were separated on a 12.5% gel and visualized by 
staining with Coomassie blue.  The two components of E1 dimer are indicated with 
asterisks. 
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Figure 7-4 
 
Figure 7-4. Western Blot of In Vitro SUMOylation Assay for RanGap1.  20 l 
reactions containing 1 l of RanGap1, 1 g of E1 enzyme, 2.5 g of E2 enzyme, 0.3 g 
of SUMO1 (left panel), or 1 g of SUMO2 or SUMO3 (right panel) were incubated at 
30 °C in the presence or absence of Mg
2+
-ATP for 1 hour.  The protein was detected 
by western blot analysis with antibodies that recognize either SUMO1 or SUMO2/3.   
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recombinant SUMO enzymes and SUMO proteins purified from bacterial cells.  In 
vitro SUMOylation of proteins provides a useful means for investigation of this 
post-translational modification.  For example, it allows the identification of novel 
proteins as potential targets for SUMOylation pathway under in vitro condition, 
serving as a starting point for examining the role of SUMOylation in vivo.  It can be 
employed to study the effect that SUMO-modification might have on specific substrate 
functions in vitro, such as protein-protein interactions, protein stability, etc.  It can 
also be applied to identify sites, motifs, or specific amino acids of SUMO-modification 
within the substrates in vitro. 
The in vitro SUMOylation assay we describe here does not include an SUMO E3 
ligase in the reaction, which may result in a higher amount usage of Ubc9.  It is the 
method of choice when the specific E3 ligase for a target is not known or unavailable.  
Even though E1 and E2 enzymes are sufficient for SUMOylation of specific substrates 
in vitro, several proteins have been demonstrated to act as SUMO E3 ligases.  These 
enzymes allow or enhance the SUMOylation of specific target proteins under certain 
conditions in vitro.  For instance, PIAS1 functions as a SUMO ligase and catalyzes the 
SUMOylation of p53 in vitro [18].  RanBP2 directly interacts with the E2 enzyme 
Ubc9 and strongly enhances SUMO1-transfer from Ubc9 to the SUMO1 target Sp100 
[14].  Therefore, recombinant SUMO E3 ligases, such as members of PIAS family and 
RanBP2 can be expressed and purified from bacteria, and included in the in vitro 
SUMOylation assay.  In this case, less amount of Ubc9 might be needed, but optimal 
Ubc9 and E3 concentrations have to be titrated for every single target protein. 
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Ni
2+
 column, which selectively retained proteins with histidine exposed on the 
surface, are often used for the purification of recombinant His-tagged proteins [19].  
Impurities were present in the SUMOylation components purified with Ni
2+
 column, 
especially the E1 enzymes (Figure 7-3).  Pure components can be obtained by 
rerunning the purified proteins from Ni
2+
 column over ion exchange chromatography, 
namely cation exchange column (SP Sepharose) or anion exchange column (Q 
Sepharose).  Since ion exchange column is based on adsorption and reversible binding 
of charged sample molecules to oppositely charged groups attached to an insoluble 
matrix, purification can be achieved by choosing a start buffer with a pH and ionic 
strength that promotes the binding of some or all contaminating substances but allows 
the protein of interest to pass through the column. 
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Chapter 8: The Future Outlook of PXR 
    8.1  PXR and Drug Metabolism 
Our body is constantly exposed to potentially harmful environmental xenobiotics 
that are ingested in the diet, inhaled, or absorbed.  Although many of the 
water-soluable chemicals are readily eliminated from the body, lipophilic xenobiotics 
are particularly problematic because they often require conversion to hydrophilic 
molecules more suitable for excretion into urine or bile.  Otherwise these lipophilic 
xenobiotics have the potential to accumulate to toxic concentrations over long periods 
of time.  A complex system has been developed to defend our body against numerous 
xenobiotics through the combined action of the phase I oxidative cytochrome-P450 
(CYP) enzymes, the phase II conjugating enzymes, and the membrane transporter 
proteins in liver and intestine.   
The expression of genes encoding many drug-metabolizing enzymes (DMEs) and 
drug transporters are inducible in response to various xenobiotic compounds, 
representing a protective role for our body against toxic insult [1].  Not surprisingly, 
the importance of drug effects and toxicity through metabolism has been widely 
appreciated and studied.  The identification and characterization of the pregnane x 
receptor (PXR, NR1I2) in 1998 revealed the molecular basis for this inducible defense 
system [2].  PXR belongs to the nuclear receptor (NR) superfamily, and is expressed 
predominantly in the liver and intestine.  Upon activation by a variety of clinically 
prescribed drugs, drug metabolites, active ingredients in several widely used herbal 
remedies, and endobiotic compounds, PXR heterodimerizes with retinoid X receptor 
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alpha (RXR, NR2B1), and up-regulates the transcription of a wide range of DMEs 
and transporter proteins [3].  Therefore, activation of PXR by these compounds 
represents the molecular basis for guarding our body against harmful assault.  At the 
same time, however, induction of DMEs by PXR activation can also lead to accelerated 
metabolism of other co-administered drugs, producing potentially life-threatening 
drug-drug, herb-drug, and food-drug interactions in patients on combination therapy. 
In the past decade, important insights have been made regarding the 
PXR-mediated drug-drug interactions.  Up-regulation of CYP3A4 alone, the 
prototypical target gene of PXR, is involved in the metabolism of >50% of all 
prescription drugs [4].  Hence, scientists are developing in vitro and in vivo models to 
test drug candidates for their ability to activate PXR.  The ideal drug candidates would 
be those that have desired therapeutic efficacy but lack PXR activity.  The availability 
of robust, high throughput and binding assays permits the rapid identification of PXR 
ligands, allowing the screening of the entire library of drug candidates for PXR activity 
[5, 6].  Primary cultures of human hepatocytes are also employed to assess the 
potential for compounds to modulate the expression of PXR target genes [7].  Due to 
the species-specific nature of the induction of genes involved in drug metabolism and 
disposition, generation and characterization of humanized PXR transgenic mice 
exhibiting human-like response to drugs evolve as appropriate in vivo tools for 
evaluating the functions of PXR in a whole animal system [8, 9]. 
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    8.2  PXR and Inflammation 
In the past decade, the molecular basis for ligand-mediated PXR gene activation 
programs has been well established to control the metabolism and transport of 
xenobiotics in mammals.  Interestingly, pharmacotherapy with potent PXR ligands 
produces several profound side effects including inflammation.  It has been known for 
forty years that treatment with rifampicin, an antibiotics used to treat tuberculosis 
which is also a prototypical PXR ligand, tends to suppress humoral and cellular 
immunological function in liver cells in patients [10-12].  On the other hand, it has 
also been observed that inflammation and infection reduce hepatointestinal drug 
metabolism capacity [13-15].  A recent study revealed a mutual repression between 
steroid and xenobiotic receptors and NF-B signaling pathways, in which PXR inhibits 
NF-B-mediated reporter activity and the expression of NF-B target genes, while 
activation of NF-B reciprocally inhibits PXR activity and the expression of PXR 
target genes [16].  However, the specific molecular mechanism underlying these 
phenomena remains unknown.   
Several recent reports indicate that key members of the nuclear receptor (NR) 
superfamily are SUMOylated to act in trans to repress the inflammatory-responses.  
For example, a molecular pathway has been identified in which PPAR-gamma 
represses the transcriptional activation of inflammatory response genes in mouse 
macrophages.  Ligand-dependent SUMOylation of the PPAR-gamma results in 
targeting itself to the promoters of several inflammatory-response genes, where it 
inhibits gene transcription by preventing clearance of multi-protein corepressor 
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complexes [17].  Subsequent evidence indicates that SUMOylation is required for the 
suppression of STAT1-dependent inflammatory responses by LXR-alpha and 
LXR-beta in IFN-gamma-stimulated brain astrocytes [18].  Interestingly, the PXR 
protein also contains consensus SUMOylation sites, but it remains to be seen whether a 
similar mechanism is applicable in transrepression of NF-B signaling by PXR protein.  
Recently published data from our lab has demonstrated that activation of the 
inflammatory response in hepatocytes strongly modulates the SUMOylation status of 
ligand-bound PXR.  The SUMOylated PXR protein contains SUMO2/3 chains and 
feedback represses the immune response in hepatocytes [19].  A hypothesis has been 
proposed that the mechanism of selective repression of the inflammatory response is 
due to SUMO-modified PXR preventing clearance of multi-protein corepressor 
complex. 
Human PXR has been implicated in the pathogenesis of inflammatory bowel 
diseases (IBD).  PXR-mediated repression of NF-B target genes in the colon has 
been shown as a critical mechanism by which PXR activation decreases the 
susceptibility of mice to DSS-induced IBD [20].  Rifaximin, a rifamycin analog, is a 
poorly absorbed oral antimicrobial agent increasingly used in the treatment of IBD.  It 
receives new labeling for reduction in the risk of the recurrence of overt hepatic 
encephalopathy in patients with advanced liver disease [21, 22].  However, the 
mechanisms contributing to the effects of rifaximin on IBD are not fully understood.  
Recent studies identify rifaximin as a gut-specific human PXR ligand [23].  The 
preventive and therapeutic role of rifaximin on IBD is demonstrated through human 
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PXR-mediated inhibition of the NF-κB signaling cascade, thus suggesting that human 
PXR may be an effective target for the treatment of IBD [24]. 
8.3 Concluding Remarks 
Research over the past decade has made it evident that PXR is critical for 
regulating expression of genes that control drug metabolism and disposition.  
Pharmaceutical companies are now routinely screening novel compounds to determine 
whether they activate PXR during safety assessment studies.  These screening assays 
should yield drugs with less potential for induction of genes linked to drug metabolism 
and disposition, and thereby reduce the risk for adverse drug interactions.  The 
identification of novel ligands and target genes continues to be an important aspect of 
PXR research.   
Recent evidence has revealed a negative regulatory role for PXR in several 
physiological functions including inflammation.  Understanding the biochemical 
details and molecular mechanisms of how PXR is converted from a positive regulator 
of hepatic drug metabolizing enzymes into a transcriptional suppressor of 
inflammation in liver tissue is emerging as a key area of study for this receptor.  The 
knowledge gained from these studies is expected to form the basis to exploit the 
interface between ligand-mediated PXR activation, post-translational modification of 
PXR, and inflammatory liver and bowel diseases, and eventually provides new 
opportunities for the development of novel therapeutic strategies to target this 
noteworthy receptor in the combat of human diseases.  
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